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Introduction and scope of the thesis
Melanoma is the most aggressive form of skin cancer and is responsible for over 70 
percent of skin cancer deaths. [1] Melanomas develop from malignant melanocytes. 
The gross majority of melanomas occur in the skin, the so-called cutaneous melanomas 
(CM). Melanoma incidence is among the top ten of leading cancer sites in the United 
States (US) with a fifth place for men and a sixth place for women. [1] Moreover, based 
on the years lost to cancer, melanoma would merit a higher ranking because relatively 
young people are affected by this malignancy. [2-4] Among Caucasian populations in 
Northern and Western Europe, melanoma incidence rates are increasing steadily by at 
least three percent each year. [5]
Melanoma prognosis depends on the stage at diagnosis. Melanoma staging is 
performed according the validated and internationally standarized Melanoma Staging 
System of the American Joint Committee on Cancer (AJCC). [6] This AJCC melanoma 
staging system is based on the TNM criteria; that is, thickness of the tumor (T), extent 
to which it has spread to the lymph nodes (N), and extent to which it has metastasized 
to other parts of the body (M). Tumor thickness, also referred to as Breslow’s thickness 
is one of the strongest prognostic factors [6] and is measured from the skin surface 
until the deepest point of invasion as described by Alexander Breslow in 1970 [7]. 
Other factors that predict poor prognosis include advanced age at diagnosis, male 
gender, ulceration, race, anatomic site (trunk, head-neck region, extremities), and 
certain histogenetic subtypes, such as acral melanoma. The histopathological 
subtypes are classified according to the World Health Organization Classification of 
Tumours. [8]
Often CM are diagnosed at an early stage while the disease is still confined to the local 
site. For these patients, prognosis is favorable with 5-year relative survival proportions 
of 98.7 percent in the United States. In contrast, if the disease has spread regionally or 
in case of distant metastasis, 5-year relative survival proportions drop to 65.2 and 15.3 
percent, respectively. [1] For these advanced stages of melanoma, effective treatment 
options are lacking [9], except may be surgical excision for localized metastasis. In 
spite of this lack of effective treatment options for advanced melanoma, melanoma 
mortality rates seem to be stabilizing or (slightly) decreasing. [10] In summary, overall 
melanoma incidence rates are increasing while mortality rates are stable or 
decreasing.  
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In rare cases, melanomas can also arise at noncutaneous sites such as primary 
melanomas of mucous membranes, the uvea or choroid of the eye, the meninges, or 
in organ tissue. [11] Due to their rarity, reliable estimates of the incidence and survival 
rates of such extracutaneous melanomas (ECM), e.g., from population-based registries, 
are sparse. Establishing the incidence rate of ECM, possible time trends in this 
incidence and the relative survival of ECM patients in The Netherlands, is a first 
objective of this thesis. 
In chapter 2 we will determine (trends in) the incidence rates of ECM in the Netherlands 
Cancer Registry. Additionally, we will present 5-year relative survival proportions 
among ECM patients in this chapter.
As mentioned earlier, melanoma mortality rates are stable or decreasing, while 
melanoma incidence rates are increasing. Since, additionally, melanoma is usually 
diagnosed in patients of a relatively young age [2-4], overall, the total number of 
patients suffering from melanoma is accumulating. Consequently, the total burden of 
melanoma is assumed to be increasing among Caucasian populations. Indeed, 
evidence from the US and Belgium has also suggested an increase in the burden of 
cutaneous melanoma. [3,12] Recent European data estimating (trends in) the different 
measures of the burden of CM, such as incidence rates, mortality rates, the prevalence, 
the number of years lost due to disability (YLD), and the number of years of life lost 
due to premature mortality (YLL), are sparse. The second objective of this thesis is to 
estimate of the burden of melanoma for the Dutch population. In chapter 3 we will 
present estimates of the burden of melanoma in The Netherlands. 
As the overall burden of melanoma is increasing; prognosis strongly depends on the 
stage at diagnosis; and, most importantly, effective treatments for advanced stages 
are lacking, there is a high potential benefit for the prevention of melanoma. However, 
most of the established risk factors for melanoma, such as fair skin type, freckles, light 
eye color, older age, history of sun burns, clinical atypical nevi, prior melanoma, and 
family history of melanoma, are not amenable to intervention. Only sun burns and 
sun exposure are, at least in theory, amenable. Indeed, sun protection measures are 
part of melanoma prevention programs. In some high risk countries, such as Australia, 
comprehensive sun protection programs have been implemented over a decade ago 
and sun screen use is widely promoted to the general public. These public health 
campaigns have increased awareness on skin cancer and the adverse events of 
excessive sun exposure, but failed to change the sun exposure behaviour in the 
general population which is referred to as the so-called ‘knowledge-behaviour gap’. 
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Lack of behavioral changes and possibly also the increased awareness explain why 
the incidence of melanoma in Australia is still increasing. [13] Therefore, alternative 
approaches in melanoma prevention, such as chemoprevention, should be considered 
for high risk populations. Chemoprevention, as defined by Sporn and colleagues, is 
the use of natural or synthetic drugs to reverse, suppress, or prevent premalignant 
molecular or histological lesions from progressing to invasive cancer. [14]
Ideal candidate drugs for chemoprevention should have additional major health 
benefits, few (long-term) adverse events and would be inexpensive. Several drug 
classes, such as statins, aspirin, non-steroidal anti-inflammatory drugs (NSAIDs) and 
angiotensin-converting enzyme inhibitors (ACE inhibitors), have been suggested to 
be of interest in melanoma chemoprevention. [15-17] However, it is unclear which of 
these and other candidate drugs for melanoma chemoprevention have the potential 
to be useful and safe. Therefore, the third and main objective of this thesis is to explore 
which candidate chemopreventive drugs could be beneficial in melanoma and which 
drugs may be unfavourably associated with the incidence or progression of 
melanoma.
In chapter 4 we will perform a qualitative review on a subset of the literature available 
on melanoma chemoprevention on these potential chemopreventive drugs. We will 
define this subset of the scientific literature with a systematic literature search in 
Medline, Embase, Web of Science, and The Cochrane Library.
To further explore if drugs have a chemopreventive effect on melanoma in humans, 
one could use several research designs, such as a prospective randomized controlled 
trial (RCT), prospective cohort study, retrospective cohort study or a case control 
study for instance by means of telephone surveys or by the use of pharmacy databases. 
However, in research practice, the choice of the study design is limited because one 
needs sufficiently long follow up and large numbers of participants to show 
chemopreventive effects on melanoma, a relatively rare malignancy that develops 
over long time periods. In addition, research funds are limited, and retrospective 
collection of drug exposure by telephone survey is time-consuming and may even be 
unreliable. For many chemopreventive candidate drugs, such as statins, NSAIDs and 
estrogens, it is reasonable to assume that exposure allocation is unrelated to the 
outcome of interest, melanoma. In explanation, at the time of prescribing these drugs, 
both doctors and patients are not aware of potential effects on melanoma incidence. 
For such research topics, where the presciber is effectively blind for the potential 
effect of interest, observational research may be as credible as RCTs. [18] Therefore, we 
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will perform a number of case-control studies in a general population-based dataset 
linking drug-dispensing data from the pharmaco-morbidity linkage network 
(PHARMO) with pathological data (PALGA) from the nationwide network and registry 
of histo- and cytopathology in The Netherlands. By means of this pharmocoepide-
miological approach, we will attempt to estimate the causal effects on the incidence 
and progression of melanoma of a few candidate chemopreventive drugs.
In chapter 5, we investigate the association between use of statins and the incidence 
of CM. In addition, potential effects of prior statins use on Breslow’s thickness at 
diagnosis of CM is studied as well as effects on time to metastasis.
As will be described in chapter 4, non-steroidal anti-inflammatory drugs (NSAIDs), 
both acetylsaliylic acid (aspirin) and non-acetylsaliylic acid-NSAIDs have been 
suggested to have beneficial effects on melanoma incidence. Therefore, in chapter 6, 
we will study the association between use of NSAIDs including (low-dose) aspirin on 
melanoma development.
In chapter 7 an etiological association study on the association between use of ACE 
inhibitors and angiotensin receptor antagonists on melanoma incidence and 
progression is executed.
Gender differences in melanoma have been established on both incidence and 
prognosis. Interestingly, although melanoma incidence is higher among women, 
survival is improved in female CM patients as compared to male CM patients. This 
female survival benefit is maintained after adjusting for well-established prognostic 
factors. [19] Until now, gender differences in melanoma are not well understood. One 
of the factors that could play a role in these gender differences are the effects of 
female hormones, such as estrogens. [20] Therefore, in chapter 8 and 9, we will study 
the association between use of estrogens and development and tumor thickness at 
diagnosis of melanoma, respectively.
Finally, in chapter 10 the results of the studies presented in this thesis are interpreted 
and placed into perspective, the potential of drug chemoprevention for melanoma is 
discussed, and suggestions for future research are postulated. The theme of this thesis 
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2Chapter 2 
Epidemiology of Extracutaneous Melanoma 
in The Netherlands
Extracutaneous melanoma
Els R. Koomen, Esther de Vries, Leon C. van Kempen, Alexander C.J. van Akkooi, 
Henk Jan Guchelaar, Marieke J. Louwman, Tamar Nijsten, Jan Willem W. Coebergh
Cancer Epidemiol Biomarkers Prev 2010, 19(6),1453-1459
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Abstract
Background:  Reliable population-based incidence and survival data on extracutaneous 
melanoma (ECM) are sparse. 
Patients and Methods:  Incidence data (1989-2006) from the Netherlands Cancer 
Registry were combined with vital status on January 1st 2008. Age-adjusted annual 
incidence rates were calculated by direct standardization and the Estimated Annual 
Percentage Change was estimated to detect changing trends in incidence. Additionally, 
we performed cohort-based relative survival analysis.
Results:  Ocular melanomas were the most common ECM subsite with European 
Standardized incidence Rates (ESR) of 10.7 and 8.2 per 1,000,000 person-years for 
males and females, respectively. In comparison, for cutaneous melanoma (CM), the 
ESRs for men and women were 122 and 155 per million person-years, respectively.
No statistically significant trends in the incidence of ECM were detected whereas an 
annual increase of 4.4 percent for men and 3.6 percent for women was detected in 
the incidence of CM.
Relative survival for ECM was poor, but differed largely between anatomical subtypes 
ranging from a 5-year relative survival of 74% for ocular melanomas to 15% for certain 
subsites of mucosal melanomas.
Conclusion:  Of all ECM subsites, ocular melanomas had the highest incidence and the 
best survival. Mucosal melanomas were the second most frequent subsite of ECM. 
Five-year relative survival for all ECM subtypes was worse if compared to CM. No 
statistically significant trends in the incidence of (subsites of) ECM were determined. 
Impact:  This study gives insight into the relative sizes of the different subgroups of 




Although rare, melanomas can arise at noncutaneous sites. Such extracutaneous 
melanomas (ECM) include ocular, meningeal and mucosal melanomas or melanomas 
on exceedingly rare sites like the adrenal gland, kidney, lung or soft tissue. Ocular 
melanomas arise in the eye and adnexa, whereas meningeal melanomas occur in the 
dura mater or leptomeninges. Mucosal melanomas may occur at different anatomical 
sites, such as in the head & neck region, female or male genitals, esophagus, anorectally 
or very rarely in the urinary tract or biliary tract. [1]
Most of the available epidemiological data on ECM is restricted to anatomic sites and 
not based on well-described populations, e.g., from geographic regions or national 
databases. [2-5] Thus, population-based incidence and survival data on ECM are 
sparse. In 2005, McLaughlin et al. published incidence data on ECM from the US and 
showed that ocular melanoma was more common among men (men: 6.8 cases per 
million, women: 5.3 cases per million women, age-adjusted to U.S. population 
standard in 2000), whereas mucosal melanomas were more common among women 
(women: 2.8 cases per million, men: 1.5 cases per million men). [6]  Unfortunately, 
trends in ECM incidence and survival were not reported. Comparable European data 
are not available. 
In general, ECM are rare (incidence rates < 10 per million person years) [2-6] and have 
a poor prognosis with 5-year survival estimates ranging from 4 to 60 percent [1]. As 
opposed to cutaneous melanomas (CM), ECM’s prognosis is poor due to late diagnosis 
as most ECM are not visible, early presenting signs and symptoms are often absent. 
Additionally, ECM seem to be biologically more aggressive than most CM. [1] 
In The Netherlands, the age-adjusted incidence rate of CM has increased significantly 
with 3.3% in men and with 2.2% in women between 1989 and 1998. [7] This is likely 
due to increases in sun exposure, and partly due to increased awareness. [7] Since 
effects of sun exposure are considered to be small or absent for the development of 
ECM, no changes in incidence rates are expected to occur over time for ECM.
The objective of this study was to contribute to the very limited information on 
population level regarding this rare group of cancers by assessing incidence rates, 
relative survival and time trends in the incidence of ECM of different anatomical sites 





Patients and methods 
Data
Incidence data from 1989 until 2006 according to sex, calendar year of diagnosis and 
anatomical site were obtained from the nationwide population-based Cancer Registry 
in The Netherlands. This registry receives lists of newly diagnosed cases on a regular 
basis from the PALGA network, the registry of histo- and cytopathology in the 
Netherlands. All pathology departments in the country participate in this nationwide 
network. Additional to these records, lists of hospitalized cancer patients are provided 
by the medical record departments and these are also checked. Sequentially, the 
medical records of patients with newly diagnosed primaries are collected. From these, 
trained tumor registrars summarize relevant information. Duplicate records are 
removed. [8]
From both hospital records and the death registry of the Central Bureau for Genealogy 
(which registers all deceased in The Netherlands via the municipal civil registries), vital 
status on January 1st 2008 was obtained. We recorded survival for the time periods 
between primary melanoma diagnosis and date of death or the latest date of 
follow-up. Patients who were alive at their last date of follow-up, were considered 
censored.
Anatomical sites of ECM were identified based on the International Classification of 
Disease for Oncology, 9th and 10th revision (ICD-9, ICD-10) and regrouped in the 
melanoma of the CNS (brain, benign brain tumors, meninges and other CNS; ICD 
codes: 1921-1922, C70-C71), ocular melanoma (eye, eye lids, orbita, choroid, corpus 
ciliare and the eye muscles; ICD codes: 1900-1909, C69), or mucosal melanoma of the 
ear, nose & throat region (nasal cavity, middle ear, sinuses, larynx, lip, pharynx and oral 
cavity; ICD codes: 1404, 1430, 1439, 1452, 1453, 1600-1609, C00-C09, C11-C14, C30-C33), 
genitals (males: penis and other not otherwise specified male genitals, females: cervix 
uteri, ovary, vagina and other female genitals, but excluding the vulva; ICD codes: 
1840-1848, 1871-1877, C52, C53, C56, C57, C60, C63), vulva (ICD code: C51), gastrointes-
tinal tract (esophagus and anus/anal canal; ICD codes: 1504, 1505, 1541-1548, C15, 
C20-C21), lung (ICD codes: 1625, C34, C38) or urinary tract (including urinary bladder; 
ICD codes: 1881, C68), and ECM of other sites (such as adrenal gland, kidney, soft tissue; 
ICD codes: 1890, C49, C74, C77). ECM of the stomach, small intestine and colorectal are 
exceedingly rare and can be metastases of an occult primary melanoma. Therefore, 
ECM registered as the subsites stomach, small intestine and colorectal (ICD codes 
1521, 1570, C16, C17 and C18) were excluded from analyses (n=10).
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The Netherlands Cancer Registry records are assumed to be complete from 1989 
onwards. [9] However, data collection before 2003 on ocular melanomas was 
incomplete because, at the time, non-pathologically confirmed ocular melanomas 
were not systematically included in the Netherlands Cancer Registry. Likewise, vulvar 
melanomas were not systematically reported prior to 1993 because a unique ICD 
code was lacking. Consequently, we included only data from 2003 and 1993 onwards 
for ocular and vulvar melanomas, respectively.
Analysis
For each site, incidence rates were calculated stratified by sex and calendar year. 
Annual incidence rates were age adjusted by direct standardization according to the 
European Standard Population, resulting in European standardized incidence rates 
(ESR) per million person-years. Subsequently, 3-year moving averages of the ESR were 
calculated. To detect changing trends in ECM incidence over time, the Estimated 
Annual Percentage Change (EAPC) was calculated. The EAPC was estimated by fitting 
a regression line with the following equation: y = mx + b, where y = ln ESR and x = 
calendar year. The EAPC is then equal to 100*(em – 1). This method assumes that the 
incidence rates increase or decrease at a constant rate in the study period (1989-2006). 
For each EAPC, 95% confidence intervals were calculated using the standard error of 
m obtained with the regression line. [7] EAPCs were calculated separately for men 
and women, for CM, all mucosal melanomas, and mucosal melanomas of the vulva 
and Ear-Nose-Throat region. 
Additionally, joinpoint analyses were carried out to determine if significant changes in 
the time trends were present and, if so, when they occurred. [10] In joinpoint analyses, 
linear line segments are connected on a log scale to identify changes in the EAPC 
values over time. [10] 
Relative survival was estimated in a cohort-based analysis by dividing the crude 
survival among cancer patients by the expected survival from the general popula-
tion-based upon the same age- and sex-distributions as has been described earlier. 
[11] Relative rather than crude survival was estimated because these reflect the excess 
mortality among the cancer patients rather than the overall survival experience of the 
patients, including the non-cancer related deaths. Standard errors were calculated 
according to Greenwood’s method. [12] 
All calculated p-values were two-sided and considered significant if p<0.05. All 
analyses were performed using SPSS 16.0 (SPSS Inc. Chicago, IL), except relative 
survival which was calculated using the SAS computer package, version 9.1 (SAS 






Between 1989 and 2006, a total number of 3134 primary invasive ECM were registered 
among Dutch citizens aged 18 years or older. In comparison, the Netherlands Cancer 
Registry recorded 42,124 primary invasive CM in the same period. The number of 
melanomas with an unknown primary was <0.2% and these were considered to have 
a cutaneous origin in this study.
Incidence
Table 1 summarizes the number of incident melanoma cases diagnosed between 
1989 and 2006 by anatomical location and sex. During this period, a total of 42,124 CM 
were diagnosed. The age-standardized incidence rates (ESR) of CM were 122 and 155 
per million person-years for males and females, respectively (Table 1). The male- 
to-female rate ratio was 0.79.
Between 2003 and 2006, ECM compromised 6.4% of all invasive melanomas. 
The proportion of ECM was slightly higher among men (7.0% versus 6.0%). 
During this period, ocular melanomas were the most commonly occurring subsite of 
ECM and represented 87% and 68% of all ECM among men and women, respectively. 
The ESRs of ocular melanoma were 10.7 and 8.2 per 1,000,000 person-years for males 
and females, respectively. Thus, the male-to-female rate ratio of ocular melanomas 
was 1.3.
After excluding ocular melanomas reported before 2003 and vulvar melanomas 
reported before 1993 (see method section for explanation), 1502 incident primary 
ECM among 1493 patients were eligible for further analyses. 
Patients with ECM had a median age at diagnosis of 68 years whereas CM patients had 
a median age of 53 years. Median ages at diagnosis and the 25th and 75th percentile 
of patients with different melanoma subtypes are presented in Table 1. Overall, ECM 
patients are generally older at diagnosis than CM patients and male ECM patients are 
younger at diagnosis (median age: 65 years) than female ECM patients (median age: 
71 years). 
Mucosal melanomas, such as vulvar (ESR 1.06) and ECM of the ear, nose and throat 
(ESR 0.88 for males and 0.71 for females) also contributed substantially to the total 
ECM incidence. The male-to-female rate ratio of mucosal melanomas was 0.48.
Only 13 incident primary ECM within the central nervous system were reported in the 
total study period (1989-2006) resulting in extreme low ESRs for men and women 




2Table 1  Invasive Cutaneous and Extracutaneous Melanomas in  
the Netherlands National Cancer Registry



















Skin 17,723 121.9 24,401 155.2 86  (86-87) 53 (40-66)
Non Skin, Non-Mucosal
CNS 4 6 0.038 7  0.052 - 51 (32-60)
Ocular 4,5 373 10.67 322 8.19 74 (67-81) 62 (54-72)
Others 4 1 0.01 4 0.03 - 61 (51-74)
Non Skin, Mucosal
Ear-Nose-Throat 4 122 0.880 139 0.708 27 (20-34) 71 (60-80)
Genitals 4 48 0.338 121 0.653 26 (18-34) 72 (58-81)
Vulva n.a. n.a. 214 1.06 40 (31-49) 75 (65-83)
Gastrointestinal tract 4 53 0.382 78 0.400 15 (8-22) 72 (59-80)
Lung 4 6 0.045 1 0.009 - 66 (59-79)
Urinary tract 4 1 0.007 6 0.031 - 71 (67-82)
1   ESR = European Standarized Incidence Rate, expressed in 1 per 1.000.000 person years.
2   Calculated 5-year cumulative overall survival relative to the general Dutch population standarized for  
age and gender.
3   Median age at diagnosis In years and 25 and 75 percentile.
4   The extracutaneous localizations were defined as:
- Central Nervous System (CNS) includes brain, benign brain tunours, meninges and other CNS. 
-  Ocular includes melanoma of the eye and its adnexa, such as the eye lids, orbita, choroidia, corpus ciliare  
and the eye muscles.
- Others includes adrenal gland, kidney and soft tissue.
- Mucosal melanomas were subdivided in several categories, such as:
-  Ear-Nose-Throat which included sinonasal and oropharyngeal mucosal melanomas (larynx, lip,  
pharynx, oral cavity, nasal cavity, middle ear and sinuses). 
-  Genitals which included for males: penis and other NOS (not otherwise specified) male genitals  
and for women: female genitals including cervix uteri, ovary, 
   vagina and other female genitals, but excluding the vulva. 
- Gastrointestinal tract which included oesophagus and anus/anal canal.
- Urinary tract which included urinary bladder and other urinary tract structures. 
5   Only data from 2003 intil 2006 were included for ocular melanomas since the Dutch Cancer Registry  




Five-year relative survival for CM unstratified for gender was 86% overall between 
1989 and 2006. Relative survival of all ECM subtypes was poor compared to those of 
CM. However, there are large differences in 5-year-relative survival estimates between 
ECM subtypes. Of all ECM, ocular melanomas had the best 5-year relative survival of 
74% whereas vulvar melanomas had a 5-year relative survival of 40%. The 5-year 
relative survival of different subsites of mucosal melanomas varied between 15% and 
40% (Table 1). 
Trends in incidence
For both sexes, the ESR for CM increased significantly between 1989 and 2006 
(Table 2). For males, the ESR for CM increased with 4.4% (95%CI: 3.9, 4.9%) per year. 
Increases among females were 3.6% (95%CI: 2.9, 4.2%). 
The age-adjusted incidence rates of all mucosal melanomas and of the selected mucosal 
region of ear-nose-throat (Fig. 1) showed an increasing, but nonsignificant trend among 
women (EAPC: 1.8%, 95%CI: –0.5, 4.2%, and EAPC: 2.8%, 95%CI: –0.1, 6.8%, respectively). 
For men, lower increases were observed in the annual incidence of all mucosal 
melanomas and these of the ear, nose and throat region (EAPC: 1.0%, 95%CI: –1.8, 3.8, 
and EAPC: 1.1%, 95%CI: –4.4, 7.1, respectively). The estimated increase in incidence of 
vulvar melanoma between 1993 and 2006 was only 0.3% (95% CI: –2.6, 3.4). 
Despite apparent changes in trend, no statistically significant joinpoints were 

































































































































































































































































































































































































































































































































































































































































































































































































































































Our results show that, between 2003 and 2006, about 6.4% of all primary melanomas 
in The Netherlands were ECM. This proportion is similar to previous reports (4-6.8%). 
[6,13] In general, ECM patients, especially those with mucosal melanomas, are older at 
diagnosis than CM patients. Similarly, Chang et al. observed a median age of ~ 70 
years for mucosal melanomas. [15] 
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Figure 1  Trends in the incidence of muscosal melanomas in 
The Netherlands: 1989 - 2006
Time Period
(mid-year of 3 year moving average)
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No statistically significant time trend in the ECM incidence was observed, whereas an 
annual increase in age-adjusted standardized CM incidence among both sexes was 
observed. 
Ocular melanoma was the most common ECM subsite and its’ incidence was 
somewhat higher than reported by McLaughlin et al. (ESR females: 10.7 versus 6.8 per 
million person-years; males: 8.2 versus 5.3 per million person-years) [6]. The male- to-
female rate ratio of 1.3, however, was similar [6].
Mucosal melanomas were the second most frequent subsite of ECM and the incidence 
we report is in agreement with the US data reported in McLaughlin’s paper (ESR men: 
1.8 versus 1.5 per million person-years; women: 2.8 versus 2.8 per million person-years) 
[6]. The male-to-female rate ratio for mucosal melanomas was 0.48 which seems to be 
rather consistent throughout the literature [6,14,15], and the female predominance is 
most likely a reflection of the lack of a male counterpart for vulvovaginal lesions. [14] 
The incidence of vulvar melanoma in our study (ESR: 1.1 per million person-years) is 
similar to a previously published study from Sweden (1960-1984) [3]. In their study, 
however, the annual age-standardized incidence of vulvar melanoma decreased with 
3.2% annually (mainly due to a decrease among younger age groups) [3], whereas our 
results showed no definite trend in incidence (EAPC 0.3%, 95% CI: –2.6 to +3.4%). These 
Swedish data are, however, outdated (data up to 1984) and were based on a consecutive 
series of cases rather than a population-based sample. [3]
Relative survival
Five-year relative survival proportions of ECM subtypes, except ocular melanoma, 
were poor compared to CM (86%) and differed substantially between subsites. 
Preferably, we would have stratified for the clinical stage of disease at diagnosis in the 
survival analysis which was not possible due to low numbers of incident ECM.
Of all ECM subsites, patients with primary ocular melanoma had the best survival with 
a relative 5-year survival of 74% (95% CI: 67-81%). Estimates from the Collaborative 
Ocular Melanoma Study (COMS) [1] were slightly lower (60%), but the 5-year disease 
specific survival of 75 percent published by Chang et al. [15] is comparable. Our 
estimate may be somewhat underestimated due to the fact that we could only use 
data from 2003 until 2006 and vital status on the 1st of January 2008 resulting in 
relatively short follow-up for part of the patients with ocular melanoma in our dataset 
and hence relatively many patients being censored alive. 
Vulvar melanomas in our dataset resulted in a 5-year survival proportion of 40% (95% 
CI: 31-49%), comparable with the 50% reported by Weinstock on US data [17] .




(95%CI: 8-22%), slightly better than the overall crude 5-year survival of 6% presented 
in a Dutch case series of anorectal melanoma (63 cases, 1960-1995) [16]. Although we 
included anorectal as well as esophageal melanomas in this subsite, survival estimates 
for patients with anorectal and esophageal melanomas did not substantially differ in 
our dataset (data not shown).
Reflection
The poor survival proportions estimated for ECM could obviously reflect the often 
advanced stages in which ECM are diagnosed. However, ECM and CM also differ 
substantially in their clinicopathologic and molecular aspects. Even between 
subgroups of CM, such as acral melanoma and chronic versus non-chronic sun 
exposed melanomas, the genetic makeup and morphological features differ. [18] The 
clinical heterogeneity of melanoma can, in part, be explained by distinct sets of 
genetic alterations. Approximately 80% of melanomas in skin without chronic 
sun-induced damage contain a mutation in either BRAF or NRAS, whereas cutaneous 
melanoma arising in non-damaged skin, as well as acral and mucosal melanomas do 
not. [19] Instead, these tumors frequently display increased gene copy number of cy-
clin-dependent kinase 4 and cyclin D1. Oncogenic BRAF mutations in ocular melanoma 
are rare, if not absent, or restricted to only a subset of cells in posterior uveal 
melanomas. [20-23] However, somatic mutations in the heterotrimeric G protein 
alpha-subunit, GNAQ, are frequently observed in uveal melanoma, but rarely in other 
melanomas. [24] Mutations and/or copy number increases of receptor tyrosine kinase 
KIT have been detected in 39% of mucosal, 36% of acral, and 28% of melanomas on 
chronically sun-damaged skin. [25] These genetic changes commonly result in various 
alternative routes to MAP kinase activation and hence proliferation. However, upstream 
oncogenic mutations in BRAF, NRAS, KIT, and GNAQ will activate additional signaling 
cascades specific for that tumor type and therefore contribute to the diversity in 
melanoma biology, prognosis, and response to therapy.
Future research
Future epidemiological research on ECM should include large (international) datasets. 
This would enable researchers to stratify for clinical stage at diagnosis in survival 
analysis and therefore to study how much of the poor prognosis of ECM is due to 
delayed diagnosis. It would also allow for studying the male-to-female ratios reported 
and time trends in incidence and survival, investigate possible geographical gradients 
in comparison with CM. Ideally, these datasets would be population-based to avoid 
biases occurring from selected patient groups. Whenever possible such international 
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databases should include aspects that may explain the clinical heterogeneity, such as 
the morphological features and mutational status of an ECM. If treatment were to be 
adequately collected, the effects of targeted therapies such as imatinib for c-kit 
mutated mucosal melanomas could be studied.
Conclusion
With incidence rates for different subsites of extracutaneous melanoma ranging from 
less than 0.1 per million person-years for ECM of the lung or urinary tract until about 
10-11 per million person-years for ocular melanomas among men, ECM is a rare type 
of melanoma. Of all ECM subsites, ocular melanomas had the highest incidence (10.7 
and 8.2 per million person-years for men and women, respectively) and the best 
survival with a 5-year relative survival of 74%.  Mucosal melanomas, such as vulvar 
melanomas, were the second most frequent subsite of ECM. Five-year relative survival 
for mucosal melanomas ranged between 15 and 40% and survival for all ECM subtypes 
was worse if compared to the 86% five-year relative survival for CM. Also in contrast 
with CM, no statistically significant trends in the incidence of (subsites of) ECM were 
determined. 
Acknowledgement
We would like to thank the Netherlands Cancer Registry for providing the data for this 
study, the EORTC Melanoma group, and especially the registry clerks, without whom 
data collection would have been impossible. Furthermore, we would like to thank 






(1) Thoelke A, Willrodt S, Hauschild A, Schadendorf 
D. Primary Extracutaneous Malignant 
Melanoma: A comprehensive review with 
emphasis on treatment. Onkologie 2004, 27, 
492-499.
(2) Ross MI, Stern SJ. Mucosal melanomas. In: Balch 
CM, Houghton AN, Milton GW, Sober AJ, Soong 
S-J, editors. Cutaneous melanoma. 3rd ed. 
Philadelphia: JB Lippincott; 1998, p. 195-206.
(3) Ragnarson-Olding BK, Kanter-Lewensohn LR, 
Lagerlöf B, Nilsson BR, Ringborg UK. Malignant 
melanoma of the vulva in a nationwide, 25-year 
study of 219 Swedish female: clinical 
observations and histopathological features. 
Cancer 1999, 86, 1273-1284.
(4) Geel AN van, Bakker MA den, Kirkels W, 
Horenblas S, Kroon BBR, Wilt JHW de et al. 
Prognosis of primary penile melanoma: a series 
of 19 Dutch patients and 47 patients from 
literature. Urology 1997, 70, 143-147.
(5) Margo CE. The Collaborative Ocular Melanoma 
Study: an overview. Cancer Control 2004, 11 (5), 
304-309.
(6) McLaughlin CC, Wu XC, Jemal A, Martin HJ, 
Roche LM, Chen VW. Incidence of noncutaneous 
melanomas in the U.S. Cancer 2005, 103, 
1000-1007.
(7) Vries E de, Schouten LJ, Visser O, Eggermont 
AMM, Coebergh JWW, Working Group of 
Regional Cancer Registries. Rising trends in the 
incidence of and mortality from cutaneous 
melanoma in the Netherlands: a northwest to 
southeast gradient? Eur J Cancer 2003, 39, 
1439-1446.
(8) Siesling S, van der Aa MA, Jan W.W. Coebergh 
JWW, Pukkala E. Time-space trends in cancer 
incidence in the Netherlands in 1989–2003. Int 
J Cancer 2008, 122, 2106-2114.
(9) Parkin D, Whelan S, Ferlay J, Raymond L, Young 
J, eds. Cancer Incidence in 5 Continents, Vol. 7 
 (IARC Scientific Publication No. 143). Lyon, 
France, International Agency for Research on 
Cancer, 1997.
(10) Kim HJ, Fay MP, Feuer EJ, Midthune DN. 
Permutation tests for joinpoint regression with 
applications to cancer rates. Stat Med 2000, 19, 
335–51.
(11) Hakulinen T, Abeywickrama KH. A computer 
program package for relative survival analysis. 
Comput Programs Biomed 1985, 19, 197–207.
(12) Greenwood M. A Report on the Natural 
Duration of Cancer. London: Ministry of Health 
HMSO 1926.
(13) Peter RU, Landthaler M, Braun-Falco O. 
Extracutaneous malignant melanoma: Clinical 
aspects and biology. Hautarzt 1992, 43, 
535-541.
(14) DeMatos P, Tyler DS, Seigler HF. Malignant 
melanoma of the mucous membranes: a review 
of 119 cases. Ann Surg Oncol 1998, 5 (8), 
733-42.
(15) Chang AE, Karnell LH, Menck HR. The National 
Cancer Data Base report on cutaneous and 
noncutaneous melanoma: a summary of 84,836 
cases from the past decade. The American 
College of Surgeons Commission on Cancer 
and the American Cancer Society. Cancer 1998, 
15, 83 (8), 1664-78.
(16) Roumen RMH. Anorectal melanoma in The 
Netherlands: a report of 63 patients. Eur J Surg 
Oncol 1996, 22, 598-601.
(17) Weinstock MA. Malignant melanoma of the 
vulva and vagina in the United States: patterns 
of incidence and population-based estimates 
of survival. Am J Obstet Gynecol 1994, 171 (5), 
1225-30.
(18) Viros A, Fridlyand J, Bauer J, Lasithiotakis k, 
Garbe C, Pinkel D, Bastian BC. Improving 
melanoma classification by integrating genetic 
chapter 2
33
and  morphologic features. PloS Medicine 
2008, 5 (6), 941-952.
(19) Curtin JA, Fridlyand J, Kageshita T, Patel HN, 
Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker 
EB, LeBoit PE, Pinkel D, Bastian BC. Distinct sets 
of genetic alterations in melanoma. N Eng J 
Med 2005, 353, 2135-2147.
(20) Rimoldi D, Salvi S, Liénard D, Lejeune FJ, Speiser 
D, Zografos L Cerottini JC. Lack of BRAF 
Mutations in Uveal Melanoma. Cancer Research 
2003, 63, 5712–5715.
(21) Wong CW, Fan YS, Chan TL, Chan ASW, Ho LC, 
Ma TKF et al. BRAF and NRAS mutations are 
uncommon in melanomas arising in diverse 
internal organs. J Clin Pathol 2005, 58, 
640-644.
(22) Maat W, Kilic E, Luyten GP, de Klein A, Jager MJ, 
Gruis NA et al. Pyrophosphorolysis Detects 
B-RAF Mutations in Primary Uveal Melanoma. 
Invest Ophtamol Vis Sci 2008, 49, 23-27.
(23) Janssen CS, Sibbett R, Henriquez FL, McKay IC, 
Kemp EG and Roberts F. The T1799A point 
mutation is present in posterior uveal 
melanoma. Br J. Cancer 2008, 99, 1673-1677 .
(24) Van Raamsdonk CD, Bezrookove V, Green G, 
Bauer J, Gaugler L, O’Brien JM, Simpson EM, 
Barsch GS, Bastian BC. Frequent somatic 
mutations of GNAQ in uveal melanoma and 
blue naevi. Nature 2009, 457, 599-603.
(25) Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic 
activation of KIT in distinct subtypes of 







Burden of disease in Dutch melanoma patients, 
1989-2006
Burden of melanoma
Cynthia Holterhues, Tamar Nijsten, Els R. Koomen, Wilma Nusselder, 
Henrieke E. Karim-Kos, Esther de Vries
36
Abstract
Background: Burden of disease is a concept describing loss of health and death due to 
diseases and has not been adequately studied for melanoma. 
Patients and Methods:  Age- and gender-specific incidence data from all patients 
diagnosed with melanoma between 1989 and 2006 were obtained from the 
Netherlands Cancer Registry. Mortality numbers were extracted from the Statistics 
Netherlands database. Life tables with the probability of developing a melanoma 
were calculated per 5-year period with use of the DevCan software. The standard life 
expectancy for both men and women per 5-year age group were estimated using 
DISMOD software. The Years Lost due to Disability (YLD) and Years of Life Lost (YLL) 
due to melanoma were calculated using these life tables and life expectancies. The 
disability adjusted life years (DALY), a general measure for the burden of a disease, was 
estimated by adding YLD and YLL. 
Results: The incidence of melanoma almost doubled between 1989 and 2006 
(cumulative incidence rate increased from 1.03-1.31% to 2.02-2.11%). The burden of 
melanoma to society increased rapidly between 1989 and 2006. On average, patients 
lived 21.6-28.2 years with a melanoma diagnosis. Melanoma resulted in a loss of 
17.8-20.1 years per before the age of 95, for those that died of their melanoma. 
Conclusion: Melanoma is becoming a great burden to Dutch society. Health care 




YLD  Years Lived with Disability; the number of incident cases times the disability 
weight (0.05) times the average duration of the case until remission or 
death
AYLD  Average Years Lived with Disability; the YLD divided by the number of 
incident cases
YLL  Years of Life Lost; the number of deaths times the standard life expectancy 
at age of death
AYLL  Average Years of Life Lost; the YLL divided by the number of deaths
YLWD  Years Lived with Disease; the number of incident cases times the average 
duration of the case until remission or death
Introduction
In the past three decades the incidence of melanoma has markedly increased in 
people of European ancestry. In 2005, melanoma was the 8th most common cancer 
in males and the 5th most common cancer in females in The Netherlands (a total of 
3515 cases among 16.4 million inhabitants) (www.ikcnet.nl). De Vries et al. have 
predicted that by 2015 the number of new cases per year will exceed 4800. [1] 
Compared with most other malignancies, melanoma affects patients at a younger 
age and has relatively good survival rates for the majority of patients, which have 
improved over time due to early detection. [2-5] This implies an increasing number of 
melanoma survivors who live with a cancer diagnosis and it’s social and psychological 
effects and may utilize health care for medical and psychological reasons related to 
their melanoma history over a prolonged period of time, which can become a great 
burden for health care providers. 
Usually, the magnitude of a cancer problem is expressed in incidence and mortality 
rates and numbers. However, the magnitude of the societal problem can also be 
expressed in a quite different way using Burden of Disease concepts that measure the 
disease burden for individuals or populations. These burden of disease measures may 
be used for research purposes, public health campaigns and for the allocation of 
limited health care resources. The burden of a disease can be estimated by calculating 
the number of years of life lost (YLL), the number of years of life lived with disease 




key importance in estimating the burden of cancer types that occur in young patients 
and often have a favorable prognosis. 
Only a few studies have investigated the burden of melanoma. Brochez and colleagues 
investigated the burden of melanoma in Belgium, expressed as years of potential life 
lost and showed that in those terms, melanoma was the second most important 
cancer of all adult-onset cancers. [7] Melanoma resulted in a loss of 8 years before the 
age of 65 in males and 6 years in females. In the United States, the burden of melanoma 
has also been expressed by years of potential life lost and these rates were one of the 
highest for adult-onset cancers. [8] None of these studies evaluated changes in the 
burden over time, nor did they include the part of the population aged over 65, which 
is continuously growing in many European countries and therefore represents a 
population group which is of increasing importance.
In the Netherlands, the burden of melanoma has never been estimated by YLL, AYLL, 
YLD or DALYs. Therefore, we estimated the size of the burden of melanoma within the 
general Dutch society with these four measures using data for 1989-2006 in 4 time 
periods (1989-1991, 1992-1996, 1997-2001, and 2002-2006). 
Patients and methods
Population
Age- and gender-specific data on newly diagnosed patients with melanoma (ICD-0 
codes: C44.0-C44.9) were obtained from the Netherlands Cancer Registry, which 
collects incidence and tumor data on all newly diagnosed cancers in the Netherlands 
from the regional comprehensive cancer centers since 1989 (i.e., only first melanoma’s 
were used for this study). We used incidence data for 1989 to 2006. Annual data on 
age and gender of cancer fatalities and population composition were obtained from 
Statistics Netherlands.
Study design
To estimate the burden of melanoma, we calculated Disability Adjusted Life Years 
(DALYs) by adding the number of Years of Life Lost (abbreviated YLL) by a person as a 
consequence of premature death due to melanoma plus the number of years of lived 
with disability (abbreviated YLD) caused by melanoma by a person . According to 
Murray et al., one DALY represents the loss of one year of life lived in full health. The 
sum of these DALYs across the population, or the burden of disease, can be thought 
of as “a measure of the gap between the current health status and an ideal health 
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situation in which the entire population lives to an advanced age, free of disease and 
disability”. [9] 
Statistical methods
All analyses were performed for 5-year periods (except for period 1989-1991, as data 
was only available for 18 years) and stratified for gender. The cumulative incidence 
was calculated per 5-year age group by dividing the number of patients with 
melanoma by the total population without melanoma and totaling these results. 
European standardized incidence rates (ESR) were then calculated by multiplying the 
incidence rates with standard European population data (http://seer.cancer.gov/
stdpopulations/). To calculate the probability of a person being newly diagnosed with 
a melanoma during the 5-year period we used the life table method, which unlike 
cumulative incidence data, takes into account that the cause of death of a melanoma 
patient might not be related to melanoma. Also, this method calculates the probability 
of being diagnosed with melanoma and dying from it, for people without a history of 
melanoma. The DevCan software program, which was developed by the National 
Cancer Institute in the United States, was used to calculate these probabilities. [10] For 
these calculations the following assumptions were made:
(a) The incidence of melanoma is constant in each 5-year period;
(b) The probability of death not being caused by melanoma is the same for melanoma 
patients as for people without a history of melanoma;
(c) The data obtained from the Netherlands Cancer Registry and Statistics Netherlands 
were for 5-year age groups. To raise the accuracy, DevCan divides these age groups 
into 10 periods of 6 months. In each 6 month age group the incidence and mortality 
rates increase in 10 equal steps and are constant in each 6 month age group. This 
leads to an exponential decrease with age in each 6-month age group. The numbers 
of patients at risk and the probability of being diagnosed with a melanoma can 
therefore be more accurately calculated;
(d) All melanoma specific mortalities are registered with the Netherlands Cancer 
Registry.
To estimate YLD, we multiplied the number of incident cases by the average duration 
a patient lives with melanoma in The Netherlands and a weighing factor, determined 
by the World Health Organization (WHO), that reflects the impact of melanoma on 
health related quality of life on a scale from 0 (perfect health) to 1 (dead). Melanoma 
disease duration was estimated using DISMOD. [11] YLLs were calculated using the 




multiplied by the standard life expectancy in the general population at the age which 
death occurs as estimated by a standard life table. [6] The average years of life lost 
(AYLL) were calculated by dividing the YLL by the number of melanoma deaths. DALYs 
were calculated as the sum of the YLL due to premature mortality in the population 
and the YLD for incident cases of the health condition (i.e., melanoma). To calculate 
the actual years a patient lives with their melanoma, the years lived with disease were 
calculated (YLWD). Therefore, we multiplied the number of melanoma patients with 
their life expectancy at time of diagnosis.
Results
Incidence and mortality
Between 1989 and 1991, an average of 1603 Dutch people were newly diagnosed with 
melanoma per year (Table 1A and 1B); this increased to 3171 individuals per year in the 
period 2002-2006. Of all newly diagnosed melanoma patients, 43.3% was male (ESR 
15.9 per 100,000 person-years) and 56.7% was female (ESR 19.5 per 100 000 
person-years) (Table 1). Cumulative incidence rates almost doubled in men (1.03% in 
1989-1991 to 2.02% in 2002-2006) and increased from 1.31% to 2.13% in the same time 
period for females. 
Age at diagnosis of melanoma increased over time; patients diagnosed in 1989-1991 
were predominantly diagnosed at an age of 35-50 years (both males and females) 
whereas people newly diagnosed with melanoma between 2002-2006 were often 
older (men: mainly 55-70 years, women: mainly 40-60 years) (Fig. 1). 
Mortality slowly increased from 182 to 333 males and 182 to 257 females by 2002-2006. 
Cumulative mortality rates also doubled up to 0.61 for males and up to 0.40% for 
females. An increase of melanoma mortality was particularly observed for men aged 
55 to 65 and females >75 years.
Probability of being diagnosed with melanoma and to die from it
DevCan produced estimations of the probability for a person to develop a melanoma 
and the probability of dying from a melanoma in a certain age group (Table 2). 
In 2006, male newborns had an overall chance of 1 in 62 to develop a melanoma, for 
female newborn this was 1 in 50. A man of 40 years old had a probability of 1.1% to 
develop a melanoma before the age of 75 years. For females, this probability was 
1.2%. Men were more likely to die of a melanoma; the probability for a 40-year old 








































































































































































































































































































































































































































































































































































































































Table 2  Percentage of men and women who develop melanoma by a  
specific age (Z), given cancer free at current age (Y), 2006
Men
5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 95+
0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.2 0.3 0.4 0.5 0.7 0.9 1.1 1.3 1.4 1.5 1.6 1.6 1.6
5 0.0 0.0 0.0 0.0 0.1 0.1 0.2 0.3 0.4 0.5 0.7 0.9 1.1 1.3 1.4 1.5 1.6 1.6 1.6
10 0.0 0.0 0.0 0.1 0.1 0.2 0.3 0.4 0.5 0.7 0.9 1.1 1.3 1.4 1.5 1.6 1.6 1.6
15 0.0 0.0 0.1 0.1 0.2 0.3 0.4 0.5 0.7 0.9 1.1 1.3 1.4 1.5 1.6 1.6 1.6
20 0.0 0.1 0.1 0.2 0.3 0.4 0.5 0.7 0.9 1.1 1.3 1.4 1.5 1.6 1.6 1.6
25 0.0 0.1 0.2 0.3 0.4 0.5 0.7 0.9 1.1 1.2 1.4 1.5 1.5 1.6 1.6
30 0.1 0.1 0.2 0.3 0.5 0.6 0.8 1.0 1.2 1.4 1.5 1.5 1.5 1.5
35 0.1 0.2 0.3 0.4 0.6 0.8 1.0 1.2 1.3 1.4 1.5 1.5 1.5
40 0.1 0.2 0.3 0.5 0.7 0.9 1.1 1.2 1.3 1.4 1.4 1.4
45 0.1 0.2 0.4 0.6 0.8 1.0 1.1 1.3 1.3 1.3 1.3
50 0.1 0.3 0.5 0.7 0.9 1.1 1.2 1.2 1.2 1.2
55 0.2 0.4 0.6 0.8 0.9 1.1 1.1 1.1 1.1
60 0.2 0.5 0.6 0.8 0.9 1.0 1.0 1.0
65 0.2 0.4 0.6 0.7 0.8 0.8 0.8
70 0.2 0.4 0.5 0.6 0.6 0.6
75 0.2 0.4 0.5 0.5 0.5
80 0.2 0.3 0.3 0.4




5 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 95+
0 0.0 0.0 0.0 0.0 0.1 0.1 0.2 0.3 0.5 0.7 0.8 1.0 1.2 1.3 1.5 1.7 1.8 1.9 2.0 2.0
5 0.0 0.0 0.0 0.1 0.1 0.2 0.3 0.5 0.7 0.8 1.0 1.2 1.3 1.5 1.7 1.8 1.9 2.0 2.0
10 0.0 0.0 0.1 0.1 0.2 0.3 0.5 0.7 0.8 1.0 1.2 1.3 1.5 1.7 1.8 1.9 2.0 2.0
15 0.0 0.1 0.1 0.2 0.3 0.5 0.7 0.8 1.0 1.2 1.3 1.5 1.7 1.8 1.9 2.0 2.0
20 0.0 0.1 0.2 0.3 0.5 0.6 0.8 1.0 1.2 1.3 1.5 1.7 1.8 1.9 2.0 2.0
25 0.1 0.2 0.3 0.4 0.6 0.8 0.9 1.1 1.3 1.5 1.7 1.8 1.9 1.9 1.9
30 0.1 0.2 0.4 0.5 0.7 0.9 1.1 1.2 1.4 1.6 1.7 1.8 1.9 1.9
35 0.1 0.3 0.4 0.6 0.8 1.0 1.1 1.3 1.5 1.6 1.7 1.8 1.8
40 0.1 0.3 0.5 0.7 0.8 1.0 1.2 1.4 1.5 1.6 1.7 1.7
45 0.2 0.3 0.5 0.7 0.9 1.1 1.3 1.4 1.5 1.5 1.5
50 0.2 0.3 0.5 0.7 0.9 1.1 1.2 1.3 1.4 1.4
55 0.2 0.4 0.6 0.8 1.0 1.1 1.2 1.2 1.2
60 0.2 0.4 0.6 0.8 0.9 1.0 1.1 1.1
65 0.2 0.4 0.6 0.8 0.8 0.9 0.9
70 0.2 0.5 0.6 0.7 0.7 0.7
75 0.2 0.4 0.5 0.6 0.6
80 0.2 0.3 0.4 0.4




probability had decreased to 0.1%. Corresponding probabilities for females were 0.2% 
for a woman aged 40 and 0.1% for women aged 65. 
Years Lived with Disability (YLD)
The average number of years that a male melanoma patient lived with melanoma, 
adjusted for disability due to melanoma (disability weight: 0.05) decreased from 1.16 
years in 1989-1991 to 1.08 years in 2002-2006. Females had a higher AYLD: 1.46 years in 
1989-1991 and 1.41 years in 2002-2006 compared to men (Table 1).
In contrast to the slight decreases in AYLD, the total YLD of melanoma in the general 
population rapidly increased for both sexes. For men, the YLD increased from 10 to 18 
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Figure 2  Years Lived with Disease (YLWD) and Average Years Lived 
with Disease (AYLWD) by year of diagnosis
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years per 100 000 inhabitants (1989 to 2006) and from 19 (1989-1991) to 31 years 
(2002-2006) for women. 
Years lived with disease (YLWD)
The Average Years Lived with Disease (AYLWD), without adjustments for disability, 
decreased for both sexes, from 23.2 to 21.6 years for men and 29.1 to 28.2 years for 
females (Table 1 and Fig. 2). The total years of life with melanoma in the general 
population has rapidly increased. For men a total of 365.8 life-years lived with 
melanoma per 100 000 inhabitants in 2002-2006 was estimated compared to 198.7 
years in 1989-1991. For women the YLWD rose from 373.3 to 616.9 (Fig. 2).
burden of melanoma
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Figure 3  Years of live lost (YLL) and Average Years of Life Lost (AYLL) 
by years of diagnosis
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Years of life lost (YLL)
In 1989-1991, a male melanoma patient lost on average 19.3 life-years (AYLL) which 
decreased to 17.8 years in 2002-2006. For females the AYLL also decreased from 22.4 to 
20.1 years. However, the total YLL to melanoma in the Dutch population almost tripled 
for men and more than doubled for females. In 2002-2006 the total YLL for melanoma 
for females was 63 years per 100 000 inhabitants (Table 1). Analyses of YLL per 5-year 
age group showed that the YLL of men aged 50-65 years increased most notably over 
1989 to 2006. For women the YLL increased especially for women aged 50 to 80 years 
and aged 35-39 (data not shown).
Disability Adjusted Life Years (DALY)
The burden of melanoma as estimated by DALYs per 100 000 inhabitants also increased 
over 1989-2006 (men: 57 to 92 and females: 73 to 94 inhabitants). The increase over 
1989-2006 was steeper for men than women, but the increase of the DALYs appeared 
comparable for both sexes in the 2002-2006.
Discussion
The high YLD and YLLs for melanoma patients emphasize the impact of melanoma on 
(specialized) health care and the increasing melanoma incidence suggests that this 
will further rise in the future. YLD and YLWD emphasize the importance of burden-of-
disease-concept measures as they estimate the number of years patients might be in 
need for additional (psychological) care. This is in contrast to incidence rates, which 
only mark the increasing number of patients that will require treatment and follow-up. 
The high estimates of the burden of disease concepts also illustrate that there is profit 
to be gained in the management of melanoma patients and its survivors. 
Increases in mortality of melanoma in the Netherlands were modest and much smaller 
than those observed for incidence; the burden of melanoma in terms of YLL the 
Netherlands increased considerably between 1989 and 2006 up to an YLL of 20. 
This high YLL is due to the fact that many patients are middle aged when diagnosed 
with their first melanoma and that most of those who die of melanoma die fairly soon 
after the diagnosis. Our results cannot be directly compared to the few other studies 
looking at burden of disease measure for melanoma, as the other studies used a 
cut-off value of 65 years. [7, 8] Although a cut-off of value of 65-years to calculate YLL 
is commonly used for the determination of premature mortality in an occupational 
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population to assess loss of productivity, analyses unrestricted by age are needed to 
assess the duration that people are affected by a disease. For this reason, we decided 
not to use this age cut-off. Moreover, most melanoma patients are diagnosed at an 
age of 55-65 years and most patients have a 5-10 year survival rate of >90%. [2] Dutch 
melanoma patients live to be on average 75 years of age, a cut-off value of 65 years 
would underestimate the YLL with about 10 years. 
AYLL is calculated as YLL divided by the number of melanoma deaths. However, if you 
include all melanoma patients (dead or alive) and not just those who died of 
melanoma, melanoma was associated with a mean loss of approximately three years 
of life for an individual melanoma patient between 2002 and 2006. Although the 
numbers of life years lost per patient and life years lived with disease are slightly 
decreasing over time, reflecting improving survival and a slightly increasing age at 
diagnosis on average, the burden of melanoma to society has increased rapidly 
between 1989 and 2006, mostly due to increases in incidence rates.
The lifetime probability of an individual melanoma patient to die from their melanoma 
was low, implying that the majority of melanoma patients will live many years after 
their diagnosis (YLD for males: 18 per 100 000 men and for females: 31 per 100 000 
women). The disability weight used in calculating the YLD was 0.05 [12], which is 
based on the prognosis of melanoma patients. Previous research has shown that 
more than a third of melanoma patients experience considerable levels of anxiety, 
mainly during diagnosis and treatment. [13] Moreover, patients’ concerns may be very 
specific (e.g., in relation to UV exposure) and not be fully captured by generic 
health-related quality of life instruments. For example, a cross-sectional study among 
more than 500 melanoma survivors up to 10 years of diagnosis showed that most 
melanoma patients reported less frequent holidays to sunny destination compared to 
the times before their diagnosis and they also reported more anxiety for the deleterious 
effect of UV-light on their skin and more use of more protective measures, including 
practicing less hobbies outside and more protective clothing. Moreover, a proportion 
of melanoma survivors reported difficulty obtaining a life insurance or mortgage. 
These findings suggest that the YLD might not fully capture the actual years patients 
are living with their melanoma and its consequences; the disability weight should 
probably be raised to capture the true impact of melanoma on quality of life. Therefore, 
we calculated the Years Lived with Disease (YLWD), not taking the disability weight 
into account, as well and observed that a melanoma patient on average has to live 20 




To our knowledge we are the first to fully report on the burden of disease concepts in 
melanoma and to estimate the probability of being diagnosed with melanoma for the 
Dutch population. Dutch females had a probability of 1.6% of developing a melanoma 
during their lifetime, for males this was 1.2%. Calculating the probability of developing 
a cancer by estimating the cumulative risk does not take other comorbidities into 
account, nor the probability of dying from a disease other than melanoma. Therefore 
we calculated the risk of developing melanoma by the life table method using the 
DevCan program that calculates the probability of developing a melanoma and the 
probability of someone dying from it. These calculations were based on a hypothetical 
cohort and the estimated results of the DevCan analyses were confirmed by a standard 
life table. A life table makes it possible to answer simple questions of patients 
pertaining to their survival or the chance of developing a melanoma in the general 
population in certain age and sex groups. A persons’ life time risk of developing a 
melanoma seemed relatively low, however the Dutch Cancer Society has shown 
before that this probability almost equals that of the chance for a women to develop 
ovarian cancer, non-Hodgkin lymphoma or lymphoma. [10] 
 
Conclusion
In conclusion, the burden of melanoma is high and is increasing suggesting a need 
for adjusting health care policies to cope with this burden. Our research also shows 
that, even though a disease may be relatively rare and/or has a good prognosis, it can 
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Chemopreventive drugs and their pharmacological 
mechanism of action, efficacy, safety and tolerability




Background: In most countries, despite sun protection measures, the burden of 
melanoma is increasing. Therefore, melanoma chemoprevention may be a promising 
approach for high risk target populations. However, it is unclear which candidate 
drugs for chemoprevention of cutaneous melanoma have the potential to be useful 
and safe. Our aim was to systematically search the literature to identify candidate 
drugs for melanoma chemoprevention and to critically review their possible 
mechanism(s) of action, the existing evidence for their chemopreventive efficacy, as 
well as their safety and tolerability.
Methods: We conducted a systematic literature search in Medline, Embase, Web of 
Science and The Cochrane Library. Subsequently, we conducted a qualitative review 
on the potential chemopreventive drugs for which human data from clinical trials or 
observational research were available.
Results: Considerable evidence exists to suggest that melanoma development may be 
prevented or delayed by aspirin, NSAIDs and statins. Less evidence is available for 
other potential chemopreventive drugs, such as fibrates, retinoids, imiquimod, 
 dehydroepiandrosterone, and acetaminophen. Long-term safety data in suitable 
chemopreventive dosages are not available for most these candidate drugs. 
Conclusion: Although considerable preclinical evidence is available for aspirin, NSAIDs, 
and statins, in our opinion, there are still not sufficient (clinical) efficacy data and 
long-term safety data in chemopreventive dosages to perform a formal risk-benefit 





AJCC  American Joint Committee on Cancer
AK  actinic keratoses
APL  acute promyelogenous leukemia
APPROVe Adenomatous Polyp Prevention on Vioxx
BCC  basal cell carcinoma
CDK  cyclin-dependent kinase
CDKI  cyclin-dependent kinase inhibitors
CI  confidence interval
CK  creatinine kinase
CNS  central nervous system
COX  cyclooxygenase
DAIS  Diabetes Atherosclerosis Intervention Study
DHEA  dehydroepiandrosterone
EMEA  European Medicines Agency
ERK  extra cellular signal-regulated kinase
FAMMM  Familial atypical multiple mole-melanoma
FDA  Food and Drug Administration
FFP  farnesyl pyrophosphate
FIELD  Fenofibrate Intervention and Event Lowering in Diabetes
FTI  farnesyl transferase inhibitors
GFR  glomerular filtration rate
GGP  geranylgeranyl pyrophosphate
GGTI  geranyl geranyl transferase inhibitors
GI  gastrointestinal
GPRD   General Practitioners’ Research Database
GSH  glutathione
G-6-PD  glucose-6-Phosphate Dehydrogenase
HMG-CoA 3-hydroxy-3-methylglutaryl coenzyme-A
HR  hazard ratio
IFN  interferon
IL  interleukin
LFA1  lymphocyte function-associated antigen 1
LM  lentigo maligna




LSR  local skin reactions
MC1R  melanocortin-1 receptor
MEK  mitogen-activated protein kinase
NAC  N-acetylcysteine
NF-κB  nuclear factor-κB
NMSC  nonmelanoma skin cancer
NSAID   non-steroidal anti-inflammatory drug
OR  odds ratio
OTC  over the counter
PPAR   peroxisome proliferator-activated receptor
RA  retinoid acid
RAR  retinoic acid receptor
RCT  randomized clinical trial
ROS  reactive oxygen species
RR  relative risk
RXR  retinoid X receptor
SCC  squamous cell carcinoma
SCID  severe combined immunodeficient mice
SIR  standardized incidence rate
Th1  T helper cell type 1
TLR  toll-like receptor
TNF  tumor necrosis factor
TXA2  thromboxane A2
VIN  vaginal intraepithelial neoplasia
VITAL  Vitamins and Lifestyle
WHO  World Health Organization
Introduction
Melanoma incidence is rising steadily in most European countries as well as in Australia 
and in the US. [1] Although melanoma of the skin is usually diagnosed while confined to 
the local site / skin (AJCC stage I or II) and melanoma mortality rates seem to be stabilizing 
or even slightly decreasing in countries with high melanoma incidence rates [2], safe and 
effective treatment options for advanced stages of melanoma are still lacking making 
the prognosis for patients with advanced melanoma (AJCC stage III or IV) poor. [3] 
Thus, the burden of cutaneous melanoma is increasing. [4] Consequently, melanoma 
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prevention has high potential benefit and is increasingly the focus in melanoma research. 
Cancer prevention can be categorized into: 1) primary prevention of the initial cancer; 
2) secondary prevention of invasive cancer in patients with premalignant conditions; 
and 3) tertiary prevention of second primary cancers. [5] As preventive measures for 
melanoma several strategies, mostly sun protection measures, have been suggested. 
However, even in countries where comprehensive sun protection programs have 
been in place for more than a decade and the use of sun screen is widely promoted, 
the incidence of melanoma is still rising. [6] Therefore, alternative approaches should 
also be considered and one of these alternatives could be chemoprevention. 
Several definitions for the term ‘chemoprevention’ have been proposed. The term 
was first used in 1976 by Sporn and colleagues. They defined ‘chemoprevention’ as 
‘the use of natural or synthetic drugs to reverse, suppress, or prevent premalignant 
molecular or histological lesions from progressing to invasive cancer’. This also 
includes preventing in situ lesions to progress to invasive melanoma. [7]
Over the last decades, chemoprevention of cancer in general has gained interest and 
has resulted in a few first successes, such as tamoxifen in breast cancer, the first Food 
and Drug Administration (FDA)-approved chemopreventive drug, celecoxib for 
familial adenomatous polyposis and diclofenac and imiquimod for actinic keratosis. 
[8] Despite this ‘proof of principle’, adverse results appeared in chemoprevention trials 
hampering progress in cancer chemoprevention. For example, beta carotene has 
been associated with an increase rather than a reduction of the incidence of lung 
cancers [9], oral alfa-tocopherol supplementation resulted in an excess second primary 
head and neck cancers [10], and rofecoxib (Vioxx®, Merck) was withdrawn from the 
market after thrombotic cardiovascular events were observed in the APPROVe 
(Adenomatous Polyp Prevention on Vioxx) trial. [11] Indeed, these examples highlight 
the need for sound preliminary evidence of chemopreventive efficacy and also for a 
critical review of safety issues and the assessment of the overall risk-benefit ratio.
Specifically, chemoprevention of melanoma has gained interest in the recent years. 
Several epidemiological studies and clinical trials from different clinical settings may 
provide evidence for the chemopreventive efficacy of cutaneous melanoma. Associations 
between drug use and melanoma incidence from observational studies may help to test 
the hypotheses on chemopreventive activity. Clinical trials that may be of interest include: 
1) cancer chemoprevention trials among healthy high risk individuals, 2) clinical trials in 
the non-oncology setting if incident cancers including melanomas were recorded as a 
secondary end point, 3) surrogate marker trials and 4) adjuvant melanoma trials. [8] Due to 
this broad range of sources of evidence, we believe the form of a true systematic review 




The aim of this qualitative review was to systematically search the literature to identify 
candidate drugs for chemoprevention of cutaneous melanoma, to critically review 
their possible mechanisms of action and to summarize the existing evidence for their 
chemopreventive efficacy, as well as safety and tolerability.
Methods
We define chemoprevention of melanoma as the use of natural or synthetic drugs to 
prevent, reverse, suppress or delay premalignant lesions from progressing into invasive 
cutaneous melanoma. This includes preventing in situ lesions from progressing to 
invasive melanoma.
Literature search
We searched Medline, Embase, Web of Science and The Cochrane Library (January 1st 
1991 until April 12th 2008) using the search terms ‘melanoma’, ‘chemoprevention’, 
‘melanoma/prevention and control’, ‘chemoprophylaxis’, ‘chemicals and drugs 
category’ and ‘drug’. The complete search strings can be issued on request. Only 
manuscripts in English were included.
We selected scientific papers on drugs aimed for chemoprevention of cutaneous 
melanoma. Papers were excluded if they did not include cutaneous melanoma, did 
not meet the definition of chemoprevention, if there was no drug intervention (e.g., a 
non-pharmacological intervention) or if it was a non-scientific publication type. 
Papers identified through cross referencing were as yet included if the studies 
concerned clinical trials or epidemiological research (meta-analyses, cohort studies or 
case control studies) generating evidence for chemopreventive activity in humans.
Drugs
We restricted our review to drugs for which human data were available from 
(randomized) clinical trials (RCT) or observational research, (i.e., meta-analyses, cohort 





Our initial literature search resulted in 1158 references from Medline, Embase, Web of 
Science and The Cochrane Library (Fig. 1). In total, 1112 of these references were 
excluded;  619 because they focused on a non-pharmacological intervention (such as 
sun protection measures, vaccines or counseling), 152 because they did not include 
cutaneous melanoma, 300 because they did not meet the definition of chemo-
prevention, 32 because they were of one the following publication types: editorial, 
case report, letter or commentary, 4 because they were not published in English and 
5 because no studies with human data were available on this (group of) drug(s). 
Additionally, 131 papers were identified through cross referencing, were as yet 
included.
General remarks
Potential Chemopreventive Drug Classes
The potential chemopreventive drugs that resulted from our systematic literature 
search were: non-steroidal anti-inflammatory drugs (NSAIDs, including selective 
 cyclooxygenase-2-inhibitors and aspirin), statins, fibrates, retinoids, imiquimod, 
 dehydroepiandrosterone (DHEA), acetaminophen, apomine, capsaicin, urokinase 
receptor antagonists, N-acetylcysteine, farnesyl transferase inhibitors (FTIs), and 
geranyl geranyl transferase inhibitors (GGTIs).
For apomine, capsaicin, urokinase receptor antagonists, N-acetylcysteine, FTIs, GGTIs, 
we did not find any human efficacy data on melanoma chemoprevention from 
observational research or clinical trials. Consequently, this review focused on NSAIDs, 
statins, fibrates, retinoids, imiquimod, DHEA, and acetaminophen.
Prerequisites
Prerequisites and requirements for research in melanoma chemoprevention and for a 
valid melanoma strategy have been defined earlier by Demierre, Nathanson, Merlino 
and Sondak (Table 1). [8;12-14]  
From the clinical viewpoint, it requires: 
(1) chemopreventive drug efficacy; 
(2) acceptable safety & tolerability; 
(3) effectiveness in clinical practice, and 





Figure 1  
Medline, Embase, Cochrane Library
& ISI Web of Knowledge 
Search terms:
melanoma, chemoprevention, chemoprophylaxis,
melanoma/prevention and control, chemicals and
drugs category and agent
Period: 1st of Jan 1991 to 12th of Apr 2008
Total exluded: 1112 (100%)
- non-pharmacological intervention 619 (55.7%)
- not cutaneous melanoma 152 (13.7%)
- definition of chemoprevention 300 (27.0%)
- publication type 32 (2.9%)
- paper not in English 4 (0.4%)









not according to definition of
chemoprevention: 300 excluded
paper not in English:
4 excluded
publication type not appropiate:
32 excluded
No human data available:
5 excluded
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Ad 1. Obviously, a strong scientific rationale and proven efficacy of the chemo-
preventive drug is required. As Demierre and Nathason described earlier [8], efficacy 
should be demonstrated in in vitro research, validated animal models, such as 
transgenic murine models. Additionally, efficacy must be observed in humans at 
(high) risk of a (second) invasive melanoma. Human efficacy data should include well 
designed phase I and II chemoprevention studies, and finally full-scale phase III trials. 
[15-17] These phase III trials should be designed to include endpoints to evaluate 
both expected and unexpected adverse events to allow full evaluation of the 
risk- benefit ratio. 
Ad 2. In melanoma chemoprevention, healthy individuals at high risk of developing 
melanoma are the target population. Thus, there is no direct therapeutic effect. 
Moreover, chemopreventive drugs are frequently given for at least 5 years during 
which adherence to the drug regimen must be maintained. Little-to-no toxicity is, 
therefore, an absolute prerequisite to ensure both long-term safety and compliance. 
chemoprevention of melanoma
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Table 1 Prerequisites for progress in cancer chemoprevention research
Prerequisite Requirements
Elements of a strong 
scientific rationale
(i) Determination of the underlying molecular mechanisms of 
carcinogenesis
(ii) Discovery of genetic markers that identify the early events in  
the carcinogenic process
(iii) Availability of drugs that can target the molecular mechanism  
of carcinogenesis
Long-term safety of 
candidate drugs
(i) Availability of long-term human safety data
(ii) Availability of animal tumor models that permit preclinical trials 
of evaluation of drug toxicity
Critical elements of a 
rigorous chemoprevention 
clinical trial design
(i) Availability of animal tumor models that permit preclinical trials 
of evaluation of drug efficacy
(ii) Compilation of data from epidemiologic, basic science, and 
cancer research literature that can yield candidate prevention 
drugs for in-vitro or in-vivo testing
(iii) Availability of molecular or histologic markers of the 
carcinogenic process to be used as endpoints and to obviate  
the need for prolonged and costly trials
(iv) Access to defined groups at very high risk for the disease
From: Demierre MF. What about chemoprevention for melanoma? Curr Opin Oncol 2006 Mar;18(2):180-4.
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A well-established safety profile may exist for drugs already marketed for alternative 
indications. However, higher drug dosages and longer treatment durations may be 
required for (melanoma) chemoprevention. Moreover, the distribution of risk factors 
for potential adverse events may differ between the target populations of these 
indications. Thus, a drug that appears to be safe for one indication may not be 
considered sufficiently safe for the use in cancer chemoprevention.  Ideally, a chemo-
preventive drug would have additional major health benefits on high-prevalent 
diseases or health outcomes.
Ad 3. Efficacious drugs may not be effective in clinical practice. A possible explanation 
is lack of adherence to the drug regimen. Important prerequisites for adherence are 
likely to be little-to-no toxicity of the drug and a sufficiently motivated target 
population 
Ad 4. It should be clear-cut for which patients the chemopreventive drug would be 
indicated. Because the absolute risk of getting a melanoma is small, chemoprevention 
should be targeted at patients at high risk of developing an invasive melanoma. 
To define the high risk populations that would benefit from chemoprevention, 
validated prediction models are warranted. 
Target population
Well-established risk factors for melanoma are history of sun burns, older age, clinical 
atypical nevi, prior melanoma, family history of melanoma (FAMMM) or mutational 
status (CDKN2A/p16INK4A mutations, CDK4 mutations, MC1R variants), and phenotypic 
traits, such as fair skin type, freckles, light eye color and photosensitivity. Among 
these, the validated and strongest predictors of melanoma incidence are likely to be 
suitable for the selection of a chemoprevention target population. 
Possible high risk populations to target could be patients with prior melanoma, 
individuals with a family history of melanoma and clinical atypical nevi, individuals 
with multiple clinical atypical nevi and/or patients with atypical mole syndrome. 
[18-21] Future advances in research on validated prediction models and biomarkers, 
will hopefully increase possibilities for more specific definitions of high risk groups on 
whom melanoma chemoprevention should target.
Non-steroidal Anti-inflammatory Drugs
NSAIDs are traditionally prescribed because of their analgesic, antipyretic and anti-
inflammatory effects. NSAIDs inhibit the cyclooxygenase (COX) enzyme reversibly 
leading to reduced synthesis of prostaglandins and thromboxane. 
Based upon their pharmacological effects, NSAIDs can be subdivided in three groups. 
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First, traditional NSAIDs, e.g. diclofenac, naproxen, sulindac, indomethacin, and 
piroxicam, reversibly inhibit both the constitutively expressed COX-1 and the inducible 
COX-2 isoform of the enzyme (i.e, nonselective COX-inhibitors). Secondly, the selective 
COX-2-inhibitors, e.g. celecoxib, etoricoxib, and rofecoxib, in regular doses, inhibit only 
the COX-2-isoform. Aspirin forms the third group because it irreversibly inactivates 
COX-1 by acetylating a serine residue in its active site and, therefore, reduces 
thromboxane A2 (TXA2) in platelets. Due to the fact that platelets cannot synthesize 
new enzyme, TXA2 synthesis does not recover until new platelets arise after 7-10 days.  
 
Mechanism of action
Overexpression of COX, especially COX-2, has been demonstrated in human cancer 
cells of several tumor types. Based upon these observations, the COX-pathway is 
hypothesized to be involved in carcinogenesis. Indeed, the ras oncogene stimulates 
and p53, a tumor suppressor, down-regulates COX-2 expression. Moreover, COX-2 
expression also seems to enhance metastatic potential of colon cancer cells and may 
be involved in resistance to chemotherapeutic drugs. [22] Thus, the primary potential 
mechanism of action of NSAIDs in cancer chemoprevention is considered to be COX 
inhibition (Table 2). [23] 
Increased COX-2 expression has been noted in the majority, but not all, melanoma cell 
lines. [24-26] Denkert et al. showed that five melanoma cell lines (A375, MeWo, 
SK-Mel-13, SK-Mel-28, and IGR-37) and 26 out of 28 (93%) patient derived primary 
melanomas showed COX-2 expression, whereas benign nevi (n=4) and epithelial cells 
were negative. After introduction of a COX-2 blocking agent, NS-398, cell line growth 
and invasive potential were inhibited. [24] Similarly, in a series of 101 ex vivo melanoma, 
96 (95%) showed COX-2 expression. More importantly, in this study, the level of COX-2 
expression was also negatively associated with disease-specific survival (p = 0.046). [25] 
Increasing evidence suggests that NSAIDs inhibit tumor growth and invasion [24;27;28] 
and can induce apoptosis [28;29]. Roh and colleagues demonstrated an inhibitory 
effect of both celecoxib and indomethacin on melanoma cell growth in a murine 
B16F10 melanoma model. [30] Also, in a study of human A-375 melanoma cells, 
incubations for 72-hour of 50 and 100 µM of celecoxib showed reduced proliferation. 
Additionally, in a Toxilight TU-cytotoxicity assay, 100 µM celecoxib was toxic to the 
cancer cells. In this experiment, indomethacin (240 and 480 µM) also inhibited cell 
proliferation, but was only slightly toxic. Neither aspirin nor piroxicam exhibited 
cytostatic or cytotoxic effects. Thus, of the tested NSAIDs (aspirin, indomethacin, 
piroxicam and celecoxib), only celecoxib and indomethacin reduced proliferation. 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































that the growth inhibitory effect of celecoxib cannot be explained solely by its 
COX-inhibitory activity. [27] 
Additional COX-independent pathways have also been suggested in other cancer 
types. [31;32] Numerous possible targets, such as lipoxygenase metabolism (ALOX15) 
[33], the proapoptopic gene PAWR [34], the anti-apoptopic gene BCL2L1 [35], activation 
of caspases {36], the activation of p38 MAP kinase [37], release of mitochondrial 
cytochrome c [38], and activation of the ceramide pathway [39], have been suggested 
to be involved. These COX-independent pathways, however, need further study. 
For example, some investigators have suggested that only higher aspirin doses lead 
to these COX-independent molecular mechanisms. [40] Moreover, aspirin may have 
additional anticancer pathways as compared to other NSAIDs, such as inhibition of 
thrombocyte-aggregation [41], NF-κB, DNA-repair systems, apoptosis, oxidative stress 
or mitochondrial calcium uptake [31].
Evidence for efficacy in humans
Although some studies were promising, conflicting results exist on NSAIDs in 
melanoma prevention (Table 3). Initially, Harris et al. reported a small case control 
study (110 cases, 609 controls, all females) in which regular NSAID use showed a 
significantly decreased relative risk (RR) of melanoma (RR = 0.45 with a 95% confidence 
interval (CI) of 0.22 to 0.95). With increasing NSAID use, melanoma risk further 
decreased (p-linear trend <0.05). Estimates for daily use of aspirin were similar 
(RR = 0.55). [42]
Subsequently, in a small retrospective cohort study of 83 melanoma patients, users of 
NSAIDs or COX-2-inhibitors, as compared to nonusers, had a lower incidence of new 
melanoma, recurrence, and metastasis (combined end point; odds ratio (OR) of 0.08, 
95% CI = 0.01-0.77). [43] However, we believe guarantee-time bias may have importantly 
influenced these results. In explanation, NSAID exposure in this study was defined as 
any prescription after first diagnosis of melanoma and prior to development of a new 
melanoma, a recurrence or metastatic lesion. Consequently, patients with longer 
survival are more likely to be categorized as a NSAID user due to the simple fact that 
their follow-up period was longer. More complex study designs and statistical analyses 
could have prevented such bias. [44] 
In a secondary analysis of the Women’s Health Study, Cook and colleagues studied 
low-dose aspirin (100 mg every other day) versus placebo. Among the 39,885 women 
included in this RCT, low-dose aspirin was not associated with melanoma risk 
(RR = 0.97, 95% CI = 0.70-1.36). [45] Similar results were obtained in a secondary analysis 
of the Cancer Prevention Study II Nutrition Cohort. Although long-term adult-strength 
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aspirin (≥325 mg for ≥5 years) was associated with lower overall cancer incidence in 
men and a non-statistically significant lower overall cancer incidence was observed in 
women, melanoma incidence was not reduced (current daily use, ≥5 years: RR = 1.15, 
95% CI = 0.83-1.59, <5 years: RR = 0.99, 95% CI = 0.79-1.25). [46]
Recently, in the Vitamins and Lifestyle (VITAL) cohort study, Asgari et al. examined the 
association between NSAID use and melanoma risk. Among 63,809 men and women, 
during a 10 year follow-up period, 349 patients with incident melanomas were 
identified including 157 in situ melanomas. Use of any NSAID for at least 4 days per 
week as compared to nonuse, did not seem to reduce the melanoma hazard rate (HR; 
HR = 1.12, 95% CI = 0.84-1.48). Similar results were obtained for any NSAID excluding 
low-dose aspirin (HR = 1.03, 95% CI = 0.74-1.43), for regular- or extra-strength aspirin 
(HR = 1.10, 95% CI = 0.76-1.58), and for nonaspirin NSAIDs (HR = 1.22, 95% CI = 0.75-1.99). 
Additionally, NSAID use was not associated with tumor invasion (p-interaction = 0.38), 
tumor thickness (p-linear trend = 0.98), or risk of metastasis (HR = 1.09, 95% CI = 
0.32-3.62). [47]
In a large population-based case control study of our group including 1,318 patients 
with invasive melanoma and 6,786 controls, incident melanoma was not associated 
with aspirin use (OR = 0.92, 95% CI = 0.76-1.12) or non-aspirin NSAID use (OR = 1.10, 
95% CI = 0.97-1.24). However, continuous use of low-dose aspirin was associated with 
a significant reduction of melanoma risk in women (OR = 0.54, 95% CI = 0.30-0.99) but 
not in men (OR = 1.01, 95% CI = 0.69-1.47). A significant linear trend (p = 0.04) from non 
use, non-continuous use, to continuous use was observed in women. [48]
Recently, the Harvard Cancer Center performed a case control study among 400 
melanoma patients and 600 matched community based controls. After adjusting for 
confounders, use of any NSAID, at least once weekly for more than 5 years as compared 
to use for less than 2 years, was associated with an adjusted OR of 0.55 (95% CI = 
0.42-0.77). For aspirin and non-aspirin NSAIDs the odds ratios were comparable (OR = 
0.51, 95% CI = 0.35-0.75 and OR = 0.64, 95% CI = 0.46-0.89, respectively). If NSAID use 
was defined as any use versus no use, the results were somewhat less pronounced 
(personal communication). 
Specific studies on selective COX-2 inhibitors are lacking. Duke and colleagues have 
planned a Cochrane review ‘COX-inhibitors in the prevention of melanoma’. [49] 
If enough eligible trials will be pursued, this review will likely provide more insight. 
In summary, due to heterogeneity in study design (ascertainment and definition of 
exposure, type of NSAID, dose, duration, patterns of use, drug adherence, study 
population etc), conflicting results and the limited number of studies, the efficacy of 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































   






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































and animal studies, however, are promising. A pivotal unresolved problem 
is the definition of the temporal and dose-response cause effect 
relationships between NSAID use and incident invasive melanoma. Thus, 
additional experimental and observational research is warranted, 
particularly on required dosages and duration.
Safety, Tolerability & Compliance
Side effects of NSAIDs are gastrointestinal (GI) complaints, such as nausea, 
vomiting, dyspepsia (10-20%), diarrhea, duodenal or gastric ulcers (10-30%), 
sometimes even leading to GI bleedings or perforation (± 2%). [50] 
In addition, skin reactions, cardiovascular and cerebrovascular events, and 
decreases in renal function also occur. Rare, but serious, side effects are 
bone marrow disturbances and hepatotoxicity. The prevalence of GI 
related side effects differs substantially between several traditional 
NSAIDs, being less pronounced for aspirin and diclofenac compared to 
piroxicam. 
COX-2-inhibitors have been developed to selectively inhibit COX-2 and 
thus to reduce side effects related to COX-1-inhibition, most importantly 
duodenal and gastric ulcers. Indeed, duodenal or gastric ulcers are less 
prevalent (± 2%) for this class of NSAIDs. [50] However, thrombotic 
cardiovascular events observed in the APPROVe trial, a chemopreventive 
trial in which patients with a history of colorectal adenomas were 
randomized to receive rofecoxib or placebo [11], have raised safety 
concerns regarding the risk-benefit ratio of COX-2-inhibitors in cancer 
chemoprevention. [51;52] Subsequent epidemiological studies have 
suggested that these events are also associated with traditional NSAIDs, 
such as ibuprofen or diclofenac. [53;54] In these studies, naproxen, as an 
exception, is associated with a reduced cardiovascular event rate. [53;54]
To prevent GI ulcers and bleeds, additional interventions such as 
Helicobacter pylori eradication and concomitant use of a proton pump 
inhibitor to the chemopreventive strategy could be considered, but this 
introduces new adverse effects and additional costs. Currently, in the 
AspECT trial a combination of aspirin plus proton pump inhibitor is studied 
for the chemopreventive activity on cancer among patients with Barret’s 
esophagus. [55] 
Aspirin may also cause bleeding through inhibition of thrombocyte- 









































































































































































   






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































excess of cardiovascular events and actually has the advantage of protection against 
cardiovascular disease. Moreover, aspirin may have additional chemopreventive 
effects as compared to other COX-inhibitors. [31;41] Nevertheless, due to the lack of 
definitive evidence on (differences in) efficacy, required dosages and duration, it is 
too early to claim aspirin as the preferential NSAID for cancer chemoprevention.
Conclusion Non-steroidal Anti-inflammatory Drugs
In vitro studies demonstrate COX-2-expression in melanoma and suggest effects of 
NSAIDs on growth inhibition, invasiveness and apoptosis. COX independent pathways, 
however, may also be involved in these anti-tumor effects. These pathways should be 
further investigated in order to disentangle dose-response relationships and identify 
the most promising NSAIDs. Although promising efficacy data were shown in other 
cancers, NSAIDs have yet to demonstrate sufficiently convincing evidence for 
efficacious melanoma chemoprevention. Convincing evidence is lacking and 
comparing the conflicting results of the limited number of published studies is 
challenging due to heterogeneity in study design and uncertainties in temporal and 
dose-response relationships. Moreover, concerns over the long-term safety of COX-2 
inhibitors and NSAIDs have tempered the enthusiasm for their use in chemopreven-
tion. Therefore, if sufficient data on efficacious drug dosages and temporal cause 
effect relationships become available, formal risk-benefit analyses should be 
performed on different scenarios of chemopreventive strategies.
Statins
Statins, or 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase inhibitors, 
are widely prescribed to reduce cholesterol levels aiming to prevent cardiovascular 
events. This drug class consists of atorvastatin, cerivastatin, fluvastatin, lovastatin, 
mevastatin, simvastatin, pitavastin, pravastatin, and rosuvastatin. Cerivastatin, 
however, has been withdrawn from the market in 2001 due to reports of 
rhabdomyolysis, especially with concomitant use of gemfibrozil. 
Statins differ in several aspects. For example, lovastatin, simvastatin, and pravastatin 
were originally derived from fungi, whereas atorvastatin and fluvastatin are 
synthetically derived. Additionally, some statins are prodrugs, e.g. simvastatin and 
lovastatin, and have a closed lactone ring that is converted by carboxyesterases to the 
open-ring acid form that inhibits HMG-CoA reductase. [56] 
Historically, an inverse association between cholesterol and the incidence of (smoking-
related) cancers has been observed [57], suggesting a link between low cholesterol and 
cancer. In addition, lovastatin and gemfibrozil were shown to promote development 
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of liver cancer in rodents. [58] However, subsequent research demonstrated paradoxical 
results suggesting decreased cancer incidences with use of lipid-lowering drugs.
Mechanism of action
The putative mechanism of action for both the cholesterol lowering and anticancer 
effects of statins is considered to be inhibition of HMG-CoA reductase, an enzyme 
upstream in the mevalonate biosynthetic pathway. Inhibition of HMG-CoA reductase 
leads to reduced synthesis of mevalonate and its downstream products.  Farnesylpyro-
phosphate (FPP), a C15-moiety, is one of these downstream products and is the precursor 
of both geranylpyrophosphate (GPP), a C20-moiety, and cholesterol. FPP and GPP are 
also referred to as isoprenoids. They are essential for the activation of a variety of 
intracellular proteins. In this process, called (iso)prenylation, farnesyl or geranylgeranyl-
moieties are coupled to the protein, resulting in a farnesylated or geranylgeranylated 
protein. These reactions are catalyzed by farnesyltransferase and geranylgeranyl-
transferase, respectively. Several proteins involved in signaling are dependent on 
prenylation for their activity, such as ras, rho, nuclear lamins, transducin c, rhodopsin 
kinase, and G proteins. Consequently, statins lead to pleiotropic effects. [59]
Several of the proteins dependent on posttranslational prenylation, either farnesylation 
or geranylgeranylation, such as ras, rhoA and rhoC, have been linked to cancer 
pathogenesis. For example, ras is a known oncogene and ~30% of human tumors 
harbor ras mutations resulting in aberrant ras activity which is dependent on 
prenylation. [59] Specifically, N-ras and B-raf mutations are observed in ~30% and 
~60% of melanomas, respectively. [60] N-ras and B-raf mutations both result in 
activation of the so-called Ras/Raf/MEK/ERK signaling pathway. [13] Raf which is 
downstream of ras, however, does not require prenylation to achieve full biological 
activity. [61] Still, in melanomas with a B-raf mutation, but no ras mutation, possible 
antineoplastic effects may be mediated through for instance rhoA or rhoC. Potential 
chemopreventive agents that may interfere in this pathway are: statins, FTIs, GGTIs, 
apomine, and perillyl alcohol. [13;59]
Furthermore, the rho family is involved in signaling and regulation of cell  differentiation 
and proliferation. [62;63] Moreover, high-throughput screens for transcriptionally 
regulated targets involved in metastasis have shown that rhoC overexpression is 
strongly associated with the metastatic potential of inoculated melanoma in mice. [64] 
Indeed, in vitro and animal melanoma studies show a potentially chemopreventive 
activity of statins. More specifically, anti-tumor effects exerted by statins have been 
shown to include: 1) inhibition of tumor growth, 2) induction of apoptosis, 3) reduce 




Ad 1. Lovastatin, mevastatin, and simvastatin, but not pravastatin, reduced tumor 
growth of human melanoma cell lines HT144, M14, and SK-MEL-28 in vitro with IC50 
values between 0.8 and 2.1 µM. [65] 
Ad 2. Jani et al. observed induction of apoptosis by lovastatin in murine B16F10 
melanoma cells through a geranylation-specific mechanism [66]; Additionally, 
increased apoptosis, in a dose-dependent manner, was observed in human M14 cells 
after 72-h incubations (4-8 µM) of lovastatin, mevastatin, and simvastatin. [65] 
In human A375 melanoma cells, Shellman et al. also showed induced apoptosis by 
lovastatin. [67] Interestingly, Shellman and colleagues also performed add back 
experiments showing that supplementation of GPP, but not FPP, blocked the apoptotic 
effect of lovastatin which indicates apoptosis must involve proteins dependent on 
geranylgeranylation. [67]
Ad 3. Atorvastatin (1-3 µM) reduced invasiveness of A375M, CHL, SK-MEL-28 and WM 
166-4 melanoma cells in an experiment performed by Collisson and colleagues. [68] 
In this experiment, atorvastatin (4 dd 10 mg/kg orally also reduced metastasis of A375M 
melanocytes in severe combined immunodeficient (SCID) mice. [68] Likewise, Jani et al. 
showed reduced metastasis by lovastatin and simvastatin in murine B16F10 melanoma 
cells. [66] Experiments reported by Glynn et al. also showed decreased invasiveness by 
lovastatin, mevastatin, and simvastatin on HT144, M14, and SK-MEL-28 cells. [65]
Ad 4. Lovastatin (2-12.5 µM) exhibited a concentration-dependent pro-angiogenic 
influence on A375M and G361 cells in an angiogenesis model with a co-culture of 
HUVEC cells (human umbilical vein endothelial cells) and human diploid fibroblasts 
(HDF). [69] However, in nonmelanoma cells, some studies with low-dosed statins have 
suggested increased angiogenesis. [59]
Some statin-mediated effects appear to be completely independent of HMG-CoA 
reductase and cholesterol lowering. E.g., some experiments with statins in the closed 
ring form, which do not inhibit HMG-CoA reductase, do show in vitro anticancer 
effects. [70] Further investigations on these cholesterol-independent pathways are 
needed. 
Examples of the cholesterol-independent pathways that have been suggested are: 
	binding to the leukocyte function antigen-1 (LFA1) which has an important role in 
leukocyte migration and T-cell activation. [71]
	inhibition of the proteasome [70;72;73] which could for instance account for effects 
on the cyclin-dependent kinase inhibitors (CDKIs) p21 and p27 [74], and increased 
fibrinolytic activity [75]. 
	altered membrane receptor function due to changes in membrane fluidity caused 
by cholesterol depletion. For example, melanocortin receptor (MC1R) [76] or 
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insulin-like growth factor receptor function [77-79], both of which are involved in 
melanocyte and melanoma growth.
In addition, some investigators suggest direct toxic effects of cholesterol lowering are 
involved. [80] Malignant cells metabolize cholesterol differently and, therefore, may 
be more sensitive. However, the evidence for this hypothesis is (very) limited.
Although in vitro and animal experiments in general show promising results, some 
critical issues should be mentioned. E.g., pravastatin, the only hydrophilic statin, does 
not exhibit clear chemopreventive effects in most experiments. Moreover, most 
studies have used statins at serum concentrations and dosages that exceed doses 
applied for the treatment of hypercholesterolemia. Lovastatin dosed at ~1 mg/kg/
day, for example, yields steady-state serum concentrations of 0.15–0.3 µM. [81] Often 
tumor cell lines were only sensitive to lovastatin at higher concentrations, e.g. 1.0-12.5 
µM. [65;67;69]
Interestingly, some agents may have synergistic chemopreventive action together 
with statins. For example, d-γ-tocotrienol (5 µM) together with lovastatin (1 µM) totally 
blocked cell growth, whereas lovastatin (12%) and d-γ-tocotrienol (8%) individually 
showed only limited growth inhibition in these concentrations. [82] Other agents that 
have been suggested in combination with statins are NSAIDs, bisphosphonates, 
GGTIs, phosphoinositide 3-kinase (PI3K) inhibitors, CDKI, MEK inhibitors, and tyrosine 
kinase inhibitors. [59]
Evidence for efficacy in humans 
Originally, RCTs testing statins for cardiovascular disease were the first to report on a 
possible decreased cancer incidence with statin use. [56] Ironically, concerns about 
increased cancer incidence with low cholesterol led to inclusion of cancer as a 
secondary safety outcome in these trials. Since then, a large number of meta-analyses 
and observational studies investigating statin use and cancer incidence were 
performed. 
Additionally, two abstracts appeared on a preliminary case control study comparing 
the use of statins among 74 melanoma cases and age, gender and race-matched 
controls. Preliminary results in this study were promising (OR = 0.55, p = 0.11). [83;84] 
However, to the best of our knowledge, the results of the final analysis have not been 
published.
Shortly after these reports, two large population-based studies reported decreased 
incidences of cancer. [85;86] Our group performed a large observational study (3129 




decrease in cancer incidence (OR = 0.80, 95% CI = 0.66-0.96). The association was 
more pronounced with prolonged use (statin use ≥ 4 yrs, OR = 0.64, 95% CI = 0.44-0.93). 
[85] Subsequently, Poynter and colleagues reported, among 1953 patients with 
colorectal cancer and 2015 controls, a significantly reduced risk of colorectal cancer 
(OR = 0.50, 95% CI = 0.40-0.63) with the use of statins (≥ 5 years versus nonusers). [86]
However, since then, research has shown conflicting, and generally disappointing 
results for statin use as a general cancer chemopreventive agents. [87-89] Moreover, 
some meta-analyses suggest differences in the associations between statin use and 
incident cases of different cancer types. [89]
Dellavalle et al. performed a formal Cochrane review on specifically incident 
melanomas as a secondary outcome of RCTs with primary cardiovascular outcomes. 
In this Cochrane review, 6 statin RCTs providing data on incident melanomas were 
included. Overall, 59 melanomas occurred among the participants randomized to 
statin treatment and 67 incident melanomas occurred in the placebo groups. 
The resulting odds ratio was 0.90 (95% CI = 0.56-1.44) indicating no statistically 
significant difference. However, due to the low numbers of incident melanomas, a 
(clinically relevant) association cannot be excluded. More importantly, three of the 
included RCTs studied pravastatin which may have, as in vitro studies have suggested, 
diminished chemopreventive activity. Interestingly, a subgroup analysis by type of 
statin showed a reduced melanoma incidence for lovastatin (OR = 0.52, 95% 
CI = 0.27-0.99). This analysis is, however, importantly limited by the fact that there was 
only one trial with lovastatin. The authors’ final conclusions were “… does not exclude 
the possibility that these drugs (i.e., statins and fibrates) prevent melanoma …”. [90]
Additional RCTs have been published since the Cochrane review. In a meta-analysis 
published in The Lancet, the Cholesterol Treatment Trialists’ (CTT) Collaborators 
included 14 RCTs of statins and found no evidence for a decreased cancer incidence 
(RR = 1.00, 95% CI = 0.95-1.06). In a sub analysis among the trials for which melanoma 
incidence was available, there was also no statistically significant change in melanoma 
incidence (RR = 1.03, 95% CI = 0.71-1.50). [88] Another six similar meta-analyses have 
reported on melanoma incidence with estimates for melanoma incidence ranging 
from 0.84 to 1.5. [87;89;91-93] However, they mainly included the same RCTs.
Table 2 presents an overview of RCTs in cardiovascular disease comparing statins with 
placebo, no treatment or usual care and from which melanoma incidence was 
reported.
These clinical trials, however, have several disadvantages which include small numbers 
of incident melanomas, relatively short follow-up for melanoma incidence (ranging 
from 3 to 6 years) and, generally, of being a retrospective reviews of cardiovascular 
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trials in which the design was not adapted for the analysis for melanoma incidence. 
For instance, they would not be stratified for factors, we would recognize now as 
critical to melanoma development, such as the family history of melanoma, skin type, 
presence or absence of clinically atypical nevi et cetera. Therefore, retrospective 
analyses on these trials will always be of limited value.
The number of epidemiological studies reporting on the potential association 
between incident melanomas and statin use is very limited. Kaye and Jick reported a 
case-control study on cancer and statin use that performed in the GPRD (General 
Practitioners’ Research Database) in the UK. In a sub analysis within this study, they 
observed a relative risk of 2.5 (95% CI = 0.78-7.3) among 79 incident melanoma cases 
between 1990 and 2002 and up to five controls matched on year of birth, sex, general 
practice, year of entry into the GPRD, and index date. The follow-up in this study 
ranged between 3 and 13.7 years with a median of 6.4 years. [94] However, the number 
of melanoma cases in this study was relatively small as reflected in the wide confidence 
interval.
In a larger case-control study, we also reported on statin use and melanoma incidence. 
In this study, we used data from the Dutch national pathological database and from 
PHARMO, a pharmacy database covering ~25% of the Netherlands. Among 1,318 
melanoma cases (primary diagnosis 1991-2004) and 6,786 controls matched on 
gender, date of birth and geographic region, we could not validate an association 
between statin use (≥½ y) and melanoma incidence (OR = 0.98, 95% CI = 0.78-1.2). 
However, the Breslow’s depth of the melanomas was reduced among statin users 
(–19%, 95% CI = –33% to –2.3%). In a pre-specified stratified analysis across gender, we 
observed that the difference was nonsignificant among women (–4.8%, 95% 
CI = –29.6% to 28.8%), and more pronounced in men only (–27.8%, 95% CI = –43.7% to 
–7.4%). The lack of an association on melanoma incidence in our study could be due 
to the relative short follow-up which was, by design, was 3 years for all individuals. 
{Koomen, 2007 1003 /id}
Noteworthy, in the PRIME study, a prospective cohort study, Gardette et al. recently 
observed a reduced cancer mortality, although statistically non-significant, among 
dyslipidemic men using statins as compared to untreated dyslipidemic men 
(OR = 0.41, 95% CI = 0.19-1.06). [96]
These observational studies, however, have the disadvantage of being non-randomized 
and observational for which (residual) confounding cannot be excluded. Moreover, 
risk factors critical to melanoma development, such as the family history of melanoma, 
skin type, presence or absence of clinically atypical nevi et cetera, will often not be 




In summary, results of secondary analyses of cardiovascular trials and of observational 
research on the potential relation between statin use and incident melanomas are 
conflicting. Both these RCTs as well as the epidemiological studies have some 
important limitations such as potential residual confounding, and small numbers of 
incident melanomas and thus limited power. Therefore, efficacy of statins in melanoma 
chemoprevention can neither be validated nor excluded.
Safety, Tolerability & Compliance
In cancer chemoprevention literature, the excellent safety profile of statins in 
cardiovascular disease has often been pointed out. [12-14;97] Indeed, statins have 
relatively mild side effects in the doses used to prevent cardiovascular event. The 
most prominent side effects of statins are the so-called statin-related myopathy (i.e., 
muscle pain and weakness), elevated creatinine kinase (CK) levels and as a rare but 
life-threatening side effect, rhabdomyolysis. In RCTs the incidence of myopathy was 
1.5-5%, whereas estimates in observational research indicated 5-10%. [98] In spite of 
the fact that the majority of side effects are mild, persistence to statins in the use for 
cardiovascular disease is poor with only ~25% of patients still compliant 5 years after 
starting statin therapy. [99] To ensure compliance and persistence, an excellent 
tolerability is needed.
In cancer chemoprevention, higher day doses may be required. In such high doses, 
the tolerability of statins has been proven to be limited due to dose-dependent side 
effects such as myopathy. In phase I /II trials for cancer treatment significant responses 
were only achieved with >25 mg/kg/day doses leading to dose-limiting toxicities 
(DLTs) including myalgia, muscle weakness, elevated CK activity, anorexia, ulcerative 
lesions, rhabdomyolysis, nausea, diarrhea, and fatigue. With very high statin doses, 
cardiomyopathy may even be a side effect. [100] In the trials mentioned, among 
others cycled dosing with 3-4 week intervals was introduced to prevent DLTs. [81;101] 
For melanoma chemoprevention, it remains uncertain which doses are required. 
However, since cell lines studies often indicate cytostatic rather than cytotoxic effects 
at achievable in vivo statin concentrations, continuous dosing is likely to be required. [102]
Numerous risk factors for statin-related myopathy have been described. [98] Among 
these risk factors is using high statin doses which, as mentioned before, may be 
required for chemopreventive effects. Some of the risk factors may be circumventable, 
such as excessive physical activity, perioperative period and concomitant use of drugs 
or grapefruit juice which precipitate drug interactions associated with elevated serum 
statin levels. For atorvastatin, lovastatin, cerivastatin or simvastatin, these are CYP3A4 
inhibitors and for fluvastatin these would be CYP2C9 inhibitors. [98] Avoiding the risk 
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factor, temporary cessation of statin therapy or drug alternatives for the inhibitors can 
be options in these cases. Non-preventable risk factors, such as advanced age, female 
gender, (relative) renal insufficiency, hypothyroidism, alcoholism or (family) history of 
myopathy or CK elevation [98], should be considered as special subgroups in formal 
risk-benefit analyses. Some of the non-preventable risk factors might be considered 
contraindications for statin therapy, e.g., (relative) renal insufficiency.
The causal mechanism of statin-related myopathy is not entirely unraveled. Among 
the proposed mechanism is depletion of ubiquinone (also referred to as coenzyme 
Q10). Ubiquinone, a side-product in the mevalonate pathway, is widely used as a 
non-drug ‘over the counter’ (OTC) anti-aging agent, but studies on its long-term 
safety are sparse. Concomitant use of ubiquinone may, however, prove to be a good 
candidate to increase statins’ tolerability. Indeed, Thibault and colleagues have used 
adding Q10 to lovastatin therapy for doses 30 mg/kg/day as a strategy to prevent 
statin-related myopathy and increase tolerability. From these preliminary data, this 
strategy seems to be promising. [81]
Further research is needed to explore the precise mechanisms involved in statin-related 
myopathy and, after required statin doses have been established, to determine the 
long-term safety of this chemopreventive strategy. 
In summary, long-term safety data for low dose statins is excellent, but may be 
less favorable for higher doses that are likely to be required for chemoprevention 
of melanoma. Development of a chemopreventive strategy including risk factors 
for statin-related myopathy and preventive measures may ameliorate the risk-benefit 
ratio.
Conclusion Statins
Statins inhibit HMG-CoA reductase leading to inhibition of isoprenylation of several 
proteins involved in melanoma development and progression, such as ras, rhoA and 
rhoC, and which are dependent on this posttranslational prenylation. HMG-CoA 
independent pathways may, however, also be involved. Experiments have shown 
anti-tumor effects of statins to include: 1) inhibition of tumor growth, 2) induction of 
apoptosis, 3) reduce invasiveness and metastasis, and 4) effects on angiogenesis. 
These in vitro and animal experiments show promising results. However, concentrations 
and dosages used in these experiments often exceed doses applied for the treatment 
of hypercholesterolemia. Additionally, chemopreventive activity may depend on 
which statin is used (e.g., lovastatin > pravastatin). 
Up to now, the results of secondary analyses on cardiovascular trials and observational 




such as lack of power, relatively short follow-up, low doses and imperfections in study 
designs. Thus, the promising results observed in preclinical experiments can neither 
be validated nor excluded. 
Although, long-term safety data for low dose statins are excellent, they may be less 
favorable for higher doses that are likely to be required for melanoma chemopreven-
tion. Development of a chemopreventive strategy including risk factors for 
statin-related myopathy and possible preventive measures, such as adding 
ubiquitinone to statin therapy, may ameliorate the risk-benefit ratio. First, however, 
efficacy in humans should be sufficiently proven.
Further studies on the involved pathways and possible cross links with other pathways, 
cholesterol-independent pathways, dependence of efficacy on melanoma mutational 
status, required dosages, possible differential effects between statins, and the 
temporal and dose-response cause effect relationships are required.
Fibrates
Fibrates are used as lipid-lowering therapy to prevent cardiovascular events. This drug 
class consists of bezafibrate, clofibrate, ciprofibrate, etofibrate, fenofibrate, gemfibrozil, 
simfibrate, and ronifibrate. The hypothesized mechanism by which fibrates alter lipid 
metabolism is thought to be peroxisome proliferators activated receptor-α (PPAR-α) 
agonism [80], which stimulates the oxidation of fatty acids. 
Mechanism of action
The interest in a possible association between use of fibrates and cancer has been 
raised by three observations. First, ecological research showed an increased cancer 
incidence with low cholesterol. [57] Secondly, gemfibrozil promoted the development 
of liver cancer in rodents. [58] Thirdly, decreased cancer incidences have been reported 
in RCTs testing lipid-powering drugs for cardiovascular disease. [56] 
The molecular mechanisms underlying potential chemopreventive properties of 
fibrates are not clearly defined. Several mechanisms have been hypothesized. For 
example, some authors believe that direct toxic effects of cholesterol lowering on 
melanoma cells may be responsible. In explanation, cholesterol lowering may have 
differential effects in malignant cells and normal cells because cancerous cells 
metabolize cholesterol differently. [80] The possible relationship between cholesterol 
and cancer are, however, poorly understood.
An alternative hypothesis concerns PPAR-α or PPAR-γ agonism by fibrates which is 
assumed to mediate growth inhibition and apoptosis. [103-105] Grabacka and 
colleagues demonstrated inhibition of migration by fenofibrate in a murine B16F10 
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and a human SkMell88 melanoma cell line. These effects were reversed by a PPAR 
inhibitor. The authors suggested PPAR-α is involved. However, in an in vitro study of 
Mössner et al. PPAR-γ specific agonists, such as rosiglitazone, inhibited cell proliferation 
in four melanoma cell lines dose-dependently, whereas a specific agonist of PPAR-α 
receptor had no such effect. [104] Therefore, some researchers believe PPAR-γ agonism 
is involved in the chemopreventive effects of fibrates on melanoma. To test the 
hypothesis that PPAR-γ is important for the risk of melanoma development, Mössner 
and colleagues also investigated the possibility that variations in the gene encoding 
PPAR-γ influence melanoma risk. In two independent case-control studies with in 
total 832 melanoma cases and 790 controls, they studied two gene variants 
(P12A[rs1801282] and C161T [rs3856806]). In one study, cases, compared to controls, 
were more likely to be a homozygous carrier of a *T allele of the C161T polymorphism 
in exon 6 of PPAR-γ (6.0 versus 2.0%; p <0.01). After adjusting for melanoma risk factors, 
such as skin type and nevus count, the association was still significant (OR = 5.2, 95% 
CI = 1.7-16.0). In the second case-control study, however, this finding could not be 
replicated. They finally concluded that the investigated PPAR-γ polymorphisms are 
not likely to constitute a significant risk factor for melanoma risk among German 
Caucasians. [106] These conflicting results, however, warrant further study. 
Alongside with growth inhibition and apoptosis, fibrates may also have antimetastatic 
effects. Grabacka et al. showed that hamsters with allograft melanoma cells and 
treated with oral fenofibrate developed significantly fewer metastatic lung foci 
compared to controls. [107] 
Evidence for efficacy in humans
In the Cochrane review by Dellavalle and colleagues, seven fibrate trials provided data 
on incident melanomas. In five of these RCTs, incident melanomas were diagnosed. 
Although there was an overall 42% reduction in melanoma incidence with use of 
fibric-acid derivatives (OR = 0.58, 95% CI = 0.19-1.82), this reduction was not statistically 
significant. Subgroup analyses by gender, trial funding, or type of fibrate, failed to 
show statistically significant differences in melanoma outcomes. [90] The value of 
these subgroup analyses is, however, limited due to small numbers.
In a meta-analysis that also included RCTs with a shorter duration (≥ ½ year in stead of 
≥ 4 years), Freeman et al., reported an overall odds ratio of 0.45 (95% CI = 0.20-1.01). [92] 
Most of the included trials, however, were also included in the Cochrane review. 
Additionally, for these clinical trials several disadvantages apply which were mentioned 
earlier (see statins – efficacy in humans).




studying fibrates have been published that reported the number of incident 
melanomas. 
Some observational studies have focused on fibric-acid derivatives and cancer 
incidence. For instance, Poynter et al. published a case-control study among 1953 
cases with colorectal cancer and 2015 controls. However, in this study, cases did not 
use fibrates more often than controls (OR = 1.08, 95% CI = 0.59-2.01). [86]
Epidemiological studies on fibrates and, specifically, melanoma incidence are thus far 
not available. Some epidemiological studies on statins and cancer or melanoma did, 
however, include a drug group of ‘other lipid-lowering drugs’ but this also includes 
bile acid-binding resins and nicotinic acid and its derivatives. {Graaf, 2004 1398 /
id;Koomen, 2007 1003 /id} Moreover, recently Gardette and colleagues demonstrated 
in the PRIME study that cancer mortality among dyslipidemic men using fibrates is 
about half the cancer mortality among untreated dyslipidemic men (OR = 0.52, 95% 
CI = 0.28-0.97). [96]
In conclusion, although secondary analyses of cardiovascular trials with fibric-acid 
derivatives in two available meta-analyses have been promising, data from 
observational research or new clinical trials are largely lacking. The lack of such new 
subsequent studies is likely to be a reflection of the diminished interest in fibrates as 
lipid-lowering therapy. 
Safety, Tolerability & Compliance
Over the last four decades, both clinical experience and large long-term RCTs in the 
cardiovascular setting have provided safety data on gemfibrozil, fenofibrate, 
bezafibrate, and ciprofibrate. Side effects related to fibric-acid derivatives include 
abdominal pain, dyspepsia, myopathy, myalgia, elevated CK levels, rhabdomyolysis, 
reversible increases in serum creatinine and urea, and cholelithiasis. Venous thrombosis, 
pulmonary emboli, and increases in homocysteine levels (clinical relevance uncertain) 
have also been reported. [108]
Myopathy, myalgia, elevated CK levels, and rhabdomyolysis are consistently reported 
with the use of fibric-acid derivatives, both in monotherapy as well as in combination 
with statins. Although rare, these side effects, especially rhabdomyolysis, are among 
the most serious safety risks of fibrate exposure. Both rhabdomyolysis and other 
muscle symptoms occur more frequently with gemfibrozil (~3.7 per 10,000 person 
years, 95% CI = 0.8-11) than with fenofibrate (~0 per 10,000 person years, 95% CI = 
0-15). The mechanism of fibrate-related myotoxicity is not entirely unraveled, but the 
risk seems to be increased for patients with diabetes, renal failure, advanced age, 
hypothyroidism, and most importantly with concomitant use of statins. [108] Notorious 
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is the concomitant use of gemfibrozil with cerivastatin or fluvastatin. Gemfibrozil 
precipitates a drug-drug interaction leading to increased exposure of these statins 
metabolized via CYP2C8/9, which in turn has been shown to be related to an incidence 
rate of rhabdomyolysis of ~1,000 per 10,000 person years. [108] Due to reports of 
rhabdomyolysis, with concomitant use of gemfibrozil, cerivastatin was withdrawn 
from the market in 2001. 
Increases in serum creatinine levels have been observed with fenofibrate, bezafibrate, 
ciprofibrate, and, less commonly, gemfibrozil. Both an increased production of 
creatinine as well as a reversible decrease in glomerular filtration rate (GFR) has been 
postulated as the molecular mechanism behind this side effect. [108] Several studies, 
however, did not show decreased renal function nor an increased incidence of renal 
failure. Moreover, in patients without impaired renal function, creatinine elevations 
are reversible upon discontinuation of the fibrate. In patients with preexistent renal 
dysfunction, however, fibrates should be used cautiously in adjusted doses. [108;109] 
Fibrates appear to be lithogenic meaning that they increase the cholesterol saturation 
in the bile and may cause gallbladder disease. Risk factors for coronary artery disease 
are, however, also risk factors for gallbladder disease. Epidemiologic studies comparing 
the incidence of gallbladder disease with and without fibrate therapy are, therefore, 
likely to overestimate the incidence of this side effect. Nevertheless, this side effect 
has been validated with trial data [108] and should be considered a relatively rare but 
potentially serious side effect. 
In the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, use of 
fenofibrate, compared to placebo, seemed to be associated with slight increases in 
the incidence of deep venous thrombosis (1.4 versus 1.0%), and pulmonary emboli (1.1 
versus 0.7%). [109] Whether these findings indicate true side effects or if they are 
artifacts due to multiple simultaneous comparisons in this dataset remains under 
debate. [108;109]
A number of potential health benefits related to use of fibrates has been demonstrated 
or suggested. For example, clofibrate has been shown to reduce myocardial infarctions, 
for example in the Coronary Drug Project and a WHO trial. In this latter study, however, 
clofibrate, compared to placebo, was reported to be associated with a significant 
increase in overall mortality. Subsequent analyses have demonstrated that the 
increase was artificially caused by the study design which resulted in a biased 
follow-up of the participants randomized to clofibrate. [109] Nevertheless, analyses of 
cardiovascular, cancer-related and overall mortality within the target population 
should be part of any chemoprevention trials since these would be essential to assess 




An additional potential health benefit was observed in the FIELD trial. Among diabetes 
patients, less progression of albuminuria was observed with fenofibrate use. [110] 
Within the Diabetes Atherosclerosis Intervention Study (DAIS) a reduction in proteinuria 
in the fenofibrate group was reported as well. [109]
Overall, the safety profile of fibrates is good if used for lipid-lowering as an alternative for, 
or additional to, statins. However, the required doses of fibrates as a melanoma chemo-
preventive drug are unclear and long-term data on overall mortality rates and rare side 
effects are limited. These data would be essential for formal risk-benefit ratio analyses.
Conclusion Fibrates
Despite the promising results in two meta-analyses, the evidence for efficacy of 
fibrates in melanoma or cancer chemoprevention is inconclusive. Additionally, a valid 
molecular mechanism for the antineoplastic effects of fibric-acid derivatives has not 
been sufficiently described so far. Thus, further research on the molecular mechanisms 
behind and required dosing for the potential chemopreventive effects of fibrates on 
melanoma is warranted and the efficacy of fibrates in melanoma chemoprevention 
cannot be validated yet. Subsequently, long-term safety and mortality data would be 
required to assess the risk-benefit balance for melanoma chemopreventive strategies 
which include the use of fibrates.
Retinoids (Vitamin A and derivatives)
The group of the so-called retinoids includes vitamin A and its derivatives. Analogs 
are either naturally occurring or synthetically derived. First generation retinoids 
include vitamin A (all-trans retinol), tretinoin (all-trans retinoic acid), and isotretinoin 
(9-cis retinoic acid). Acitretin and etretinate belong to the 2nd generation retinoids, 
whereas adapalene, bexarotene, and tazarotene are examples of 3rd generation 
retinoids. 
Retinoids are in use as acne treatment or anti-aging agent, but may also be used for 
several other indications, such as acute promyelogenous leukemia (APL). [80;111] 
Natural retinoids are also present in dietary sources, and are involved in several 
physiological processes among which vision, embryonic development, and regulation 
of growth and cell differentiation. [112] 
Mechanism of action
Retinoids are thought to exert most of their effects by binding to retinoid acid 
receptors (RAR) and retinoid X receptors (RXR) in the cellular nuclei leading to altered 
gene transcription. [112;113] Different genes encode the α, β, and γ receptors which in 
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turn have two (RAR-α, RAR-γ) or four (RAR-β) splice variants. Tretinoin binds and 
activates only the RAR receptors, whereas isotretinoin is both a RAR and RXR agonist. 
[112] Rexinoids, 3rd generation retinoids, selectively bind to RXR which is hypothesized 
to be especially involved in proapoptotic effects. One of these agents, bexarotene, 
has been approved by the FDA for cutaneous T-cell lymphoma. [13] Because melanoma 
is known to be relatively resistant to apoptosis, retinoids and rexinoids, in particular, 
may also be interesting candidates for melanoma chemoprevention.
Chemopreventive effects exerted by retinoids/rexinoids may include: 1) inhibition of 
tumor growth, 2) promotes cell differentiation, 3) induction of apoptosis, 4) proangio-
genetic effects, and 5) reduced invasiveness and metastasis.
Ad 1. Tretinoin markedly reduced cell growth of B16 murine melanoma cells at a 
concentration of 10-7 M. [114] Additionally, mice treated with vitamin A before being 
inoculated with murine melanoma cells had significantly decreased tumor growth 
compared with controls. [115] Moreover, CD437, a synthetic RAR-γ selective retinoid, 
inhibited the cell growth in vitro of three human melanoma cell lines (MeWo, SK-Mel23, 
and MV3) in a concentration-dependent matter (IC50 value: 5 x 10-6 M), whereas 
tretinoin did not. In the same study, CD437 was shown to decrease tumor volume in a 
xenograft MeWo mouse model. [116] 
Ad 2. Retinoids have also been shown to promote cell differentiation of the mouse 
B16 melanoma cell line. [111]
Ad 3. CD437 was observed to induce apoptosis in MeWo melanoma cells in vitro after 
72 h incubation at a concentration of 5 x 10-6 M. [116] Likewise, in another study, CD437 
also promoted marked apoptosis in A375 melanoma cells at this concentration. [117] 
Ad 4. Tosetti et al. postulated additional antiangiogenic effects of retinoids since 
tretinoin has shown antiangiogenic effects in several systems. [118] although antian-
giogenesis was demonstrated in other tumor types, it has not been demonstrated 
(yet) for melanoma.
Ad 5. In an experiment by Edward and colleagues, pretreatment with 10-6 M tretinoin 
of metastatic B16 melanoma cells resulted in a significant inhibition of lung colonization 
after injection of 105 cells into the tail vein of mice. [119]
Although RAR and RXR receptors are generally thought to be involved in these 
chemopreventive effects, the exact mechanisms remain unclear. Moreover, studies 
with synthetic retinoids have revealed that apoptosis and growth inhibition mediated 
by these agents are likely to be independent of this retinoid signaling pathway. 
[120;121] These RAR/RXR independent pathways are supported by several 
observations:




- retinoid receptor antagonists failed to inhibit apoptosis induced by synthetic 
retinoids. 
- retinoid related molecules that do not bind to retinoid receptors can be effective 
inducers of apoptosis. [121]
Alternative mechanisms that may be involved are inhibition of mitogen-induced c-fos 
expression [114], NF-κB activation mediated by retinoid acid inducible gene I through 
a CARD-containing adaptor protein VISA [117], and enhanced production of reactive 
oxygen species (ROS) dependent on Rac activity [122]. Examples of additional 
hypothesized signaling pathways include increased expression of p16, p21, p27, p53, 
and bax, decreased expression of Id1 protein, and down-regulation of mitogen-acti-
vated protein kinase and bcl-2. [80]
Overall, in vitro studies of murine and melanoma cell lines have produced some 
evidence for chemopreventive effect of retinoids and rexinoids on melanoma. 
However, the evidence as yet is not well enough established and the involved 
mechanisms are not distinctly defined.
Evidence for efficacy in humans
Anticancer effects of retinoids in certain types of human cancers are well-established. 
For instance, tretinoin (Vesanoid®) is used in the treatment of APL and has been 
approved by the FDA for this indication. In addition, high-dose isotretinoin has been 
successfully used in the chemoprevention of nonmelanoma skin cancer (NMSC) in 
patients with xeroderma pigmentosum. It reduced the incidence of NMSC by 63%. 
[123] The evidence for a role of retinoids in melanoma chemoprevention is, however, 
preliminary. Studies on the dietary intake of vitamin A have shown promising results. 
In a case control study among 542 melanoma cases and 538 controls, Naldi et al. 
reported an OR of 0.57 (95% CI = 0.39-0.83) for the highest quartile of retinol intake 
versus the lowest quartile. [124] Similarly, Feskanich and colleagues, in a cohort study 
among 162,000 Caucasian US women, observed a relative risk ratio for incident 
melanoma of 0.39 (95% CI = 0.22-0.71) for consumption of ≥1800 mcg/day of retinol as 
compared to <400 mcg/day (p-linear trend = 0.01). [125] Strong correlation between 
different food items and food groups as well as between diet and other health 
behaviors, however, dramatically complicate the interpretation of such nutritional 
and observational studies.
To our knowledge, there are no studies evaluating the effect of retinoids on melanoma 
incidence in humans. Despite this lack of definite data, a number of studies have 
evaluated the effect of topically or orally applied retinoids on surrogate markers 
lesions of melanoma, dysplastic or atypical nevi. Originally, Meyskens and colleagues 
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performed two case series with topical tretinoin and oral isotretinoin, respectively, for 
patients with dysplastic nevi. Only 3 and 8 patients, respectively, completed the study. 
Importantly, these studies did not include a control treatment. [126;127] 
Edwards and Jaffe reported a preliminary randomized double-blind trial in which they 
randomized 21 patients with multiple large dysplastic nevi to either 0.05% tretinoin or 
placebo solution, both topically. Of the 8 patients randomized to tretinoin, 3 
discontinued the study. Two of these patients discontinued due to local irritation. 
Seven of the 15 dysplastic nevi that were treated with tretinoin had completely 
disappeared or had reverted to normal, benign nevocellular nevi. [128] However, the 
small number of patients and the large proportion of drop-outs in the tretinoin group 
preclude definite conclusions. [128] 
Halpern et al., in a more recent trial, studied the effect of topical treatment with once 
daily 0.05% tretinoin or, if tolerated, twice daily 0.1% tretinoin for 6 months versus no 
treatment. An effect was observed on transformation of clinical appearance (including 
color, size, and border irregularities), and likewise, a statistically significant was shown 
on histological change toward benignity (for cellularity, cellular atypia, and proliferative 
cellular nuclear antigen). [129] Correspondingly, Stam-Postuma and colleagues 
evaluated topical treatment for 4 months with either 0.1% topical tretinoin, 0.1% 
tretinoin plus 1% hydrocortisone, or placebo cream. In their study, topical tretinoin 
0.1% showed only clinical improvement with no improvement in the degree of atypia, 
possibly due to the limited number of biopsies. {Stam-Posthuma, 1998 1407 /id}
Due to the lack of validation of the predictive value of dysplastic nevi as a predictor of 
future incident invasive melanomas, the interpretation of these surrogate marker 
studies remains uncertain. As an additional limitation, these studies used different 
definitions for ‘dysplastic nevi’. Noteworthy, toxicity has been substantial in these 
studies as indicated by the large proportion of drop outs and the high rate of patients 
experiencing side effects. Interestingly, some authors reported reappearance of a 
dysplastic nevus 1 year after cessation of topical tretinoin therapy. (128 and 
Stam-Postuma et al., verbal communication)
Safety, Tolerability & Compliance
Retinoids’ side effects include skin irritation following topical treatment and cheilitis 
(lip inflammation), xerosis, ocular effects, hepatotoxicity, hair loss, teratogenicity, bone 
toxicity, and serum lipid abnormalities following oral treatment. [80] Dose-dependent 
mucocutaneous irritation affects nearly all patients and is often the dose limiting side 
effect [113], but it is, in many patients, a temporary side effect [129].  




(serious) side effects. However, the use of topical retinoids in skin cancer chemo-
prevention trials, for example for patients with dysplastic nevi or in transplant patients, 
has been restricted by the irritation they cause. New, less irritating, formulations could 
be of interest. However, adherence to the application regimen with topical treatment 
may prove to be too big a hurdle for the use of topical retinoids in melanoma chemo-
prevention. Systemic retinoid therapy on the other hand has been associated with 
substantial toxicity [80] and thus may also lead to relatively rates of discontinuation. 
Another concern, is the teratogenicity of retinoids. For example, isotretinoin exposure 
during pregnancy may cause craniofacial, cardiac, thymic and central nervous system 
(CNS) defects in about 30% of the developing fetuses. [131] Among children born 
without anatomical defects, an increased incidence of developmental delays and 
other CNS effects has been observed. Preventing fetal exposures has proven to be a 
difficult task requiring comprehensive risk management programmes. [131] After dis-
continuation of retinoid treatment pregnancy should be avoided until the drug is 
essentially cleared from the body. For some retinoids, such as etretinate and acitretin, 
this period is up to 2 years. This feature excludes its use as a chemopreventive agent 
among women of childbearing age. Retinoids should therefore only be considered 
for high risk target populations that would exclude women under the age of 45.
Conclusion Retinoids
Although retinoids have been considered a candidate for melanoma chemo prevention 
over the last decades, data on the efficacy in humans are still largely lacking. Evidence 
from experimental research is also inconclusive. Moreover, teratogenicity and limited 
tolerability lead to concerns whether retinoids as a monotherapy could be suitable as 
a melanoma chemopreventive strategy. Research should, therefore, focus on possible 
synergistic combinations with other chemopreventive agents. 
Imiquimod and analogs
Imiquimod is prescribed and approved by the FDA for the treatment of external 
genital and perianal warts (caused by human papilloma virus), multiple actinic 
keratoses and superficial basal cell carcinomas. [13] It is an immune modifier that 
stimulates the immune system through Toll-like receptors, particularly TLR-7. [12] 
Imiquimod has been shown to induce apoptosis and, therefore, has also generated 
interest as a topically applied potential chemoprevention agent. [132]
Mechanism of action
The pivotal mechanism of action of imiquimod is stimulation toll-like receptors (mainly 
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TRL7) on dendritic cells, B cells and plasmacytoid cells which triggers a T helper cell 
type 1 (Th1) immune response and induces transcription of Th1 cytokines, such as 
interferon-α (IFN-α), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and IL-12. 
[13;132-134] In this way, imiquimod activates mature dendritic cells after binding to 
TRL7 and activation signals will be sent to the T cells with the aid of co-stimulatory 
molecules such as CD40, CD80 and CD86.  [132] Consequently, the Th1 immune 
response results in the activation of naïve T cells to transform into antigen-specific T 
cells directed against antigens expressed on condylomata, basal cell carcinomas and 
other potentially immunogenic skin lesions. [132]
Until recently, experiments with imiquimod did not focus on possible chemopreven-
tive effects towards cutaneous melanoma. However, recently, some preliminary 
evidence was generated by Schön and colleagues. They performed experiments to 
test for effects of imiquimod and resimiquimod on apoptosis and also possible direct 
toxic effects. No direct toxic effects were observed on four different melanoma cell 
lines (Mel-HO, Mel-2A, A375, and MeWo) and normal human melanocytes (established 
from five different donors). Thus, they did not observe direct cytotoxicity. However, 
marked concentration-dependent pro-apoptotic effects on the Mel-HO and A375 
melanoma cell lines were demonstrated with imiquimod concentrations ranging 
from 5 to 50 µg/ml. Normal melanocytes, Mel-2A or MeWo melanoma cells showed 
markedly weaker, if detectable at all, induction of apoptosis with imiquimod. In 
contrast, resiquimod, an analog of imiquimod, did not induce apoptosis in either of 
the cell lines studied. [133]
Evidence for efficacy in humans
Cancer chemopreventive effects of imiquimod have been observed in several settings, 
mainly involving (precursor lesions) of skin cancer. For example, phase II RCTs in which 
patients with actinic keratoses (AK), a premalignant condition that may progress to 
squamous cell carcinoma (SCC), were treated with 5% imiquimod three times per 
week topically, have shown statistically significant improvement in clinical and 
histological appearance, and the average number of AK. [132] Additionally, open label 
phase II studies have also demonstrated beneficial effects on superficial and nodular 
basal cell carcinoma (BCC). Similarly, preliminary studies have suggested regression 
after local application of 5% imiquimod cream for additional precursor lesions, such 
as Bowen’s disease (SCC in situ), and vaginal intraepithelial neoplasia (VIN). [132] 
The evidence for melanoma chemoprevention specifically, however, is scarce. 
In two case reports, regression of lentigo maligna (LM, melanoma in situ) lesions that 




patients, Wolf et al. observed complete clearance of LM lesions after 13 weeks of 
application each night of 5% imiquimod cream. [136] We believe these results, 
although positive, should not be considered true melanoma chemoprevention 
because if left untreated not all LM lesions will progress to invasive lentigo maligna 
melanoma (LMM) and the latent period is estimated to be 10-50 years. {Stevenson, 
2005 1510 /id}  Likewise, in a case of disseminated cutaneous metastatic melanoma, 
local control of tumor growth has been observed after treatment with imiquimod 
three times per week for 18 weeks. [138] Although this may indicate that imiquimod 
could be beneficial for cutaneous metastatic melanoma if radiotherapy or surgery is 
impossible [138], if these results predict chemopreventive activity is uncertain.
No human studies, to our knowledge, have evaluated the effect of imiquimod on 
melanoma incidence. Thus, imiquimod has not yet been studied for true primary 
melanoma chemoprevention.
Nevertheless, human data on the effects of topical imiquimod on atypical nevi, 
surrogate markers lesions of melanoma are available. Somani and colleagues, in a 
small case series of three patients, evaluated the effect of imiquimod applied five 
nights per week for 12 weeks on a selected clinical atypical nevus. Imiquimod 
treatment failed to cause lesional resolution in these patients. [134] Likewise, Dusza et 
al. have studied topical imiquimod in a pilot study among 10 patients with atypical 
nevi and at least 8 large nevi (≥ 5 mm) on the trunk. Standardized photographs were 
compared at baseline and 4 weeks after completion of 16 weeks of imiquimod 
treatment (5% cream applied 3 times per week). In addition, histological assessment 
was performed of each patient’s 4 largest study nevi. Size and morphology showed 
no obvious changes, but 4 of 14 treated nevi and 0 of 14 untreated nevi showed 
histological changes suggestive of partial regression (p = 0.03). [139]
Investigators of the University of Arizona are currently testing an analog of imiquimod 
among patients with dysplastic nevi. [12] This study may be an important step forward 
in unraveling the chemopreventive potential of imiquimod and its analogs. 
In summary, some, but not all, of these preliminary studies have shown promising 
results. More importantly, definite data on melanoma incidence or validated precursors 
are lacking. 
Safety, Tolerability & Compliance
In general, the side effects of topical imiquimod are mild to moderate. Side effects 
include local skin reactions (LSR), nausea, vomiting, headache, muscle weakness, fever, 
flu-like symptoms and fungal infection. [80] 
LSR are most frequent, dose and frequency dependent and usually subside after a 
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resting period. Severe LSR usually are the DLT and some studies have reported that 
16% of patients (4/25) required 4-week rest periods after a four-week treatment period 
with 5% imiquimod cream three times weekly. [132] 
Although LSR are not considered to be severe medical conditions, they may have 
important implications for adherence in long-term therapy that would be required for 
melanoma chemoprevention. 
Systemic side effects are rarely reported [132], but presumably are more likely to occur 
if large areas of the body would be treated or with application on areas with thin skin 
such as the face.
Since imiquimod treatment is often restricted to a duration of 6-16 weeks [132] , the 
long-term safety data required to evaluate the risk benefit ratio for melanoma chemo-
prevention are lacking.
Conclusion Imiquimod and analogs
Imiquimod, and possibly some of its analogs, can be considered candidates for 
melanoma chemoprevention. Thus far, however, data from in vitro and in vivo 
experiments as well as human efficacy data are scarce and inconclusive. Additionally, 
long-term safety data are lacking.
Acetaminophen
Acetaminophen is a frequently used analgesic and antipyretic drug that, in most 
countries, is available both as an OTC drug as well as on prescription. Acetaminophen 
is also referred to as paracetamol and has been demonstrated to be a selective COX-3 
inhibitor. [140] Its anti-inflammatory action is relatively weak and therefore it is not 
considered to be a NSAID.
Mechanism of action
Experimental studies on acetaminophen’s effects on melanoma murine models or 
cell lines are very limited. Recently, however, Vad and colleagues have reported on 
two such studies. They tested an acetaminophen concentration of 100 µM which 
showed considerable toxicity towards B16F0 and B16F10 murine melanoma cells and 
SK-MEL-28, MeWo, and SK-MEL-5 human melanoma cell lines, resulting in a loss of cell 
viability of 40 ± 3, 45 ± 7, 66 ± 8, and 60 ± 5%, respectively. No significant toxicity was 
observed in three nonmelanoma cell lines (BJ, Saos-2, PC-3). Thus, selective toxicity 
towards melanoma cells with an IC50 of ~100 µM was observed. Adding glutathione 
(GSH) prevented toxicity in SK-MEL-28 melanoma cells, whereas 1-bromoheptane, a 




acetaminophen led to ROS formation and mitochondrial toxicity in these cells. 
The authors suggest that tyrosinase plays a role in acetaminophen’s toxicity and that 
acetaminophen is a tyrosinase substrate. [141]
In a second study, Vad et al. studied the in vivo efficacy and toxicity of acetaminophen 
in a B16F0 skin melanoma tumor model in mice. At acetaminophen doses of 60, 80, 
100, and 300 mg/kg/day, from day 7 until 13 post melanoma cell inoculation, tumor 
growth inhibition by 7 ± 14, 30 ± 17, 45 ± 11 and 57 ± 3%, respectively, was demonstrated. 
If acetaminophen was dosed from day 1 through day 13, the inhibition was similar. [142]
Overall, these two studies show promising, but limited, evidence for chemo preventive 
activity of acetaminophen against melanoma.
Evidence for efficacy in humans
Human data on the effect of acetaminophen on melanoma are very limited as well. 
Interestingly, Wolchok et al. observed two partial responses in a phase I dose-escala-
tion study among 27 patients with stage III/IV melanoma. In this study, patients 
received acetaminophen doses every 3 weeks (10, 15 or 20 g/m2) combined with 
carmustine (BCNU, 10 to 150 mg/m2), every other cycle. To prevent acetaminophen 
toxicity,  6-8 hours after acetaminophen infusion had stopped, N-acetylcysteine (NAC) 
was infused (loading dose of 140 mg/kg in 1 h with subsequently 17.5 mg/kg/h for at 
least 19 h or until acetaminophen levels had dropped below 20 mg/L). [143] Obviously, 
however, these results may simply reflect effect of carmustine and may not predict 
any chemopreventive potential.
Some epidemiological studies investigating NSAIDs and melanoma incidence have 
used acetaminophen as a comparison drug. For instance, Harris and colleagues 
reported that they did not observe an association between acetaminophen and the 
risk of malignant melanoma. In their case control study, among 110 women with 
melanoma and 609 controls, they observed an OR of 0.95 (95% CI = 0.45-1.98). [42]
Asgari and colleagues, in a large cohort study, also included exposure to acetaminophen 
in their cohort study in which they investigated the association between melanoma 
incidence and NSAID exposure. However, they did not report findings on the 
association between use of acetaminophen and incident melanoma. [47] 
Friis et al. have also investigated the association between acetaminophen use and 
cancer (among which melanoma). In contrast with the studies previously mentioned, 
their interest was raised by concern about the carcinogenic potential of acetaminophen. 
This concern originates from the fact that phenacetin, the precursor of acetaminophen, 
was withdrawn from the market due to an established link with urinary tract tumors.
The standardized incidence rate (SIR) observed by Friis et al. in the total cohort of 
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acetaminophen users was 0.9 (95% CI = 0.6-1.2). After excluding patients with 
prescriptions of aspirin and other NSAIDs, the SIR was 0.6 (95% CI = 0.2-1.3). Thus, an 
association cannot be excluded nor confirmed based on these data. [144]
Safety, Tolerability & Compliance
In normal doses, acetaminophen only rarely causes side effects. However, when liver 
enzymes catalyzing the normal conjugation reactions are saturated, acetaminophen 
will be metabolized by mixed function oxidases. As a result, N-acetyl-p-benzoquino-
ne-imine, a toxic metabolite, is formed which is inactivated by conjugation with GSH. 
If GSH is depleted, toxic effects on the liver and also in the kidney will occur. [145]
Side effects of acetaminophen are dermatologic and allergic reactions, such as 
urticarial rash or exanthema, hypothermia, and renal failure after chronic exposure. 
Among patients with Glucose-6-Phosphate Dehydrogenase (G-6-PD) deficiency, 
acetaminophen may cause anemia, hemolysis and methemoglobinemia. [145]
In doses just above the normal therapeutic doses, however, acetaminophen may 
cause liver failure. Patients with special risk factors, such as preexistent liver failure, 
exposure to CYP2E1 inducers, such as carbamazepine, isoniazide or barbiturates, or 
chronic alcohol exposure, have an increased risk of liver failure if exposed to 
acetaminophen overdose. Single acetaminophen overdose can be relatively safely 
treated with NAC infusion. Chronic acetaminophen overdose, however, cannot and 
often leads to the need for liver transplantation. [145] Therefore, if future experiments 
would demonstrate that high doses of acetaminophen are required for melanoma 
chemoprevention, safety aspects are likely to preclude its use as such. 
Conclusion Acetaminophen
Preliminary promising results have been generated for acetaminophen in human 
melanoma cells, a murine melanoma model and in a phase I study treating phase III/
IV melanoma patients (combined with carmustine). The first few epidemiological 
studies, however, have been disappointing. Acetaminophen doses in these studies 
may have been too low. In general, evidence for acetaminophen as a potential chemo-
preventive drug is inconclusive and very preliminary.
Dehydroepiandrosterone
Dehydroepiandroterone (DHEA) is a physiologic steroid that is produced in response 
to adrenocorticotropin (ACTH) stimulation by the adrenal gland. [146] Physiologically, 
DHEA is predominantly present as dehydroepiandrosterone sulfate (DHEAS), and is a 




roles of DHEA and dehydroepiandrosterone sulfate (DHEAS) have remained unclear.
In many counties, DHEA is marketed as a dietary supplement and, therefore, are 
available in OTC formulations which do not require approval of the regulatory 
authorities, such as the FDA and European Medicines Agency (EMEA). Beneficial 
effects of DHEA have been claimed for numerous indications. For most of these, 
however, evidence is preliminary, if not lacking at all. One of the claims is chemopre-
ventive potential toward cutaneous melanoma. [148] 
Mechanism of action
A small number of experiments have investigated the effects of DHEA on melanoma. 
Richardson et al., in an attempt to investigate why women have a survival benefit in 
metastatic melanoma, have performed in vitro experiments with DHEA. At a 
concentration of 1nM DHEA, they observed significantly enhanced invasion of A375 
melanoma cells. In contrast, in vitro experiments by Kawai and colleagues, showed 
DHEA dose-dependently inhibited the growth of B16 mouse melanoma cells and 
enhanced melanin production, which may indicate induction of differentiation. [149]
In conclusion, there is hardly any experimental evidence to support claims of chemo-
preventive activity of DHEA towards melanoma. 
Evidence for efficacy in humans
To the best of our knowledge, only a single study investigated the association 
between DHEA and incident melanoma in humans. In a nested case-control study, 
the mean serum DHEA and DHEAS levels of 23 melanoma cases and 43 controls 
(matched for age, sex and race) were compared. No statistically significant differences 
in de DHEA(S) levels were detected between cases and controls. [148]
Safety, Tolerability & Compliance
In physiological doses DHEA is considered to be safe. However, good quality long-term 
safety data for higher doses are lacking.
Conclusion Dehydroepiandrosterone
Both experimental and human data on the chemopreventive potential of DHEA(S) 
have been disappointing. However, the number of studies that have been reported is 





Initially, our literature search resulted in a large number of references. However, most 
of these had to be excluded and about 75% of the finally included references did not 
emerge from the systematic literature search. We believe this is a reflection of the fact 
that ‘chemoprevention’ is not defined as a MESH term. Research would certainly 
benefit from such a MESH term.
Although there was a large number of preclinical studies available for some candidate 
chemopreventive drugs, the interpretation remains troublesome. Particularly, 
preclinical in vitro and animal models usually have not been validated. Similarly, 
biomarkers and precursor lesions have also not been validated. Moreover, different 
definitions for precursor lesions, such as atypical / dysplastic, have been used in the 
present literature.
Additionally, experimental research usually includes one or two agents of a larger 
drug class. Some drug classes, such as NSAIDs, may, however, be chemically rather 
diverse. We believe experimental research should include at least one example of 
each chemical subclass. In explanation, what may be interpreted as lack of effectiveness 
of a complete drug class, could very well be a result of differential effects of different 
subclasses or even of individual agents. The same problem may arise in observational 
research. For example, the disappointing results for statins in observational research 
do not exclude differential effectiveness for lovastatin. Freeman and colleagues 
calculated that based upon the lovastatin subgroup analysis (which included only 
one trial), 244 people would need to be treated for 5 years to prevent one case of 
melanoma. Similar effectiveness (which cannot be assumed a priori) in a high risk 
population would decrease this number needed to treat and may even result in a 
realistic chemopreventive strategy.
Since the temporal dose-response and cause-effect relationships between the 
duration and dose of chemopreventive drugs and incident invasive melanoma are 
unknown, it is not clear which study design is to be preferred. Duration of drug use 
and also follow-up in many studies may have been too short and daily doses may not 
have been high enough. 
For chemopreventive drugs to move forward from in vitro research, animal experiments 
and observational studies towards RCTs and ultimately clinical practice, overall acceptable 
risk-benefit ratio for the target population is to be expected. To achieve this, after efficacy 
has been proven, a sine qua non in this issue, full risk-benefit analyses should be performed 
to show the overall health impact for subpopulations at high risk of developing (a second) 




outcomes (Fig. 2). For example a risk-benefit analysis of aspirin should not only include 
cancer reductions in melanoma, but also in colorectal, esophagus, stomach, lung, breast, 
and ovarian cancer, as well as benefits on other health aspects, such as reductions of 
myocardial infarction, pulmonary embolism, and occlusive cerebrovascular events. In 
addition, risks of long-term aspirin treatment should include all important drug related 
adverse events, such as GI bleeds, ulcers, perforation, and haemorrhagic stroke. [55] 
However, the balance between health benefits and risks is complicated by several issues, 
such as the lack of clear-cut definitions for the target population to be treated, but also by 
age. Specifically, with increasing age not only do the absolute risks of cardiovascular 
events and GI bleeds increase, but simultaneously melanoma risks are changing. Lack of 
evidence on the temporal and dose-response cause-effect relationships even further 
complicate these issues since the expected prevalence of adverse effects depends on 
required dose and duration. Consequently, the influence of different chemopreventive 
strategies, varying in drug dose, duration, definition of the target population in order to 
include individuals at highest risk of cancer development and excluding individuals at 
highest risk of developing adverse events, with or without additional interventions to 
prevent adverse effects, and the age-specific changes in the risk–benefit ratio should be 
investigated. Recently, an international expert group, however, concluded that “gaps in 
our understanding of appropriate dose, duration, and age of use, do not support a formal 
risk–benefit analysis”. [55]
Nevertheless, among high risk (sub)populations, melanoma chemoprevention may 
prove to be an innovative approach additional to sun protection measures to control 
the increasing burden of melanoma in the future.
Conclusion
Considerable preclinical evidence of efficacy as a melanoma chemopreventive drug 
exists for aspirin, NSAIDs and statins. Data on clinical efficacy and long-term safety 
with doses required for melanoma chemoprevention, however, are still sparse. 
Validated preclinical models are urgently needed to move melanoma chemopreven-
tion forward. In future research, special attention should be paid to explore possible 
differential effects within a drug class, temporal dose-response relationships, and to 
possible synergistic or antagonistic effects. Research should also focus on how to 
define the target populations. 
Chemoprevention may prove to be an innovative approach additional to sun 
protection measures to control the increasing burden of melanoma among high risk 
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individuals. Lack of definite data on efficacy in humans and profound long-term safety 
data in the required doses, however, preclude the use of chemopreventive drugs for 
melanoma in current practice. Success factors for melanoma chemoprevention to be 
useful in patient practice will likely be:
•	 Little-to-no toxicity, including mild but inconvenient side effects to not only ensure 
safety, but also tolerability and adherence
•	 A sufficiently motivated target population, e.g. patients with previous melanoma 
(or other types of cancer) or premalignant lesions would be more likely to be 
motivated to use a chemopreventive drug for at least 5 to 10 years.
•	 A clear-cut definition of the high risk subpopulations at whom chemoprevention 
should target based upon validated prediction models, mutational status and, if 
possible, validated early biomarkers of invasive melanoma risk
•	 A clear-cut definition of contraindications and predictors for individuals prone for 
the adverse events the chemopreventive drug may cause in order to withhold the 
drug from these individuals or to present additional preventive measure to them.
chemoprevention of melanoma
4
Figure 2  Risk-Benefit Balance of Melanoma Chemoprevention Strategies
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Abstract
Background:  Statins show anticancer activity in melanoma cells. We investigated the 
association between statins and incidence and Breslow thickness of cutaneous 
melanoma (CM). 
Patients and Methods:  Data were used from PHARMO, a pharmacy database, and 
PALGA, a pathological database in the Netherlands. Cases had a primary CM diagnosis 
between January 1st 1991 and December 14th 2004, were ≥ 18 years and had ≥ 3 
years of follow-up in PHARMO before CM diagnosis. Controls were matched for 
gender, date of birth and geographic region. Analyses were adjusted for age, gender, 
year of diagnosis, number of medical diagnoses and the use of NSAIDs and 
estrogens. 
Results:  Finally, 1318 cases and 6786 controls were selected. CM risk was not associated 
with statin use (≥ 0.5 year) (adjusted odds ratio (OR) = 0.98, 95% confidence interval 
(CI) = 0.78-1.2). However, statin use was associated with a reduced Breslow thickness 
(–19%, 95% CI = –33, –2.3, p = 0.028). 





Cutaneous melanoma (CM) accounts for 77 percent of all deaths due to skin cancer. 
The incidence of CM is increasing considerably, about 3 percent each year. [1]
Until now, treatment of advanced CM has been disappointing. [2] Preventive public 
health measures aiming at early diagnosis have therefore received much attention. 
Chemoprevention would be another approach to inhibit the development or 
progression of CM. In vitro studies have shown that several agents including 3-hy-
droxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) have the potential 
to alter CM behaviour. [3] Statins are interesting candidates for chemoprevention 
because they are widely used and have an excellent long-term safety. [4]
Statins inhibit the cholesterol biosynthesis through inhibition of the enzyme 
HMG-Co-A reductase and subsequently cause depletion of mevalonate, a precursor 
of cholesterol and farnesyl- and geranylgeranyl-moieties essential for posttranslation-
al activation of several intracellular proteins through prenylation. By inhibiting 
prenylation, statins may affect several proteins such as the Rho family involved in 
signalling and regulation of cell differentiation and proliferation. [5-6] High-through-
put screens for transcriptionally regulated targets in the metastatic process have 
shown that RhoC overexpression dramatically increases the metastatic potential of 
inoculated melanoma in mice. [7]
Therefore, statins may potentially affect incidence and metastasic spreading of CM. 
Indeed, in severely combined immunodeficient (SCID) mice atorvastatin prevented 
RhoC isoprenylation, invasion and metastasis of A375M melanocytes. [8]
Epidemiological studies and meta-analyses have suggested that use of statins is 
associated with a lower risk of developing cancer in general. [9-14] However, most 
studies do not have sufficient sample size to study site-specific cancers. [11] For 
colorectal cancer a case-control study with 1809 cases and 1809 controls was 
published by Coogan and colleagues [15], but for CM no studies with sufficient sample 
size have been published.
In an earlier nested case-control observational study we confirmed a significant risk 
reduction of cancer of 20% in statin users compared to non-users. For incident skin 
cancers, the risk reduction was 36% but statistically not significant (adjusted odds 
ratio (OR) = 0.63; 95% confidence interval (CI) = 0.22-1.84). [9] Although a Cochrane 
Review demonstrated no significant association between statin use and CM incidence 
(OR = 0.90, 95% CI = 0.56-1.4), the authors concluded further exploration of the use of 
statins in melanoma prevention is warranted. [16-17] 
The primary objective of this study is to investigate the effect of statins on the 
statin use and melanoma
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incidence and the Breslow thickness of CM. Also, a pilot study was performed to study 




Data were used from the PHARMO database, containing drug dispensing records of a 
defined population of over 2 million Dutch residents, thus representing more than 12% 
of the Dutch population. Residents are included regardless of type of insurance. [18] 
Participants of PHARMO enter the database with the first prescription filled in a PHARMO 
pharmacy and are observed until the last prescription. Since, in the Netherlands, most 
individuals visit a single pharmacy, dispensing histories are virtually complete. [19] 
The computerized drug dispensing histories contain all dispensed prescriptions and 
include information on type, quantity, dosage form, strength, dispensing date and 
prescribed daily dose of the dispensed drug. PHARMO was linked to PALGA, the Dutch 
nationwide registry of histopathology and cytopathology, using a variation of a reliable 
probabilistic algorithm. [20] PALGA contains abstracts of all pathology reports with 
encrypted patient identification and diagnostic terms which are in scope with SNOMED 
classification. Since 1990 the registration reached 100% participation and, in 2004, data 
on over 9 million patients had been archived. [21] Therefore, PALGA represents all Dutch 
patients and is the basis for the Netherlands Cancer Registry.
Study population
Cases had a primary CM diagnosis in PALGA between January 1st 1991 and December 
14th 2004 and were also registered in PHARMO in this period. End of follow-up was 
defined as the date of CM diagnosis (index date). For the pilot study, 90 days (i.e., the 
usual prescription duration) after last date in PHARMO or date of metastasis, which 
ever occurred first, was used as end of follow-up. 
For each case, all records in PALGA were interpreted by one of the two investigators 
(AJ, ERK). From these records the researchers extracted and recorded diagnosis and 
date of primary CM, Breslow depth (mm), CM subtype according to WHO classification 
[22] and body location (head-neck, trunk or extremities) as well as occurrence and 
date of pathologically confirmed metastasis of the lymph node (LN), skin and/or 
internal organs between Jan 1st 1991 and March 14th 2005 (90 days after end of study 
period). To assess interobserver variation, 300 cases were randomly selected and 
scored by both researchers.
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Potential cases were excluded if, in PHARMO, the date of entry was unknown, gender 
was unknown, follow-up in the three years before CM diagnosis was incomplete, or, in 
PALGA, if the date of CM diagnosis was before the age of 18 or before January 1, 1991, 
the melanoma was not pathologically confirmed, or if the primary melanoma was not 
on the skin (e.g. in the eye) or if the melanoma was in situ (Fig. 1).
For every eligible case, an average of five controls was sampled from the population 
available in PHARMO, matched for gender, date of birth (± 2 years) and geographic 
region. Potential cases could not be selected as controls. To calculate follow-up for 
controls, controls were assigned the index date of the matched case. 
Controls were excluded if, in PHARMO, the date of entry was unknown, if they were 
younger than 18 years at the index date, if the follow-up in the three years before 
index date was incomplete, or if they were diagnosed in PHARMO with previous 
melanoma according to the International Classification of Disease (Fig. 1).
Drug Exposure 
Statin exposure was defined as the use of one or more statins for at least 6 months of 
cumulative prescription duration in the 3 years before CM (i.e. we assumed this 
minimal exposure to be required for the hypothesized biological mechanism). All 
statins commercially available in the Netherlands within the study period were 
included: pravastatin, simvastatin, cerivastatin (since withdrawn), atorvastatin, 
rosuvastatin and fluvastatin (ATC codes: C10AAXX). 
To further detail statin use, several variables related to statin exposure were created 
(Fig. 2), all with the 6 month threshold. The cumulative number of dispenses, 
cumulative dispensed dose and the cumulative prescribed duration were calculated. 
The average day dose was defined as the cumulative dose divided by the cumulative 
duration. Lag time was defined as the difference between the index date and the last 
day of statin use as calculated from the last dispense. 
Potential confounders
Ever use of drugs possibly related to progression and development of CM was 
investigated, such as Non-steroidal Anti-Inflammatory Drugs (NSAIDs including 
COXibs) and anticonception and hormonal substitution estrogens (OAC and HRT, ATC 
codes: G03AXXX & G03CXXX). Use of fibrates, heparins and lipid-lowering drugs other 
than fibrates or statins was recorded, but the number of cases and controls using 
these drugs were too small (<1.0 %) to be used for further analysis. Ever use of 
estrogens was studied among female cases and controls. 
In order to estimate health care consumption, which may be a confounder, a variable 
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was created counting the total number of unique (i.e. singular) medical diagnoses 
(International Classification of Disease 9th revision, clinical modification; ICD9-CM) in 
PHARMO in the 3 years before CM. 
In a pilot study, we investigated the association between statin use and time to 
metastasis among cases with pathologically confirmed metastasis (LN, skin and/or 
systemic). These cases were categorized in ever statin users and non statin users in 
the period between 1 year before CM diagnosis and metastasis. For this pilot, statin 
use was not detailed any further because of the limited sample size and the presence 
of metastasis risk prior to diagnosis.
Statistical analysis
Because CM may behave differently across gender, we analyzed the total study 
population, but also men and women separately. To test for statistical differences, χ2 
and Student’s t-tests were used for categorical and continuous variables respectively. 
Non-normal distributions (tested using the Kolomogorov-Smirnov test) were log-
transformed. All statistical tests were two sided, with a rejection of the null hypothesis 
at p < 0.05. 
A multivariate logistic regression model was used to calculate adjusted OR and 95% CI 
for the association between CM incidence and statin use. The different statin variables 
were categorized based on quartiles among all users. Multiple linear regression, which 
used log transformed Breslow thickness as a dependent variable, was used to estimate 
the effect of statin use on local CM progression (adjusted coefficients and 95% CI). In 
this analysis, the statin variables were divided in categories of equal distances to 
facilitate the interpretation of the findings.
In the pilot study, a Kaplan Meier curve and Cox proportional hazard model were used 
to estimate the hazard ratio between statin use and time to metastasis among cases 
with pathologically confirmed metastasis. 




Figure 1 demonstrates the ascertainment of cases and controls. In total 3561 subjects 
who were registered in PHARMO had a SNOMED code ‘Melanoma’ in PALGA. Of these 
cases, 1318 (37.0%) met the inclusion criteria. The main reason for not meeting inclusion 
criteria was registration in different time periods in PALGA and PHARMO or an 
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incomplete follow-up in PHARMO in the three years before CM diagnosis. Accordance 
between the two authors in a random sample of 300 cases was high (Kappa values > 
0.85), suggesting small interobserver variation. Of the 16133 controls matched on 
gender, age (± 2 years) and geographical region, 6786 (42.1%) could be included in the 
study (Fig. 1).
Risk of CM development and statin use
Mean age of cases and controls was 55.3 and 55.9 years (p > 0.05; Table 1A). Fifty-nine 
of the cases versus 60% of controls were female (p > 0.05). Male cases had significantly 
more unique diagnoses than male controls (0.84 versus 0.66, p = 0.02; Table 1B). 
Among females there was no significant difference. Statins were used for more than 
half a year in the study period by 7.3% of the cases and 7.4% of the controls (p > 0.05). 
Of the statins used, 62.4% was simvastatin, 14.2% pravastatin, 4.7% fluvastatin, 16.9% 
atorvastatin, 1.3% rosuvastatin and 0.5% cerivastatin. None of the statin related 
variables were significantly different between cases and controls. Women with CM 
were less likely to have used statins for more than 3 years (1.2% versus 2.4%, p = 0.04) 
and to have a cumulative dose between 1001-1500 DDD (0.6% versus 1.8%, p = 0.02). 
In men, cases using statins were more likely to have a lag time of 0.5 years or longer 
than controls who used statins (p = 0.03).
The average statin day dose prescribed to patients was 1.38 DDD/day [standard 
deviation (SD) 0.82 DDD/day]. Comparing prior drug use demonstrated significantly 
more use of NSAIDs and estrogens in the 3 years prior to diagnosis among CM patients 
(Tables 1A and Table 1B). 
After adjusting for confounding factors in a multivariate model, none of the statin 
related variables were significantly associated with CM incidence in the total study 
population (Table 2A). Although not statistically significant, a higher average daily 
statin dose was associated with a lower relative risk of CM, especially among women 
and to a lesser extent in men (Table 2B). The differences in the distribution of several 
characteristics of statin use observed in Table 1A and Table 1B remained significant 
after adjusting for confounding variables. Compared to female non statin users, 
women who had 3 or more years of statin use were about half as likely to have 
developed CM (adjusted OR = 0.49, 95% CI = 0.25-0.99). Female CM patients were also 
significantly less likely to have used a substantial cumulative dose than those without 
CM (for 1001-1500 DDD, adjusted OR = 0.35, 95% CI = 0.14-0.88, compared to 0 DDD). 
Men with CM were more than twice as likely to have used statins for less than a year 
and have a lag time of 0.5 years or more after adjusting for confounding variables. 
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Breslow depth at 
diagnosis of CM
1 Cases excluded Total n = 2243 100 %
1 = Entrydate missing  n=78 3.5 %
2 = Age at diagnosis < 18 yrs  n=19 0.8 %
3 = Follow up 3 yr before CM incomplete n=1408 63 %
4 = CM not pathologically confirmed  n=343 15 %
5 = Primary CM before 1991  n=93 4.1 %
6 = no cutaneous MM (i.e. eye)  n=205 9.1 %
8 = in situ CM  n=44 2.0 %
9 = no matched controls included  n=53 2.4 %
2 Controls excluded Total n = 9347 100 %
1 = Entrydate missing  n=640 6.8 %
2 = Age at diagnosis < 18 yrs  n=30 0.3 %
3 = Follow up 3 yr before CM incomplete n=8673 93 %
4 = possible CM patient (ICD code ‘CM’)  n=4 0.04 %
Cases + metastasis
      n = 475
  241 cases   
  excluded 3
Cases + metastasis
      n = 234
Time to
metastasis
3 Cases with metastasis excluded Total  n = 241 100 %
1 = Entrydate missing n=21 8.7 %
2 = Age at diagnosis < 18 yrs n=2 0.8 %
3 = Follow up 1 yr before CM incomplete n=192 80 %
4 = Breslow thickness missing n=21 8.7 %
5 = Tumour location missing n=5 2.1 %
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Table 1A Characteristics of all cases and controls
Cases




Gender a            male 540 (41.0%) 2714 (40.0%)
female 778 (59.0%) 4072 (60.0%) 0.51
Age at diagnosis b     yrs 55.3 (± 15.9) 55.9 (± 15.5) 0.18
Total unique diagnoses b      number  0.71 (± 1.52) 0.61 (± 1.55) 0.04
NSAIDs a           Yes 627 (47.6%) 2942 (43.4%)
No 691 (52.4%) 3844 (56.6%) 0.01
Estrogens a           Yes 264 (20.0%) 1117 (16.5%)
No 1054 (80.0%) 5669 (83.5%)  0.002
Statin use a Non-exposed 1222 (92.7%) 6283 (92.6%)
Exposure >0.5 yr 96 (7.3%) 503 (7.4%) 0.87
Number of Dispenses a 0 1222 (92.7%) 6283 (92.6%)
1-8 27 (2.0%) 131 (1.9%) 0.79
9-11 17 (1.3%) 118 (1.7%) 0.21
12 24 (1.8%) 111 (1.6%) 0.64
>12 28 (2.1%) 143 (2.1%) 0.97
Cumulative prescription 
duration a,c          
0 yrs 1222 (92.7%) 6283 (92.6%)
0.5-1.0 yrs 17 (1.3%) 53 (0.8%) 0.07
1.0-2.0 yrs 18 (1.4%) 115 (1.7%) 0.40
2.0-3.0 yrs 25 (1.9%) 140 (2.1%) 0.70
>3.0 yrs 36 (2.7%) 195 (2.9%) 0.78
Cumulative dose a 0 DDD 1222 (92.7%) 6283 (92.6%)
1-600 DDD 32 (2.4%) 125 (1.8%) 0.17
601-1000 DDD 24 (1.8%) 110 (1.6%) 0.61
1001-1500 DDD 21 (1.6%) 145 (2.1%) 0.21
>= 1501 DDD 19 (1.4%) 123 (1.8%) 0.35
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Breslow thickness of CM and statin use
Cases with unknown Breslow depth or location of the CM were excluded (93 versus 51). 
Of the residual 1174 CM cases, 51.4% had a Breslow thickness <1.0 mm, 66.8% was of 
the superficial spreading type and 93.2% showed no regression (Table 3). Eighty-six 
percent was located on the trunk or extremities. Tumor characteristics such as Breslow 
depth, CM subtype and body location differed significantly between males and 
females. Tumor regression, however, did not differ significantly between male and 
female cases.
In our multivariate linear regression model, each of the associations between Breslow 
thickness and the statin variables in the 3 years prior to CM diagnosis were negative 
with p-values close to statistical significance (p < 0.10) (Table 4). Using statins for 6 
months or longer significantly reduced the average Breslow thickness with 19.2% 
when compared to non-users (95% CI = –33.2%, –2.3%, p = 0.03). After adjustment for 
gender, these findings were confirmed in men but not in women. In men, every 
increase of 4 dispenses or 0.66 DDD in average day dose was associated with a 
significantly reduced Breslow thickness (–10.7%, 95% CI = –18.5%, –2.2%, p = 0.015 and 








Average day dose a 0 DDD 1222 (92.7%) 6283 (92.6%)
0.01-0.99 DDD 29 (2.2%) 127 (1.9%) 0.44
1.00-1.32 DDD 23 (1.7%) 94 (1.4%) 0.33
1.33-1.99 DDD 27 (2.0%) 153 (2.3%) 0.65
>= 2.00 DDD 17 (1.3%) 129 (1.9%) 0.13
Lag time a,d    Non-exposed 1222 (92.7%) 6283 (92.6%)
< 0.5 yrs 87 (6.6%) 481 (7.1%) 0.55
>= 0.5 yrs 9 (0.7%) 22 (0.3%) 0.06
a   Number of cases and controls presented, tested for statistical difference with χ2-test.
b   Mean value presented, tested for statistical difference with t-test 
c   Time interval between first prescription and estimated last day of use based on last dispense and amount 
dispensed in the three years before diagnosis of cutaneous melanoma.
d   Time interval between estimated last day of use based on last dispense and amount dispensed and date of 
diagnosis of cutaneous melanoma.
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Table 2A Multivariate analysis of risk factors 3 years before diagnosis of CM
Adjusted OR a 95% CI
Statin use Non-exposed 1.00 referent
>0.5 yr 0.98 0.78 – 1.2
No. of Dispenses 0 1.0 referent
1–8 1.0 0.70 – 1.6
9–11 0.73 0.44 – 1.2
12 1.1 0.71 – 1.7
>12 1.0 0.67 – 1.5
Cumulative prescription duration 0 yrs 1.0 referent
0.5–1.0 yrs 1.7 0.97 – 2.9
1.0–2.0 yrs 0.80 0.48 – 1.3
2.0–3.0 yrs 0.91 0.59 – 1.4
>3.0 yrs 0.96 0.66 – 1.3
Cumulative dose 0 DDD 1.0 referent
1–600 DDD 1.3 0.89 – 2.0
601–1000 DDD 1.1 0.72 – 1.8
1001–1500 DDD 0.74 0.47 – 1.2
>= 1501 DDD 0.78 0.48 – 1.3
Average day dose 0 DDD 1.0 referent
0.01–0.99 DDD 1.2 0.79 – 1.8
1.00–1.32 DDD 1.3 0.79 – 2.0
1.33–1.99 DDD 0.91 0.60 – 1.4
>= 2.00 DDD 0.67 0.40 – 1.1
Lag time b    Non–exposed 1.0 referent
< 0.5 yrs 0.94 0.73 – 1.2
>= 0.5 yrs 2.0 0.92 – 4.4
a   Adjusted for age, gender, year of diagnosis, total number of unique ICD diagnoses, the use of NSAIDs  
and estrogens. 
b   Time interval between estimated last day of use (based on last dispense and amount dispensed)  
and date of diagnosis of CM.
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Table 2B  Multivariate analysis of risk factors of men and women 3 years  




95% CI Adjusted 
OR b
95% CI
Statin use Non–exposed 1.0 referent 1.0 referent
>0.5 yr 1.2 0.88 – 1.6 0.75 0.51 – 1.1
No. of Dispenses 0 1.0 referent 1.0 referent
1–8 1.3 0.73 – 2.2 0.86 0.44 – 1.7
9–11 0.8 0.44 – 1.6 0.62 0.26 – 1.4
12 1.3 0.72 – 2.3 0.93 0.45 – 1.9
>12 1.4 0.82 – 2.3 0.61 0.29 – 1.3
Cumulative prescription 
duration
0 yrs 1.0 referent 1.0 referent
0.5–1.0 yrs 2.1 1.1 – 4.2 1.1 0.43 – 3.0
1.0–2.0 yrs 0.91 0.47 – 1.7 0.68 0.31 – 1.5
2.0–3.0 yrs 0.82 0.45 – 1.5 1.1 0.57 – 2.0
>3.0 yrs 1.4 0.90 – 2.2 0.49 0.25 – 0.99
Cumulative dose 0 DDD 1.0 referent 1.0 referent
1–600 DDD 1.6 0.96 – 2.6 1.0 0.53 – 1.9
601–1000 DDD 1.2 0.66 – 2.2 1.1 0.54 – 2.1
1001–1500 DDD 1.2 0.67 – 2.0 0.35 0.14 – 0.88
>= 1501 DDD 0.83 0.44 – 1.6 0.71 0.32 – 1.6
Average day dose 0 DDD 1.0 referent 1.0 referent
0.01–0.99 DDD 1.4 0.81 – 2.4 0.99 0.53 – 1.9
1.00–1.32 DDD 1.5 0.85 – 2.5 0.88 0.37 – 2.1
1.33–1.99 DDD 1.3 0.73 – 2.2 0.63 0.33 – 1.2
>= 2.00 DDD 0.75 0.40 – 1.4 0.53 0.21 – 1.3
Lag time c Non–exposed 1.0 referent 1.0 referent
< 0.5 yrs 1.1 0.79 – 1.5 0.72 0.48 – 1.1
>= 0.5 yrs 2.9 1.0 – 8.1 1.3 0.36 – 4.6
a   Adjusted for age, year of diagnosis, total number of unique ICD diagnoses and the use of NSAIDs. 
b   Adjusted for age, year of diagnosis, total number of unique ICD diagnoses, the use of NSAIDs and estrogens. 
c   Time interval between estimated last day of use (based on last dispense and amount dispensed) and date  
of diagnosis of CM.
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Time to CM metastasis and statin use - pilot study
Of all 3561 CM cases, 475 (13.3%) had pathologically confirmed metastasis (Fig. 1). 
Of these 475 cases with metastasis, 234 (49.3%) could be included in the analysis 
(average age was 54.7 years and 46.2% were females). The average number of months 
to metastasis was significantly higher for statin users than for non-users (28.4 [SD 26.9] 
versus 16.5 [SD 22.7], p = 0.03) (Fig. 3).
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Table 3 Melanoma characteristics of the primary CM of the cases
Total







   mm 1.75 2.06 1.53 <0.001 a
Breslow in AJCC Categories
   0–1 mm 604 (51.4%) 223 (45.8%) 381 (55.5%)
   1.01–2 mm 284 (24.2%) 123 (25.3%) 161 (23.4%)
   2.01–4 mm 188 (16.0%) 85 (17.5%) 103 (15.0%)
   >4 mm  98  (8.3%) 56 (11.5%) 42  (6.1%) 0.001 b
Type of melanoma
   Superficial spreading 784 (66.8%) 315 (64.7%) 469 (68.3%)
   Nodular 187 (15.9%) 96 (19.7%) 91 (13.2%)
   Lentigo maligna 153 (13.0%) 59 (12.1%) 94 (13.7%)
   Unknown / others 50  (4.3%) 17  (3.5%) 33  (4.8%) 0.02 b
Regression of primary tumor
   Yes 80  (6.8%) 31  (6.4%) 49  (7.1%)
   No / Unknown 1094 (93.2%) 456 (93.6%) 638 (92.9%) 0.61 b
Location of primary tumor
   Head / neck 160 (13.6%) 86 (17.7%) 74 (10.8%)
   Trunk 490 (41.7%) 270 (55.4%) 220 (32.0%)
   Extremity 524 (44.6%) 131 (26.9%) 393 (57.2%) <0.001 b
a Number of male versus female cases tested for statistical difference with t–test, equal variances not assumed.
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After adjustment for gender, age, year of CM diagnosis, body site, Breslow thickness, 
histological subtype, presence of regression, use of NSAID and estrogens in a Cox 
proportional hazard model, ever statin use between the year prior to CM diagnosis 
and date of metastasis reduced the likelihood of metastasis but was no longer 
significant (HR = 0.69, 95% CI = 0.42-1.1). A survival analysis model that excluded 
Breslow thickness was performed as well. This model showed a significant effect of 




None of the statin related independent variables in our study consistently supports a 
risk reduction of statin use on the incidence of CM (Table 2A and Table 2B). Possibly, 
the average daily doses in our population (median: 1.3 to 2.0 DDD) are not high 
enough to prove a chemopreventive effect. The follow-up may be too short and 
persistence (i.e. compliance with statin intake) may be poor, a problem of statin 
therapy as described by Johnson and colleagues. [23] However, our findings are in 
concordance with the Cochrane Review. [16-17]
Breslow thickness at diagnosis
To our knowledge, this is the first study investigating an association between statin 
use and Breslow depth at diagnosis of CM. Our data suggest that statin use is associated 
with a significantly reduced Breslow thickness at diagnosis (–19.2%, 95% CI = –33.2, 
–2.3, p = 0.03). As non statin-users in our database had a mean Breslow thickness of 1.8 
mm, this would indicate an average reduction in the depth of the lesion of 0.35 mm 
with statin use. This is an important finding since the Breslow thickness at diagnosis is 
one of the strongest determinants for prognosis. [24-25]
Among men this effect was even more pronounced with a reduction in Breslow 
thickness of –27.8% (95% CI = –43.7%, –7.4%, p = 0.01). Male non-statin users had a 
mean Breslow thickness of 2.1 mm, therefore statin use for 0.5 year or more would 
result in a mean reduction of 0.58 mm. Because especially male cases had a significant 
higher number of unique ICD diagnoses compared to male controls (0.84 versus 0.66, 
p = 0.02), one could also argue that statin use among men is simply associated with 




PALGA and PHARMO are general population-based databases that closely reflect the 
Dutch population. [20-21] Moreover, pharmacy data are gathered prospectively. 
Therefore, recall bias is avoided.
Another strength of our study is that PHARMO enabled us to study dose-effect 
responses. For example, our data suggest thinner melanoma in patients who use 
higher doses of statins.
Since risk factors for melanoma do not play a role in the prescription of statins, 
confounding by indication seems unlikely. However, statin users are likely to have 
more health care contacts and, therefore, might be more likely to be diagnosed with 
melanoma. We included the number of unique medical diagnoses (ICD codes) in our 
study to adjust for this. Nevertheless, not all health consumption may be reflected in 
these diagnoses and ascertainment bias is still possible.
A limitation of our study is the relatively high frequency of simvastatin prescriptions; 
63% of the prescriptions were simvastatin. Because the inhibitory effect of statins may 
not be equal for all statins [26], the results of our study cannot be generalized to all 
statins.
We were not able to study the effects of statin use longer than 3 years before CM, but 
all patients included did have full follow-up for the 3 years before diagnosis of CM. For 
some sub analyses the sample sizes may be too small. Most cases were excluded 
because they were registered in PHARMO in a different time period. Following this 
line of reasoning, with a required follow-up of only one year the number of cases 
would increase from 1318 (37.0%) to 1697 (47.7%).
PHARMO does not provide information on lifestyle variables, such as sun exposure, a 
risk factor for the development of melanoma. It seems unlikely however that the use 
of statins is associated with sun exposure. However, it is possible that statin use is 
associated to the intake of certain foods and some authors have suggested that 
specific food items may influence the incidence of melanoma. [27]
Therefore, we cannot rule out residual biases or confounding as possible explanations 
for our findings. A possible causal relationship with regard to our findings should be 
studied in a prospective randomized trial. 
Time to metastasis
In a small sample of about 250 patients, univariate analysis suggested that statin use 
may delay time to metastasis. After adjusting for Breslow thickness and other factors, 
this association was no longer significant (HR = 0.69, 95% CI = 0.42-1.1). To differentiate 
between the direct effects of statins on the process of metastasis and their effect on 
statin use and melanoma
5
126
metastasis through Breslow thickness, we also performed an analysis excluding 
Breslow thickness. This model did show a significant effect of statin use on time to 
metastasis (HR = 0.58, 95% CI = 0.36-0.94), which suggests that the effect of statins on 
time to metastasis may not only be caused by the effect of statins on the Breslow 
thickness.
Unfortunately we were not able to perform a sensitivity analysis, excluding cases with 
a positive sentinel node procedure (N=52), since only one statin user had a positive 
sentinel node procedure. Therefore, bias due to early detection of metastasis in a 
sentinel node procedure is possible.
Conclusion
Our observational study suggests a protective effect of statins on the progression of 
melanoma. A validation of our findings is justified, preferably in a prospective 
randomized study. Also linkage of datasets like ours to death registers may be helpful 
in the further exploration of the effect of statins on (progression of) melanoma.
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Abstract
Background:  This case-control study investigates the potential chemoprophylactic 
properties of non-steroidal anti-inflammatory drugs (NSAIDs) on the incidence of 
cutaneous melanoma (CM).
Patients and Methods:  Data were extracted from the Dutch PHARMO pharmacy 
database and the PALGA pathology database. Cases had a primary CM between 1991 
and 2004, were ≥ 18 years and were observed for 3 years in PHARMO before diagnosis. 
Controls were matched for date of birth, gender and geographical region. NSAIDs and 
acetylsalicylic acids (ASAs) were analyzed separately. Adjusted odds ratio (OR) and 
95% confidence interval (CI) were calculated using multivariable logistic regression, 
and results were stratified across gender. 
Results:  1318 CM cases and 6786 controls were eligible to enter the study. CM incidence 
was not significantly associated with ever ASA use (adjusted OR = 0.92, 95% CI = 
0.76-1.12) or ever non-ASA NSAID use (adjusted OR = 1.10, 95% CI = 0.97-1.24). However, 
continuous use of low-dose ASAs was associated with a significant reduction of CM 
risk in women (adjusted OR = 0.54, 95% CI = 0.30-0.99) but not in men (adjusted OR = 
1.01, 95% CI = 0.69-1.47). A significant trend (p = 0.04) from no use, non-continuous 
use to continuous use was observed in women.  
Conclusion:  Continuous use of low-dose ASAs may be associated with a reduced 




Cutaneous melanoma (CM) is a growing health problem, as CM incidence rates are 
steadily rising in both Europe [1] and the United States [2]. However, mortality rates 
seem to have leveled off, probably caused by increased awareness resulting in early 
detection of CM. [3] Although local CM is generally successfully treated with surgery, 
for metastatic disease therapeutic results remain disappointing. [1,4] Consequently, 
focus of melanoma research has shifted from therapy to prevention and early 
detection. 
Chemoprevention may complement current preventive measures and is defined as 
the use of natural or synthetic agents to prevent, reverse, suppress or delay 
premalignant lesions from progressing into invasive cancer. [5] Non-steroidal anti-in-
flammatory drugs (NSAIDs) have shown promising results in various solid cancers [6] 
and may have chemopreventive potential in CM. [7] In vitro studies in melanoma cell 
lines have shown that NSAIDs can induce apoptosis [8,9] and inhibit tumor growth 
and invasion. [8,10,11] 
The proposed anti-cancer mechanism of NSAIDs is inhibition of cyclooxygenase-2 
(COX-2). This enzyme is inducable by inflammatory stimuli, is overexpressed in different 
neoplasms, and is probably linked to carcinogenesis through various mechanisms, for 
example, angiogenesis, apoptosis, inflammation, and immune function. [6, 12] 
However, NSAIDs may inhibit cancer through various COX-independent pathways as 
well. [13,14] This could be of particular importance in CM, as NSAIDs inhibit growth of 
CM cell lines independent of COX-2 [8-10,12,15] and COX-2 is not consistently expressed 
in CM. [9,11,16-18]
Thus far, most of the epidemiological studies assessing the chemoprophylactic effects 
of NSAIDs on CM incidence focus on acetylsalicylic acids (ASAs). A randomized 
controlled trial (RCT) and a large cohort study did not find an association between 
low- or high-dose aspirin use and CM incidence. [19,20] Studies investigating a 
possible association of CM and non-ASA NSAIDs are limited. Recently, a large cohort 
study did not observe an association with either ASA or non-ASA NSAIDs on CM 
incidence. [21] However, two smaller epidemiological studies suggested a reduced 
risk on CM incidence and progression in NSAID users. [22,23] Therefore, the potential 
chemoprophylactic properties of NSAIDs remain unclear due to heterogenity in study 
design and conflicting results.  
The objective of this study is to investigate a possible protective effect of ASA and 
non-ASA NSAIDs on CM incidence in a large population-based sample by linking the 
Dutch pathology registry with a pharmacy database.  





This study was designed as a case-control study, using population-based data from 
two Dutch databases. PHARMO is a network of linked databases including a pharmacy 
database containing more than 2 million Dutch residents, representing 12% of the 
total Dutch population. The residents were included regardless of type of insurance. 
[24] An individual enters the PHARMO database when obtaining the first prescription 
in a PHARMO pharmacy, and is observed until the last prescription. As most patients 
in The Netherlands visit a single pharmacy, drug-dispensing records are virtually 
complete. [25] The prospectively gathered computerized drug-dispensing records 
contain the date of dispense, type, quantity, dosage form, strength, and daily dose of 
the prescribed drug. 
PHARMO was linked to PALGA, the Dutch registry of histo- and cytopathology, using 
a variation of a reliable probabilistic algorithm. PALGA contains abstracts of all Dutch 
pathology reports encrypted with patient identification and diagnostic terms in 
scope with the SNOMED classification, and reached 100% participation from 1990 
onwards, and therefore is the basis of the Netherlands Cancer Registry. [26] 
The protocol of this study was approved by the scientific and privacy committees of 
both PALGA and PHARMO, and was granted exempt status by the ethics board of the 
Leiden University Medical Centre.
Study population
Cases were defined as individuals with a CM diagnosis in PALGA between January 1st 
1991 and December 14th 2004 and who were also registered in PHARMO in this 
period. The endpoint of the observation period up was defined as the date of CM 
diagnosis (index date). For each case, two investigators (AJ, ERK) extracted final 
diagnosis, date and Breslow’s depth from the PALGA pathology reports with high 
accordance (kappa values > 0.85). [27] Cases were excluded if, in PALGA, the date of 
primary CM diagnosis was before the age of 18 years or before January 1st 1991, the 
primary melanoma was not pathologically confirmed, was in situ, or was non-cutaneous, 
or in PHARMO, the date of entry was unknown, gender was unknown, or time of 
observation before CM diagnosis was < 3 years (Fig. 1) .
For every eligible case, an average of five controls matched for gender, date of birth 
(± 2 years) and geographic region (~100 regions based on clusters of local pharmacies) 
was sampled from PHARMO. To calculate the time of observation for the controls, 
they were assigned the index date of the matched case to be able to determine the 
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3 year observation period. Controls were excluded if, in PHARMO, the date of entry 
was unknown, they were younger than 18 years at the index date, the time of 
observation before index date was < 3 years, or a diagnosis of melanoma was recorded 
according to the International Classification of Disease (ICD9-CM) in the hospital 
linkage database of PHARMO (Fig. 1).
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Total: n = 8104
1 Cases Excluded Total n=2243 100 %
1 = Entry date missing
2 = Age at diagnosis <18 yrs
3 = OP 3 yr before CM incomplete
4 = CM not pathologically confirmed
5 = Primary CM before 1991
6 = No Cutaneous MM (e.g. eye)
7 = in situ CM

















2 Controls Excluded Total n=9347 100 %
1 = Entry date missing
2 = Age at diagnosis < 18 yrs
3 = OP 3 yr before index date incomplete











For all cases and controls, systemic NSAID use, restricted to the 3-year observation 
period before the index date, was extracted from the PHARMO database using the 
anatomical therapeutical classification (ATC) codes of the World Health Organization 
(WHO). All NSAIDs, including ASAs, available in The Netherlands were included (Table 1). 
Drug dispenses containing < 7 pills were excluded (for example, after a dental 
extraction), but weekly prescribed NSAIDs were included (for example, weekly 
pharmacy deliveries to nursery homes).  
ASAs were investigated separately from non-ASA NSAIDs because, next to COX-2 
inhibition, they inhibit thrombocyte aggregation, which has been linked to 
carcinogenesis. [28] Furthermore, ASAs are almost exclusively prescribed for long-term 
continuous use and not for intermittent use as an analgetic, in contrast with non-ASA 
NSAIDs.
ASA Use
Among all users, ASA use was categorized by prescribed dosage. Individuals who 
used low-dose ASA (30-100 mg daily) were categorized in continuous (that is, use of 
≥ 990 U of ASA during the observation period of 3 years or 1095 days) and 
non-continuous users. Higher doses of ASA (≥100 mg) were dispensed far less 
frequently and were mostly prescribed for on-demand use, suggesting temporary 
use as an analgetic. It was not possible to extract continuous users from this group of 
high dose ASA users because of the low cumulative quantities of pills used during the 
observation period. Therefore, all users of high dose ASA were analyzed separately. 
Non-ASA NSAID use
Non-ASA NSAIDs, such as ibuprofen and diclofenac, were prescribed irregularly, with 
a wide variation of daily prescribed doses, and to be used on demand. Therefore, 
assumptions for continuous or non-continuous use could not be made, and 
categorization was limited to the number of pills prescribed. For the categories of 
cumulative number of pills, the cutoff values were chosen to reflect levels of exposure: 
non-users, individuals who were likely to be exposed for < 2/3 of the observation 
period of 3 years (1-600 pills during 1095 days), individuals using on average more 
than one pill daily in 3 years (>1000 pills) and an intermediate group. 
Potential confounders 
Ever use of drugs related to progression and development of CM, such as statins [27] 
and estrogens [29], were considered possible confounders. The use of heparins, 
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Table 1 ATC codes and corresponding NSAID
ASAs ATC code % of total 1
Acetylsalicylic acid B01AC06 / N02BA01 22,5
Carbasalate calcium B01AC08 / N02BA15 19,1
Total ASA use 41.6




Rofecoxib 3 M01AH02 3,0
















Tolfenamic acid M01AG02 <0,1
Metamizole sodium N02BB02 <0,1
Total Non ASA NSAID use 58.4
1   All available NSAID ATC codes were included in the study. Presented are ATC codes corresponding  
with 1 or more prescription among cases and controls.
2  Percentage of the total 22,279 prescriptions among cases and controls. 
3  Withdrawn from the Dutch market in 2004.
ASAs = Acetylsalicylic acids; ATC = anatomical therapeutic chemical classification system;  
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fibrates, and other llipid-lowering drugs was also recorded. 
However, the number of individuals using these drugs 
was too small (<1.0%) to be used in further analysis. 
To adjust for a possible surveillance bias (that is, patients 
who seek medical care are more likely to be diagnosed 
with other disease including CM), a proxy of health-care 
and pharmacy-seeking behaviour was created by 
calculating the total number of unique ATC codes 
(excluding all NSAIDs) and the total number of unique 
ICD9-CM codes (that were primary discharge diagnosis 
after hospitalization) which were both recorded in the 
database in the 3 years before the index date. The ICD 
code for melanoma found for each case was not included 
in the total number of unique ICD codes to avoid 
overmatching. Both confounders proved to be significant 
in all multivariable analyses performed and also showed a 
significant interaction with each other. This interaction 
term was added in the multivariable analysis (p <0.01). 
Statistical Analysis
A chi-square test was used to test for statistical differences 
between categorical variables, for continuous variables a 
Student’s t-test or a Mann-Whitney U test was used as 
appropriate. A multivariable logistic regression model 
was used to calculate adjusted odds ratios (OR) and 95% 
confidence intervals (CI) to analyze the association 
between dependent CM incidence and NSAID use and its 
defined categorizations of exposure. 
As CM development, progression and survival, as the 
effect of potential chemo prophylactic drugs, may differ 
across gender [27,28,30,31], a pre-specified separate 
analysis for men, women and the total group was carried 
out. 
All statistical tests were two sided, with a rejection of the 
null hypothesis at p <0.05. All statistical analyses were 
performed using SPSS 14.0 (.2) (SPSS Inc. Chicago, IL).
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The ascertainment of the cases and controls has been described previously. [27] 
Briefly, of the 3561 subjects who were registered in PHARMO (Institute for Drug 
Outcome Research) and had a systemized nomenclature of medicine (SNOMED) code 
‘melanoma’ in PALGA (the natoinwide network and registry of histo- and cytopathology 
in The Netherlands), 1318 cases (37.0%) met the eligibility criteria (Fig. 1). Patients were 
mostly excluded because the registration periods in PHARMO and PALGA did not 
match, leading to incomplete pharmacy records in PHARMO in the 3-year observation 
period before CM diagnosis. Of the 16133 controls matched on gender, age and 
geographical region, 6786 (42.1%) met the inclusion criteria.  
About 60% of the study population was female, with a mean age of 55 years (Table 2). 
Compared with the controls, cases had a significantly higher number of unique 
non-melanoma international classification of disease (ICD) diagnoses (0.71 versus 0.61, 
p = 0.04), which was confirmed in men, but not in women. Also, cases had a higher 
number of unique medications prescribed (7.53 unique ATC codes versus 6.93, 
p <0.01), which was confirmed in both men and women. As reported earlier, women 
with melanoma used more estrogens compared to the control population (31.6% 
versus 24.8%, p <0.001). [29]
ASA use and CM incidence  
More than 40% of the total NSAID use consisted of ASA use (Table 1). The proportion 
of CM patients who used ASA was comparable to the controls, except for high dose 
ASAs (Table 2). Female cases were significantly less likely to be a continuous user of 
low-dose ASAs than their matched controls (1.7% versus 3.1%, p = 0.03). In men, no 
significant difference in the distribution of ASA exposure was observed. After adjusting 
for age, gender, year of diagnosis, prior use of statins and estrogens, and unique 
number of ICD and ATC codes in a multivariable model, none of the ASA exposure 
variables was significantly associated with CM incidence in the total study population 
and in men (Table 3). However, in women, continuous use of low-dose ASA for 3 years 
was associated with a reduced risk of developing a CM of almost 50% (adjusted 
OR = 0.54, 95% CI = 0.30-0.99). In addition, in women, there was a significant 







































































































































































































































































































































































































































































































































































































































































































































































Non-ASA NSAID use and CM incidence
The most commonly dispensed non-ASA NSAIDs were diclofenac (20,5%), ibuprofen 
(14,5%) and naproxen (10.0%) (Table 1). Female and, to a lesser extent, male CM patients 
were more likely to have ever used non-ASA NSAIDs compared to controls (Table 2). 
Of the non-ASA NSAID users, the overwhelming majority used < 600 pills during 3 
years and only 2.3% and 2.9% of cases and controls, respectively, used more than 600 
pills. In the distribution of the categories of the cumulative number of pills, the only 
significant difference was observed in the lowest category of 1-600 pills for the total 
study population and women.  
In the multivariable models that adjusted for multiple confounders, no significant 
associations were found, although relative low non-ASA NSAID exposure (1-600 pills) 
was borderline significantly associated with a modest increase in CM risk (OR = 1.12, 
95% CI = 0.98-1.23, Table 3). In further subgroup analysis, the use of 1-4 prescriptions 
of non-ASA NSAIDs in 3 years was significantly associated with a marginally increased 
risk of CM (OR = 1.15, 95% CI = 1.01-1.30, data not shown). Higher levels of exposure 
appeared to be protective for all subgroups, but none of these associations were 
significant (Table 3).
Discussion 
NSAID use and risk of CM
Continuous use of low-dose ASAs during 3 years was associated with a reduced 
likelihood of developing CM in women but not in men. 
In contrast, none of the non-ASA NSAID variables were significantly associated with 
risk of having a CM in the multivariable model (Table 3). However, infrequent use of 
pills (1-600 pills in 3 years), was significantly associated with the incidence of CM in 
univariate analysis (Table 2), but this was not significant in the multivariable model 
after adjusting for health-care consumption (Table 3), suggesting that this and possibly 
other confounders affected the univiarate model. Interestingly, a similar association 
has been reported in a case-control study in prostate cancer. [33] This illustrates that 
health care utilization may be an important confounder in pharmaco-epidemiological 
studies. 
The use of larger quantities of non-ASA NSAIDs (>600 pills in 3 years) seemed to be 
protective for CM but did not reach significance, which could be explained, in part, by 
a relatively short time of observation (3 years), limited sample size in this subgroup 
(<225 patients), and/or that non-ASA NSAIDs were administered as analgetics (the 
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prescribed frequency of use by physicians was most often ‘when needed’); thus 
implying non-continuous exposure. On account of small numbers, separate analyses 
for selective-COX-2 inhibitors could not be carried out.
The observed difference in chemoprophylactic effects between non-ASA NSAIDs and 
ASAs may be dependent on the patterns of use or on a different mechanism of action. 
First, low-dose ASAs are most commonly prescribed as daily cardiovascular preventive 
drugs, whereas non-ASA NSAIDs and high dose ASAs are commonly used irregularly 
as analgetics. Second, ASAs may have additional anti-cancer effects in comparison to 
non-ASAs, such as inhibition of thrombocyte- aggregation [28], or effects cancer-related 
systems as apoptosis, NF-κB, DNA-repair systems, oxidative stress, or mitochondrial 
calcium uptake. [14]
We did not find a reduced CM incidence among overall non-ASA NSAID or ASA users, 
which is in accordance with three large observational studies. A large cohort study of 
regular and high dose ASA (>325 mg) exposure observed no protective effect on CM. 
[20] A second cohort confirmed the absence of an association between ASA or 
non-ASA NSAID use and CM incidence. [21] This study, however, has several limitations, 
that is, low-dose aspirin exposure was excluded in subgroup analyses, ~40% of cases 
were CM in situ, and stratification across gender was not carried out. Our results, 
showing an association of low-dose ASA use in women with CM is in contrast with an 
RCT among females for whom low-dose aspirin use (100 mg every other day) for an 
average of 10 years did not affect CM incidence (68 versus 70 incident cases, 
p = 0.87). [19] This study however was limited by a small number of CM cases, 
non-continuous exposure, and was not population-based. 
In other malignancies, multiple studies investigating the chemopreventive properties 
of ASA and non-ASA NSAIDs have been published. A review showed that in colorectal, 
breast and lung cancer, the risk reductions by non-ASA NSAIDs and ASAs were 
comparable [6], which contradicts our results that suggest a different effect. Results 
of a case-control study on prostate cancer, however, were comparable: prolonged use 
of ASAs showed a protective effect, whereas use of non-ASA NSAIDs did not. [33] In 
lung [34], breast [35] and prostate [33] cancer, exposure to regular or high-dose use of 
ASAs did, but exposure to low-dose ASA did not, decrease the incidence of these 
cancers, which is not in line with our findings in CM patients.
nsaids and melanoma risk
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 However, comparing the results of studies assessing the chemoprophylactic effect of 
NSAIDs is challenging because studies differ in several important ways such as 
ascertainment of drug exposure (for example, self-reported or pharmacy database), 
definition of exposure, type of NSAID (ASA or non-ASA), dose, duration, patterns of 
use (for example, sporadic, intermittent, chronic), drug adherence, study population 
(for example, general population, cohorts from tertiary centers), melanoma (for 
example, invasive or in situ CM), sample size, and subgroup analyses (that is, 
stratification across gender). A pivotal unresolved problem is the definition of the 
dosage of NSAID, which could have chemoprophylactic effects.  
Gender differences
Stratification across gender showed a gender difference in favor of women, especially 
for continuous use of low-dose ASAs. This apparent discrepancy between men and 
women is not well understood and may be explained by pharmacological and 
melanoma differences. Pharmacodynamics and pharmacokinetics of ASA differ 
between men and women: the effect on platelets differs across gender and women 
achieve higher concentrations with equal doses being administrated. [32] As ASA may 
influence oxidative stress, the gender difference in antioxidant enzymes may have a 
role. [36] Remarkably, a recent RCT investigating antioxidant supplementation showed 
an increase of CM incidence in women, but not in men. [37] Another explanation may 
be that melanoma biology itself may not be comparable in men and women, as CM 
survival differs significantly across gender when adjusted for other prognostic factors. 
[30,31] Differences in adherence to cardiovascular drugs, however, are not likely to 
explain the observed gender differences. [38] 
Interestingly, we previously reported a gender difference in the effects of statins on 
CM incidence and progression using the same study population. [27] Future (epide-
miological) studies are warranted to explore CM gender differences.
Strengths and weaknesses
This is the largest population-based study that investigates the effect of NSAID use on 
CM incidence in more than 1350 cases. The CM cases were confirmed by a pathology 
report, and drug exposure was prospectively assessed by a highly reliable pharmacy 
database. [39] In PHARMO, detailed information on drug use was available, such as the 
number of dispenses, the number of dispensed pills, and dosage. As the dosages (in 
WHO’s defined daily doses) of NSAIDs differ largely between the indications for which 
they are prescribed, we were not able to include this information. Furthermore, since 
a large proportion of the NSAIDs are used as analgetics ‘on demand’, no data were 
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available regarding the duration of use for these types of NSAIDs. Therefore, duration 
of use could not be included in the analyses, except based on the number of pills 
prescribed. As several NSAIDs are available over the counter without a prescription, 
the actual use of NSAIDs is underestimated. Therefore, if this would influence our 
results, it is most likely that this would produce bias toward the null.  However, this 
misclassification is likely to be equal among cases and controls; hence, bias is likely to 
be minimal. In this study, NSAID use was ascertained in the 3 years before CM diagnosis, 
which may have been too short to detect the effect of NSAID exposure. [6] However, 
increasing the observation period to 5 years decreased the sample size substantially 
(from 1318 to 931 CM cases). Although a proxy for health care consumption was 
included in the multivariable model, surveillance bias may still have affected our 
results. Information on life-style factors such as sun exposure was not available, but 
the confounding effect of sun exposure on NSAID use seems to be limited.   
Conclusion
In conclusion, long-term use of (low-dose) ASA was associated with a reduced risk of 
CM in women, but not in men. Future observational and ultimately interventional 
clinical studies are needed to confirm these findings.
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Abstract
Background:  A reduced incidence of nonmelanoma skin cancer among users of An-
giotensin-converting enzyme inhibitors (ACEi) and Angiotensin Receptor blockers 
(ARb) has been reported. A similar effect is suggested for cutaneous melanoma. We 
aimed to investigate the possible association between use of ACEi and ARb and the 
risk of cutaneous melanoma . 
Patients and Methods:  A general population-based case control study with the 
PHARMO database, containing drug-dispensing records from community pharmacies 
and the national pathology database (PALGA) was conducted. Cases were patients 
with a primary cutaneous melanoma between January 1st 1991 and December 14th 
2004, aged ≥ 18 years and having ≥ 3 years of follow-up prior to diagnosis. 
Results:  Finally, 1272 cases and 6520 matched controls were included. Multivariable 
conditional logistic regression showed no statistically significant associations between 
the incidence of melanoma and the use of ACEi (adjusted odds ratio (OR) = 1.0, 95% CI 
= 0.8-1.3) or ARb (adjusted OR = 1.0, 95% CI = 0.7-1.5). 
Conclusion:  In this study, the use of ACEi or ARb does not seem to protect against the 
development of cutaneous melanoma. However, we cannot exclude an association 





Chemopreventive effects in cancer have been suggested for angiotensin-converting 
enzyme (ACEi) inhibitors and angiotensin receptor (ARb) blockers in both in vitro 
studies, animal studies and epidemiologic studies. [1-6] In vitro and in vivo effects 
have been demonstrated on cell proliferation, gene expression, migration and 
invasion and angiogenesis. [1] These effects may be mediated through angiotensin II 
or bradykinin. [1] However, other mechanisms, such as inhibition of metalloproteases 
[4], reduction of the activity of plasminogen activator inhibitor-I [7], generation of 
angiostatin from plasmin [8] or activity as a free-radical scavenger [9] if a free sulhydryl 
donor is present in the molecule, e.g., captopril and zofenopril, may also be involved. 
Depending on which mechanisms are involved, chemopreventive effects may be 
considered to be an overall class effect for both ACEi and ARb, may be present for only 
ACEi or may be restricted to exposure to ACEi with a certain chemical structure.
In human head and neck squamous skin cancer cells, Yasumatsu and Nakashima observed 
a significant inhibitory effect on tumor growth and blood vessel formation mediated 
by perindopril. [5] Specifically for cutaneous melanoma, an in vitro study showed that 
captopril has antitumor activity in a human melanoma xenograft model. [10] 
For melanoma, chemoprevention is of special interest because of rapidly increasing 
incidence (http://www.cancer.org/, Cancer Facts and Figures 2008, accessed February 
3rd 2009) and the lack of survival prolonging therapies for advanced disease. [11] 
Recently, two epidemiological studies among users of ACEi and ARb reported on 
reduced risks of nonmelanoma skin cancer. [6,12]
With respect to the expected safety profile, ACEi and ARb would be good candidates 
because they are widely used in clinical practice with few side effects. However, to 
our knowledge, no observational studies have been performed that specifically 
investigate the chemoprophylactic properties of ACEi and ARb in melanoma. 
Therefore, we investigate the potential association between the risk of cutaneous 
melanoma and exposure to (different chemical drug classes of) angiotensin-convert-
ing enzyme inhibitors and angiotensin receptor blockers.
Patients and methods
Study design
We conducted a general population-based case control study exploring the use of 
ACEi and ARb among individuals with and without cutaneous melanoma. The protocol 
use of ace-inhibitors, ar-blockers and melanoma
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of this study was approved by the scientific and privacy committees of both PALGA 
and PHARMO, and was granted exempt status by the ethics board of the Leiden 
University Medical Centre. An outline of the methods is presented here. Additional 
details are presented in earlier work. [13] 
Data were extracted from the PHARMO (PHARmaco MOrbidity) linkage network and 
the PALGA database. PHARMO contains virtually complete drug-dispensing records of 
over 2 million Dutch residents, included regardless of the type of health insurance or 
other relevant factors and representing >12% of the Dutch population (http://www.
pharmo.nl, Databases, accessed October 7th 2009). These computerized drug-dis-
pensing histories contain all dispensed prescriptions and include type, quantity, 
dosage form, strength, dispensing date and prescribed daily dose of the dispensed 
drug. 
PALGA is the Nationwide Network and Registry of Histo- and Cytopathology and 
contains pathology abstracts with diagnostic terms in scope with SNOMED 
classification of all Dutch patients (100% registration since 1990) and is the source of 
the Netherlands Cancer Registry. PHARMO and PALGA are linked using a variation of a 
reliable probabilistic algorithm. [14,15]
Two investigators read all pathology reports to validate the melanoma diagnoses. 
Interobserver variation was assessed on 300 randomly selected cases. 
Cases were included if they had a primary diagnosis of cutaneous melanoma between 
January 1st 1991 and December 14th 2004 in PALGA, were aged 18 years or older at 
diagnosis and had at least 3 years of complete follow-up in PHARMO prior to diagnosis. 
For every case, an average of five controls, matched for age (± 2 years), gender, and 
geographical region, was included. To calculate follow-up, controls were assigned the 
index date of the matched case. Potential controls were excluded if, in PHARMO, a 
date of entry was unknown, they were younger than 18 years at the index date, 
follow-up in the 3 years before index date was incomplete or if they were diagnosed 
in PHARMO with previous melanoma according to the International Classification of 
Disease. If more controls were elligible, the excess number of controls was randomly 
deleted.
Drug exposure
For cases and controls, dispenses of all commercially available ACEi and ARb 
(Anatomical Therapeutic Classification (ATC) codes: C09AAxx and C09CAxx), restricted 
to the 3-year observation period before the index date, were included. To avoid 
misclassifying cases and controls as ACEi or ARb users, drug exposure was defined as 
at least 6 months of cumulative prescription duration in the 3 years before melanoma 
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(e.g., after one or two first dispenses patients may discontinue for several reasons, 
effects on melanoma incidence of such short periods of use are considered to be 
unlikely). 
ACEi were further classified in three drug classes according to their chemical structure 
(Table 1). 
The level of exposure to ACEi and ARb was expressed in defined daily doses (DDD) 
according to WHO definitions (http://www.whocc.no/atcddd/indexdatabase/, last 
accessed February 6th 2009). Drug exposure was further detailed with three additional 
drug exposure variables, all with the 6-month threshold. In explanation, the cumulative 
dispensed dose, the cumulative prescribed duration and the average day dose within 
the 3-year period were calculated. The average day dose was defined as the cumulative 
dose divided by the cumulative duration. We categorized these drug exposure 
variables across tertiles or the median depending on the number of users. 
use of ace-inhibitors, ar-blockers and melanoma
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Table 1  Chemical drug class and ATC codes for commercially available  
ACE inhibitors














 ATC code= Anatomical Therapeutic Classification code.
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Potential confounders
Ever drug use of drugs possibly related to progression or development of melanoma, 
statins, estrogens and non-steroidal anti-inflammatory drugs were considered as potential 
confounders. [16] Use of fibrates and lipid-lowering drugs other than fibrates or statins 
was recorded, but the number of cases and controls using these drugs were too small to 
be used in further analysis. To test as an additional potential confounder, the total number 
of unique (singular) codes of the International Classification of Disease 9th revision, as an 
estimate of health care consumption which may affect the likelihood of melanoma 
diagnosis, was calculated for each participant in the 3 years before diagnosis.
Statistical analysis
A multivariable conditional logistic regression model was used to calculate adjusted 
OR and 95% confidence interval (CI) for the association between incident cutaneous 
melanoma and the use of ACEi and ARb. Potential confounders (the total number of 
unique medical diagnoses, ever drug use of in the 3-year period of respectively statins, 
estrogens, and non-steroidal anti-inflammatory drugs) were included in the 
multivariable model if they influenced the regression coefficient by 10% or more. [17] 
In sensitivity analyses, stratification across the chemical drug class was performed 
because some of the reported mechanisms of actions would predict chemopreven-
tive effects only for ACEi with a certain chemical structure (see introduction). 
Additionally, separate analyses were performed for men and women. All statistical 
analyses were performed using SPSS 16.0 (SPSS Inc., Chicago, IL).
Results
Study population
In the baseline study, 1,318 melanoma cases and 6,786 matched controls were 
included.13 Of these, 46 cases and 266 controls were excluded because they used an 
ACEi or ARb for less than 6 months. The mean age of the cases and controls was 
respectively 54.9 years [standard deviation (SD) 15.9] and 55.5 years [SD 15.4] (Table 2). 
Accordance between two investigators on the validation of melanoma diagnosis was 
high (Kappa value > 0.85) in a random sample of 300 cases, suggesting small 
interobserver variation.
Exposure to ACE inhibitors and AR blockers
ACEi were used by 85 cases (7%) and 433 controls (7%). Among the ACEi users, 401 
(92%) used a carboxyl derivative, 106 (24%) used a sulfhydryl derivative and 24 (6%) 
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used a phosphoryl derivative.  ARb were used by 30 cases (2.5%) and 148 controls 
(2.4%). Cases and controls using ACEi or ARb was prescribed a median average day 
dose of 1.0 DDD per day (interquartile range: 0.7-2.0 DDD) and 1.0 DDD per day 
(interquartile range: 1.0-1.8 DDD), respectively. The use of ACEi was not significantly 
use of ace-inhibitors, ar-blockers and melanoma
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n % n %
Gender
    male 519 (41 %) 2598 (40 %)
    female 753 (59 %) 3922 (60 %)
Drug use
    ACE inhibitor users a 85 (7 %) 433 (7 %)
          Carboxyl a,b 65 (5 %) 332 (5 %)
          Sulfhydryl a,b 19 (2 %) 87 (1 %)
          Phosphoryl a,b 2 (0.2 %) 22 (0.3 %)
    AR blocker a 30 (2 %) 148 (2 %)
    estrogen users c,d 259 (34 %) 1090 (28 %)
    statin users c 104 (8 %) 511 (8 %)
    NSAID users c 591 (47 %) 2740 (42 %)
Total unique diagnoses
   mean number         0.7              0.6
Age at diagnosis e
    18-34 yr 134 (11 %) 579 (9 %)
    35-44 yr 223 (18 %) 1125 (17 %)
    45-54 yr 274 (22 %) 1445 (22 %)
    55-64 yr 259 (20 %) 1384 (21 %)
    65-74 yr 223 (18 %) 1159 (18 %)
    75 yr and older 159 (13 %) 828 (13 %)
a  At least 6 months of drug use.
b  See Table 1 for chemical drug class classification of ACE inhibitors.
c  Ever drug use.
d  Females only, 753 cases and 3922 controls.
e   Cases: mean ± standard deviation: 54.9 years ± 15.9 years and range: 18-94 years;  
Controls: mean ± standard deviation: 55.5 years ± 15.4 years and range: 18-95 years.
ACE = Angiotensin-Concerting Enzyme, AR = Angiotensin Receptor,  
NSAID = Non-steroidal Anti Inflammatory Drug.
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associated with the incidence of cutaneous melanoma (adjusted OR = 1.0; 95% CI = 
0.8-1.3). Increasing cumulative prescription duration, cumulative dose or average day 
dose also did not show a statistically significant effect of ACEi on cutaneous melanoma 
incidence (Table 3). After adjustment for age at melanoma diagnosis and the number 
of medical diagnoses, the use of ACEi was not associated with a decreased Breslow 
thickness (estimated percentage change in Breslow depth: 2.1%, 95% CI: -17.4% to 
26.2%). We previously described the calculation method used. [13]
For ARb no significant associations were demonstrated if users (>0.5 year) are 
compared to non-users (adjusted OR = 1.1; 95% CI = 0.7-1.5) and if among them the 
cumulative prescription duration, cumulative dose or average day dose was compared 
(Table 3). The use of ARb was also not associated with a decreased Breslow thickness 
after adjustment for the number of medical diagnoses and age at melanoma diagnosis 
(2.4%, 95% CI = -25.3% to 40.6%). 
Sensitivity analysis
Stratification across the three chemical drug classes was performed in a sensitivity 
analysis. For carboxyl and sulfhydryl ACEi, the association was similar to the results for 
the overall effect of ACEi (adjusted OR = 1.0, 95% CI = 0.8-1.3 and adjusted OR = 1.1, 
95% CI =: 0.7-1.7, respectively). Very few cases and controls used phosphoryl ACEi, 
resulting in a large confidence interval (adjusted OR = 0.6, 95% CI = 0.1-2.4). Additionally, 
separate analyses for men and women, showed similar results (data not shown).
Discussion
In this study the use of ACEi or ARb does not seem to protect against the development 
of cutaneous melanoma. However, our study cannot exclude an association between 
ACEi and ARb exposure and either a (moderately) increased or decreased incidence of 
cutaneous melanoma. It is, for instance, possible that exposures with a longer duration 
or to higher doses of ACEi or ARb are needed for an association to be detected. 
A decreased Breslow thickness among the cases using ACEi or ARb, as compared to 
the melanoma patients who did not use ACEi nor ARb, could be considered a clue for 
this possibility. However, the use of ACEi or ARb was not associated with decreased 
Breslow depth.
The major strengths of this study were the large population-based sample of 
pathology confirmed melanoma cases and the prospectively collected and detailed 
information about drug dispenses. A limitation of the study is the relatively small 
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Table 3  Prior Use of ACE Inhibitors or Angiotensin II Receptor Antagonists  
in the Study Population
Cases Controls OR a 95% CI
USE OF ACE INHIBITORS b
Users versus non-users n=1272 n=6520
n % n %
 non-exposed 1187 93.3 % 6087 93.4 % 1.0 referent
exposure >0.5 yr 85 6.7 % 433 6.6 % 1.0 0.8 – 1.3
Cumulative prescription duration c
non-exposed 1187 93.3 % 6087 93.4 % 1.0 referent
non-exposed 32 2.5 % 151 2.3 % 1.1 0.7 – 1.5
1-750 days 19 1.5 % 100 1.5 % 1.0 0.6 – 1.5
751-1000 days 34 2.7 % 182 2.8 % 1.0 0.7 – 1.4
Cumulative dose
0 DDD 1187 93.3 % 6087 93.4 % 1.0 referent
1-600 DDD 26 2.0 % 153 2.3 % 0.9 0.6 – 1.3
601-1200 DDD 33 2.6 % 130 2.0 % 1.2 0.9 – 1.8
> 1200 DDD 26 2.0 % 150 2.3 % 0.9 0.6 – 1.3
Average day dose
0 DDD/day 1187 93.3 % 6087 93.4 % 1.0 referent
0.01-1.00 DDD/day 45 3.5 % 225 3.5 % 1.0 0.7 – 1.4
1.01-1.50 DDD/day 10 0.8 % 62 1.0 % 0.9 0.5 – 1.6
> 1.5 DDD/day 30 2.4 % 146 2.2 % 1.0 0.7 – 1.5
USE OF AR BLOCKERS d
Users versus non-users n=1217 n=6235
 non-exposed 1187 97.5 % 6087 97.6 % 1.0 referent
exposure >0.5 yr 30 2.5 % 148 2.4 % 1.0 0.7 – 1.5
Cumulative prescription duration c
non-exposed 1187 97.5 % 6087 97.6 % 1.0 referent
1-750 days 20 1.6 % 70 1.1 % 1.4 0.9 – 2.1
>750 days 10 0.8 % 78 1.3 % 0.7 0.4 – 1.3
Cumulative dose
0 DDD 1187 97.5 % 6087 97.6 % 1.0 referent
1-1000 DDD 22 1.8 % 82 1.3 % 1.3 0.8 – 2.0
> 1000 DDD 8 0.7 % 66 1.1 % 0.7 0.3 – 1.4
Average day dose
0 DDD/day 1187 97.5 % 6087 97.6 % 1.0 referent
0.01-1.00 DDD/day 16 1.3 % 89 1.4 % 0.9 0.6 – 1.5
> 1.0 DDD/day 14 1.2 % 59 0.9 % 1.2 0.7 – 2.0
a Adjusted for the total number of unique medical diagnoses and the use of statins.
b All commercially available ACE inhibitors in The Netherlands between 1991 and 2004.
c Time interval between first prescription and estimated last day of use based on last dispense and amount 
dispensed in the three years before diagnosis of cutaneous melanoma.
d All commercially available AR blockers in The Netherlands between 1991 and 2004.
OR = Odds Ratio, CI = Confidence Interval, ACE = Angiotensin-Concerting Enzyme, AR = Angiotensin Receptor.
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number of ACEi and ARb users leading to limited statistical precision, especially for 
the stratified analyses. Another limitation is the relatively short follow-up (3 years). We 
decided to use only cases and controls with complete follow-up to guarantee that 
cases and controls were active members of the PHARMO network and thus all 
prescription drugs dispensed would be registered in PHARMO. Due to sample size 
limitations, we were not able to study the effects of drug use longer than 3 years 
before cutaneous melanoma. However, the length of follow-up in our study was 
comparable with the median follow-up in a previous study in which exposure to ACEi 
and ARb was significantly associated with reduced risks of basal cell carcinoma and 
squamous cell carcinoma. [12] 
Residual confounding may have affected our findings. ACEi and ARb users are likely to 
have more health care contacts and therefore might be more likely to be diagnosed 
with melanoma. We included the number of unique medical diagnoses (ICD codes) in 
our study to adjust for this. Nevertheless, not all health consumption may be reflected 
in these diagnoses and ascertainment bias cannot be excluded.
Common risk factors for melanomas, such as family history of melanoma, skin type, 
sun exposure history and socioeconomic status, are not available in PHARMO and 
PALGA. Therefore, we could not adjust for these factors. Skin type and family history 
of melanoma are, in our opinion, unlikely to affect the likelihood of prescription of 
ACEi and ARb. Thus, confounding by indication by these seems unlikely. Sun exposure, 
however, may be indirectly related to ACEi and ARb exposure because it may be 
associated with increased physical activity and a reduced chance of hypertension. 
Likewise, high social economic status is associated with increased sun exposure and 
may also be associated with a reduced chance of hypertension. Both these potential 
biases would in an underestimation of any effect of ACEi and ARb and would thus 
produce bias toward the null. 
An additional source of residual confounding may be exposure to NSAIDs obtained as 
over-the-counter drugs that will not always be registered in PHARMO. However, such 
misclassification is likely to be equal among cases and controls; hence, bias is likely to 
be minimal.
Despite the limitations mentioned, we believe the results of our study with adjusted 
ORs near to 1.0 emphasize the possibility that ACE inhibitors and AR blockers at current 




In this study, the use of ACEi or ARb does not seem to protect against the development 
of cutaneous melanoma. However, we cannot exclude an association between ACEi 
and ARb exposure and an increased or decreased incidence of cutaneous 
melanoma. 
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Abstract
Background:  Multiple studies showed conflicting results on the association between 
oral contraceptive use and the development of cutaneous melanoma (CM). We 
investigated the association between estrogen use and CM incidence. 
Patients and methods:  Data from PHARMO Pharmacy database and PALGA, the pathology 
database in the Netherlands, were linked. Women, ≥ 18 years, with a pathology report of 
a primary CM between January 1st 1991 and December 14th 2004 and ≥ 3 years of 
follow-up prior to CM diagnosis were eligible cases. Controls were matched for age and 
geographic region. Multivariate logistic regression was used to calculate adjusted odds 
ratio (OR) and 95% confidence interval (CI) for the association between CM incidence 
and estrogen use, oral contraceptives (OC) and hormonal replacement therapy (HRT), 
separately. 
Results:  In total, 778 cases and 4072 controls were included. CM risk was significantly 
associated with estrogen use (≥ 0.5 year; adjusted OR=1.42, 95% CI: 1.19-1.69). This effect 
was cumulative dose-dependent (p-trend < 0.001). CM risk was also significantly 
associated with the use of HRT (≥ 0.5 year: OR=2.08; 95% CI: 1.37-3.14) and OC (≥ 0.5 year: 
OR=1.28; 95% CI: 1.06-1.54). 
Conclusion:  Our study suggests a cumulative dose-dependent increased risk of CM with 




The influence of estrogens on the incidence of cutaneous melanoma (CM) in women 
has been supported by a number of observations. Firstly, indicating the effect of 
estrogens on melanocyte proliferation, hyperpigmentation is a side-effect of oral 
contraceptive (OC) use and may also occur during pregnancy (chloasma) or with the use 
of hormonal replacement therapy (HRT). [1] Secondly, until the age of ~45 years, CM 
incidence rates exceed those in men, after which the incidence rates in men rise 
markedly, but level off in women. Since the incidence rates of CM in women mimic those 
of breast cancer, female sex steroids have been hypothesized to be involved in the 
development of CM in women. [2] Additionally, recent studies have demonstrated 
improved survival among women compared to men with CM after adjusting for 
demographic and tumor characteristics. [3, 4] One of the possible explanations may be 
influence of estrogens because it has been suggested that estrogens are associated 
with melanomas with a relative good prognosis such as superficial spreading melanomas. 
[4] In a previous study we observed that ever use of estrogens was associated with an 
increased incidence of CM. [5] Moreover, women with a history of breast cancer have 
been reported to be at higher risk of CM and vice versa. [6] Also, estrogen-binding 
receptors have been detected in melanomas and benign nevi [7].
On the basis of these observations, several epidemiological studies have investigated 
the association between OC use and CM development. These studies show, however, 
inconsistent results. About 25-30 years ago, a higher CM incidence was suggested 
among women using OC compared to women who never used OC in three cohort 
studies. [8-10] Nevertheless, subsequent (case control) studies failed to confirm a 
significant effect of OC on the incidence of CM. [11-15] However, a few large studies with 
long-term follow-up and a relatively high proportion of women having used OC for a 
long period of time did show a significant two- to four-fold increased likelihood to 
develop CM. [16-18] In a pooled analysis of 10 case-control studies Karagas et al. [2] 
observed no excess CM risk associated with OC use for 1 year or longer compared to 
non-users. However, these studies are limited in sample size and included selected study 
populations. Prior estrogen use was assessed by interviews or questionnaires, which 
may result in a recall bias. Moreover, no differentiation was made between OC and HRT. 
In this case control study, we linked a population-based pharmacy database with the 
national pathology database to assess the association between the incidence of CM and 
estrogen, OC and HRT use, separately.  
 





Data were used from the PHARMO database, containing drug-dispensing records of a 
defined population of more than 2 million Dutch residents representing >12% of the 
Dutch population. Residents are included regardless of type of health insurance or other 
relevant factors. [19] 
The core file of the PHARMO system is a patient-roster file which includes of all patients 
an entry- and exitdate. To this roster file, the drug dispensing records of all pharmacies, 
and pathology records are linked on a patient-centric level. Since most individuals 
designate a single pharmacy in The Netherlands, dispensing histories are virtually 
complete. [20] The computerized drug-dispensing histories contain all dispensed 
prescriptions and include type, quantity, dosage form, strength, dispensing date and 
prescribed daily dose of the dispensed drug. PHARMO was linked to PALGA, the Dutch 
nationwide registry of histo- and cytopathology, using a variation of a reliable 
probabilistic algorithm. [21] PALGA contains abstracts of all pathology reports with 
encrypted patient identification and diagnostic terms being in scope with SNOMED 
classification. Since 1990 the registration reached 100% participation and in 2004 over 9 
million patients were archived. [22] Therefore, PALGA represents all Dutch patients and is 
the basis for the Netherlands Cancer Registry.
We reported our study according to the STROBE guidelines. [23]
Study population
Cases had a primary CM diagnosis in PALGA from 1 January 1991 to 14 December 2004 
and were also followed by PHARMO at any point in this period. End of follow-up was 
defined as the date of CM diagnosis (index date). 
For each case all records in PALGA were read by one of two investigators (AJ, ERK). From 
these records, ERK and AJ extracted and recorded final diagnosis, date, anatomical 
location and CM subtype according to WHO classification [24] of the primary CM. 
To assess interobserver variation, 300 cases were randomly selected and scored by both 
researchers.
Potential cases were excluded if, in PHARMO, a date of entry was unknown, gender was 
unknown, follow-up in the 3 years before CM diagnosis was incomplete, or, in PALGA, 
the date of CM diagnosis was before the age of 18 or before January 1 1991, the CM was 
not pathologically confirmed, the primary CM was not on the skin (e.g. in the eye) or if 
the CM was in situ (Fig. 1).
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For every eligible case, an average of five controls was sampled from the population 
available in PHARMO, matched for date of birth (± 2 years) and geographic region 
(individual matching). Potential cases could not be selected as controls. To calculate 
follow-up, controls were assigned the index date of the matched case. 
Potential controls were excluded if, in PHARMO, a date of entry was unknown, they were 
younger than 18 years at the index date, follow-up in the 3 years before index date was 
incomplete, or if they were diagnosed in PHARMO with previous CM according to the 
International Classification of Disease (Fig. 1).
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Figure 1  Flow chart study population †
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total: n = 4,850
1 Cases excluded Total n = 1,275 100 %
1 = Entrydate missing n=34 2.7 %
2 = Age at diagnosis < 18 yrs n=15 1.2 %
3 = Follow up 3 yr before CM incomplete n=810 64 %
4 = CM not pathologically confirmed n=195 15 %
5 = Primary CM before 1991 n=59 4.6 %
6 = no cutaneous MM (i.e. eye) n=102 8.0 %
8 = in situ CM n=30 2.4 %
9 = no matched controls included n=30 2.4 %
2 Controls excluded Total n= 5,463 100 %
1 = Entrydate missing n= 373 6.8 %
2 = Age at diagnosis < 18 yrs n= 9 0.2 %
3 = Follow up 3 yr before CM incomplete n= 5,079 93  %
4 = possible CM patient (ICD code ‘CM’) n= 2 0.04 %
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Drug Exposure 
Estrogen exposure was expressed in defined daily doses (DDDs) according to the WHO 
definitions. It was defined as the use of one or more estrogens containing formulations 
for at least 6 months of cumulative prescription duration in the 3 years before CM 
because a minimal exposure was assumed to be required for the hypothesized biologic 
mechanism (Fig. 2). All estrogens commercially available and approved in The Netherlands 
in the study period were included. Estrogen use was differentiated between OC (ATC 
codes: G03AAXX and G03ABXX) and HRT (ATC code: G03CAXX). For OC, daily use for 21 
days and subsequently a 7 days period of non-use was assumed and therefore we 
divided the prescribed daily dose by 0.75 (= 21 of 28). Some OC formulations are used for 
22 days with a 6-day drug-free period. However, this applied to only 6.2% of the 
prescriptions and the error is < 5%. Therefore, we did not correct for this. 
For locally applied HRT, i.e. vaginal therapy, only dispenses with a prescribed dose 
corresponding with a minimal systemic exposure of 0.25 DDD/day orally were included. 
To further detail estrogen use, the cumulative dispensed dose and the cumulative 
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Ever use of drugs possibly related to progression and development of CM such as 
non-steroidal anti-inflammatory drugs (NSAIDs including COX-2-inhibitors) and statins 
was assessed [25]. Use of fibrates and lipid-lowering drugs other than fibrates or statins 
[25] was recorded, but the number of cases and controls using these drugs were too 
small (<1.0 %) to be used in further analysis. 
To estimate health care consumption, which may affect the likelihood of CM diagnosis, 
the total number of unique prescriptions (ie, number of different ATC codes excluding 
estrogens) recorded in PHARMO in the 3 years before CM was included. 
Statistical analysis
To test for statistical differences, χ2 and Student’s t-tests were used for categorical and 
continuous variables respectively. All statistical tests were performed two-sided with 
rejection of the null hypothesis at a p-value <0.05. 
A multivariate logistic regression model was used to calculate adjusted odds ratio (OR) 
and 95% confidence interval (CI) for the association between CM incidence and estrogen 
use. In the multivariate model we included confounders with a p-value <0.10 in univariate 
analysis. The different estrogen variables were categorized based on tertiles among all 
users. We categorized HRT variables across the median because of the relative small 
numbers. 




In total, 2053 female subjects who were registered in PHARMO had a SNOMED code ‘CM’ 
in PALGA, of which 778 (37.9%) met the inclusion criteria (Fig. 1). Most of the potential 
cases were excluded because the time periods they were registered in PALGA and 
PHARMO did not match, or the follow-up in PHARMO in the 3 years before CM diagnosis 
was incomplete. The accordance in extracting the relevant information from the 
pathology records between the two authors was high (Kappa values >0.85). Of the 9535 
controls matched on age (± 2 years) and geographical region, 4072 (42.7%) were eligible 
to enter the study. 
Mean age of cases and controls was 53.6 and 54.6 years (p >0.05; Table 1). The number of 
unique prescriptions excluding estrogens was borderline significant with cases having 
more prescriptions than controls (8.25 versus 7.74, p = 0.047).




Table 1  Prior estrogen use (hormonal replacement and contraceptives)  
and characteristics of the study population
Cases
(778 )
n            % 
Controls 
(4072 )




Age at diagnosis b yrs 53.6 ± 16.5 54.6 ± 16.1 0.13 - -
Total unique  
diagnoses b
number 0.62 ± 1.33 0.59 ± 1.50 0.55 - -
Total unique 
prescriptions c
number 8.25 ± 7.37 7.74 ± 6.48 0.05 - -
NSAIDs d yes 388 49.9 1817 44.6 - -
no 390 50.1 2255 55.4 <0.01 - -
Statins d yes 40 5.1 265 6.5 - -
no 738 94.9 3807 93.5  0.15 - -
Estrogen use e non-exposed 577 74.2 3270 80.3 1.00 referent




non-exposed 577 74.2 3270 80.3 g 1.00 referent
1-700 days 75 9.6 279 6.9 <0.01 1.51 h 1.15 – 1.98
701-1100 days 63 8.1 301 7.4 0.24 1.19 h 0.89 - 1.58
>1100 days 63 8.1 222 5.5 0.001 1.61 h 1.20 - 2.16
Cumulative dose 0 DDD 577 74.2 3270 80.3 g 1.00 referent
1-650 DDD 63 8.1 271 6.7 0.06 1.31 h 0.98 - 1.75
651-1000 DDD 68 8.7 270 6.6 0.01 1.44 h 1.08 - 1.90
> 1000 DDD 70 9.0 261 6.4 <0.01 1.51 h 1.14 – 1.99
a   Adjusted for the total number of unique prescriptions dispensed (excluding estrogens) and the use of NSAIDs.
b   Mean value presented ± standard deviation, tested for statistical difference with t-test, equal variances assumed.
c   Mean value presented ± standard deviation, tested for statistical difference with t-test, equal variances not 
assumed.
d   Number of cases and controls presented, tested for statistical difference with χ2-test.
e   Estrogen use: hormonal replacement therapy (HRT) and oral contraceptives (OC).
f    Time interval between estimated last day of use (based on last dispense and amount dispensed) and date of 
diagnosis of CM. The cumulative prescription duration may exceed  maximum number of days of follow up  
(3 years) due to overlapping dispenses.
g   p-value for trend analysis: <0.001
h   p-values calculated for each category of estrogen-users compared with non-users. 
NSAIDs, non-steroidal anti-inflammatory drugs; OR, odds ratio; CI, confidence interval; DDD, defined daily dose.
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Estrogen use
Estrogens were used for more than half a year in the study period by 25.8% of the cases 
and 19.7% of the controls (p <0.001; Table 1). Of estrogens used, 83.4% was ethinyloestra-
diol, 9.1% was oestradiol, 4.8% were conjugated estrogen, 2.0% was oestriol and 0.6% 
was mestranol. 
Cases and controls did not differ in the average day dose of estrogens. Cases were 
prescribed an average estrogen day dose of 0.73 DDD/day [standard deviation (SD) 0.19] 
and controls were prescribed 0.75 DDD/day [SD 0.16]. 
In univariate analysis, estrogen use (≥ 0.5 year), ever NSAID use, a cumulative prescription 
duration (1-700 days or >1100 days) or a cumulative dose of estrogens (651-1000 DDD or 
>1000 DDD) were significantly associated with the incidence of CM (p < 0.05). 
After adjusting for confounding factors in a multivariate model, estrogen use (≥ 0.5 year) 
remained significantly associated with a higher risk of developing CM (adjusted OR = 
1.42, 95% CI = 1.19-1.70). 
Compared to controls, CM patients were significantly more likely to have used higher 
cumulative doses. Compared to female non estrogen users, women who used estrogens 
>1100 days were ~60% more likely to have developed a CM (adjusted OR = 1.61, 95% CI 
= 1.20-2.16). For the cumulative prescription duration as well as the cumulative dose, a 
statistically significant trend was detected (p <0.001).
Oral Contraceptives
OC was used in the study period for more than half a year by 21.5% of the cases and 
17.7% of the controls. Of the oral contraceptives used, 99.3% was ethinyloestradiol and 
0.7% was mestranol. In univariate analysis, OC use (≥ 0.5 year) was significantly associated 
with the incidence of CM (p < 0.05; Table 2). After adjusting for confounding factors in 
a multivariate model, OC use remained significantly associated with development of CM 
(adjusted OR = 1.28, 95% CI = 1.06-1.54). Compared to female non estrogen users, women 
who used estrogens longer than 1100 days were more likely to have developed CM 
(adjusted OR = 1.56, 95% CI = 1.16-2.10). Female CM patients were significantly more likely 
to be included in the highest category of cumulative dose than those without CM 
(>1000, adjusted OR = 1.44, 95% CI = 1.08-1.94, compared to 0 DDD). For the cumulative 
prescription duration (p-trend analysis <0.01) as well as the cumulative dose (p =  0.01), 
a statistically significant trend was found.
Hormonal Replacement Therapy
HRT was used for more than half a year in the study period by 4.2% of the cases and 2.0% 
of the controls (p = 0.001; Table 2). Of the HRT used, 56.9% was estradiol, 29.9% were 




Table 2  Prior use of oral contraceptives (OC) or hormonal replacement  








ORAL CONTRACEPTIVES        n % n % p-value
Prior OC use b non-exposed 611 78.5 3351 82.3 1.00 referent
exposure 
>0.5 yr
167 21.5 721 17.7 0.01 1.28 1.06 – 1.54
Cumulative 
prescription duration b,c 
0 days 611 78.5 3351 82.3 d 1.00 referent
1-700 days 56 7.2 235 5.8 0.08 1.31 e 0.96 – 1.77
701-1100 days 50 6.4 271 6.7 0.94 1.02 e 0.75 – 1.40
>1100 days 61 7.8 215 5.3 <0.01 1.56 e 1.16 – 2.10
Cumulative dose b 0 DDD 611 78.5 3351 82.3 d 1.00 referent
1-700 DDD 55 7.1 256 6.3 0.29 1.18 e 0.87 – 1.60
701-1000 DDD 50 6.4 230 5.6 0.28 1.21 e 0.88 – 1.67
>1000 DDD 62 8.0 235 5.8 0.01 1.44 e 1.08 – 1.94
HORMONAL REPLACEMENT THERAPY
Prior HRT use b  non-exposed 745 95.8 3990 98.0 1.00 referent
exposure 
>0.5 yr
33 4.2 82 2.0 0.001 2.08 1.37 – 3.14
Cumulative 
prescription duration b,c 
0 days 745 95.8 3990 98.0 d 1.00 referent
1-671 days 18 2.3 43 1.1 <0.01 2.16 1.24 – 3.78
>671 days 15 1.9 39 1.0 0.02 1.98 1.08 – 3.62
Cumulative dose b 0 DDD 745 95.8 3990 98.0 d 1.00 referent
1-671 DDD 18 2.3 44 1.1 <0.01 2.13 1.22 – 3.71
>671 DDD 15 1.9 38 0.9 0.01 2.02 1.10 – 3.70
a  Adjusted for the total number of unique prescriptions dispensed (excluding estrogens) and the use of NSAIDs.
b  Number of cases and controls presented, tested for statistical difference with χ2-test.
c   Time interval between estimated last day of use (based on last dispense and amount dispensed) and date of 
diagnosis of CM. The cumulative prescription duration may exceed maximum number of days of follow up  
(3 years) due to overlapping dispenses.
d   p-values calculated for each category of estrogen-users compared with non-users. 
e  p-value for trend analysis: ≤0.01
 
OC, oral contraceptive; HRT, hormonal replacement therapy; OR, odds ratio; CI, confidence interval; DDD,  
defined daily dose.
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conjugated estrogens, 12.5% was estriol and 0.6% was ethinyloestradiol. In univariate 
analysis HRT use (≥ 0.5 year) and the highest categories of cumulative prescription 
duration and dose of HRT were significantly associated with the incidence of CM (p < 
0.05; Table 2). After adjusting for confounding factors in a logistic multivariate model, 
HRT use (≥ 0.5 year) was still significantly associated with development of CM (adjusted 
OR = 2.08, 95% CI = 1.37-3.14). In the multivariate model, female CM patients were two 
folds more likely to have used HRT for a longer duration and higher cumulative doses 
than those without CM. 
Subgroup analysis
Restricting the multivariate analysis to the effect of estrogen use (≥ 0.5 year) on the 
incidence of superficial spreading CM showed comparable results (adjusted OR = 1.46; 
95% CI = 1.18-1.81). If the analysis was restricted to nodular CM, lentigo maligna and 
others, the risk estimate is slightly lower (adjusted OR = 1.12,  95% CI = 0.74-1.69). 
Discussion
Estrogens – in general
Estrogen use, both OC and HRT therapy, was associated with an increased incidence of 
CM. Although we can only speculate about the causality based on observational studies, 
the significant dose-effect relationships we detected do support our hypothesis. 
Previous studies are not in accordance with our findings. This may be due to lower 
cumulative doses of estrogens being used or limited sample sizes. Early case control 
studies [8-10], which also supported an increased risk of CM with estrogen use, are likely 
to have included higher doses (doses of estrogens used have declined since the 1970’s).
On the based of an overall CM incidence among women in The Netherlands in 2000 of 
16 per 100.000 person-years [26], a female population of 8,02 million [27] of which 20% 
uses estrogens and an estimated relative risk of 1.42, the crude estimate for the incidence 
of CM among non-users of estrogens would be 15 per 100.000 person-years and would 
increase to 21 per 100.000 person-years with estrogen use.
Oral Contraceptives versus Hormonal Replacement Therapy
Although the adjusted OR of the association between OC and HRT and CM are not 
statistically different, the difference is striking (OC: OR = 1.28, 95% CI = 1.06-1.54, HRT: OR 
= 2.08, 95% CI = 1.37-3.14). Theoretically, there are several important differences between 
OC and HRT. The age distribution differs (ie, HRT is used in post and OC in pre menopausal 
estrogens increase the incidence of melanoma
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women). However, both age at diagnosis as well as an multiplicative interaction term of 
estrogen use and age were not statistically significant in multivariate analysis. In this 
study, it is impossible to differentiate between the effects of the HRT and more variable 
or lower endogenous estrogens on development of CM. Also, HRT consist of estrogen 
monotherapy, whereas OC usually is a combination of an estrogen with a progestagen. 
No effects of progestagens on the incidence of CM have been published. However, as 
Dobos pointed out, very limited data are available on the progestagen effects on the 
biological behavior of CM. [28] In contrast to OC, which nearly always contains ethiny-
loestradiol, HRT mostly contains oestradiol, conjugated estrogens or oestriol. The 
regimen in which OC and HRT differs because HRT can be used intermittently or 
continuously and OC is normally used once daily for a period of 21 days/month. 
Estrogens used as HRT are often applied locally. To affect CM incidence a systemic 
exposure is warranted, therefore, we only included HRT dispenses that were likely to 
result in a minimal systemic exposure of estrogens (≥0.25 DDD/day orally). Obviously, 
our results also do not apply for estrogens applied locally in relatively low doses (for 
instance vaginal therapy twice weekly).
Strengths and limitations
This is the largest case-control study exploring the effects of estrogen use on CM 
incidence including >750 female cases. Both cases and controls in our study were 
sampled from PALGA and PHARMO. These databases are general population-based and 
reflect the Dutch population well. [21-22] Moreover, pharmacy data are gathered 
prospectively avoiding recall bias. Since we had detailed drug dispensing information, 
we were able to study dose-effect responses, differentiate between OC and HRT, and 
exclude low-dosed topically applied estrogens. Confounding by indication seems 
unlikely because risk factors of CM do not affect the prescription of OC. It seems highly 
unlikely that menopausal complaints (e.g., flushing and vaginal atrophy) or causes of 
menopause (e.g., hysterectomy) are associated with the incidence of CM, unless 
estrogens are prescribed for osteoporosis. Because osteoporosis is associated with low 
endogenous vitamin D levels and low sun exposure, which affect CM incidence in 
opposite directions [29], the association between HRT use and CM development may be 
affected. Unfortunately, vitamin D levels and measures of life-style factors such as sun 
exposure were not available in the PHARMO database. To our knowledge, only one study 
has studied the association between estrogen use and sun exposure and demonstrated 
that HRT users did not differ in sun exposure compared non-users, but users were more 
likely to use sunbeds. [30] For OC, the association with sun (bed) exposure use has not 
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been documented. To minimize the ascertainment bias, the analyses were adjusted for 
a proxy of health care consumption (i.e. the number of unique ATC codes). We limited 
the study to the effects of estrogen use in the 3 years prior to CM diagnosis to not 
exclude too many patients. For some subgroup analyses, especially for the use of HRT, 
the sample sizes may be too small. Most cases were excluded because they were 
registered in PHARMO in a different time period. 
Unfortunately, the variation in average day dose of estrogens, expressed in DDD, among 
users was minimal and therefore any possible associations between average day dose 
and CM incidence would not have been detectable in our population. Therefore we did 
not include average day dose in our analysis.
Conclusion
This large observational study suggests a cumulative dose-dependent increased risk of 
CM with the use of estrogens. In our study, women who used estrogens for more than 
half a year were about 40% more likely to have developed a CM than women who did 
not use estrogens or less than half a year (adjusted OR = 1.42, 95% CI = 1.19-1.70). A 
validation of our findings is warranted, preferably in a (prospective randomized) study 
with detailed propectively gathered information on both drug use as well as sun (bed) 
exposure. Moreover, more experimental research is warranted to elucidate the effects of 
estrogens, progestagens and gender on CM development and progresison.
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Abstract 
Background:  Recently, we demonstrated there was a cumulative dose-dependent 
association between the use of estrogens and the incidence of melanoma (CM). This 
association was demonstrated for both oral contraceptives (OC) and hormonal 
replacement therapy (HRT). Some in vitro studies, however, have suggested a direct 
inhibitory effect on melanoma tumor growth. Therefore, the use of different types of 
estrogens, OC and HRT, may be associated with a decreased Breslow thickness. 
Consequently, the clinical impact of our previous findings may be limited. In this 
study, we investigate if estrogen use (≥ 0.5 year), OC or HRT, are associated with a 
decreased Breslow thickness.  
Patients and Methods:  For this study, we linked the national Dutch pathology database 
(PALGA) to a pharmacy database (PHARMO). Cases were women with a primary 
cutaneous melanoma between January 1st 1991 and December 14th 2004, aged ≥ 18 
years and having ≥ 3 years of follow-up prior to diagnosis of cutaneous melanoma. 
Results:  In total, 687 women with melanoma were included. Univariable linear 
regression analysis suggested a decreased Breslow thickness with the use of OC and 
HRT. Statistically significant interaction was observed between age and estrogen use 
(p <0.01) suggesting effect modification by age. However, in stratified multivariable 
analyses for different age groups (< 45 years, 45-55 years, ≥ 55 years), no statistically 
significant associations between the use of OC or HRT and Breslow thickness were 
observed. 





Influences of estrogens on cutaneous melanoma (CM) are suggested by several 
observations. First, CM incidence rates in women mimic incidence rates of breast 
cancer. [1] Therefore, estrogens have been hypothesized to be involved in the 
development of CM in women. Second, women with a history of breast cancer have 
been reported to be at higher risk of CM and vice versa. [2] In addition, estrogen-bind-
ing receptors have been detected in melanomas and benign nevi. [3] Moreover, 
indicating effects on melanocyte proliferation, hyperpigmentation can occur as a 
side-effect of oral contraceptives (OC), during pregnancy (chloasma) or with the use 
of hormonal replacement therapy (HRT). [4] 
Observational studies investigating the association between estrogen use and CM 
development are, however, conflicting. [1] Recently, in a large population-based 
case-control study, we demonstrated a cumulative dose-dependent association between 
the use of estrogens, for both OC and HRT, and the incidence of CM. [5] The clinical 
relevance of our findings, however, requires further study. In explanation, estrogens may 
specifically be associated with melanomas with a relative good prognosis such as 
superficial spreading melanomas. [6] More importantly, both in vitro and in vivo studies 
have demonstrated that estrogens may have a direct inhibitory effect on melanoma 
tumor growth. [7-10] It may be, therefore, that the clinical impact of estrogen effects on 
melanoma is more limited than would be expected. In addition, the effects of estrogens 
on melanomas may differ with the type of estrogen, OC or HRT, which is used. [8] 
The objective of this study, therefore, is to investigate whether use of different types 
of estrogens, OC and HRT, is associated with a decreased Breslow thickness across 
women of different age groups.  
Patients and methods 
Setting
Data were extracted from PHARMO, a pharmacy database representing > 12% of the 
Dutch population who are included regardless of type of health insurance.  [11]  The 
core file of the PHARMO system is a patient-roster file that includes entry and exit 
dates for all patients. To this roster file, the drug dispensing records of all pharmacies, 
and pathology records are linked on a patient-centric level. Dispensing histories are 
virtually complete. [12] The drug dispensing histories contain all dispensed 
prescriptions and include type, quantity, dosage form, strength, dispensing date and 
estrogens and melanoma's breslow thickness
9
184
prescribed daily dose of the dispensed drug. PHARMO was linked to PALGA, the Dutch 
nationwide registry of histo- and cytopathology, with a variation of a reliable 
probabilistic algorithm. [13] PALGA represents all Dutch patients and forms the basis 
for the Netherlands Cancer Registry. Abstracts of all pathology reports are recorded in 
PALGA, and these have encrypted patient identification and include diagnostic terms 
in scope with SNOMED classification. In 2004, over 9 million patients were archived. 
Since 1990, the registration reached 100% participation. [14]
Study population
The study population has been described previously. [15] Briefly, cases had a primary 
CM diagnosis in PALGA between January 1st 1991 and December 14th 2004 and were 
included in PHARMO. The date of CM diagnosis was considered the end of follow-up. 
All records from the eligible cases in PALGA were read by one of two investigators (AJ, 
ERK). Final diagnosis, date, anatomical body location, continuous Breslow depth, 
regression and CM subtype according to WHO classification were recorded. 
Accordance was high (kappa values >0.85) in a random sample of 300 cases. [15] 
Potential cases were excluded if, in PHARMO, a date of entry was unknown, gender 
was unknown, or if follow-up in the three years before CM diagnosis was incomplete. 
In addition, patients were excluded if, in PALGA, the date of CM diagnosis was before 
the age of 18 or before January 1 1991, the CM was not pathologically confirmed, the 
primary CM was not on the skin (e.g. in the eye) or if the CM was in situ.
Drug Exposure 
All estrogens were included that were commercially available and approved in 
The Netherlands during the study period. Estrogen use was differentiated between 
OC (anatomical therapeutic chemical (ATC) codes: G03AAXX and G03ABXX) and HRT 
(ATC code: G03CAXX) and was expressed in defined daily doses (DDD) according to 
the WHO definitions. All administration routes were included. Locally applied HRT, 
however, was only included if the estimated systemic exposure was comparable with 
at least 0.25 DDD/day orally.
Exposure was defined as the use of one or more estrogens containing formulations 
for at least 0.5 year in the 3 years before CM. To further detail estrogen use, we also 
calculated the cumulative dispensed dose and the cumulative prescribed duration in 
the 3 years before CM. The cumulative dispensed dose was calculated as the sum of 
all dispensed estrogens in DDD. The cumulative prescribed duration was calculated 
as the time period between first dispense and last dispense plus the estimated time 




Drugs possibly related to progression and development of CM were considered 
potential confounders. These included Non-steroidal Anti-Inflammatory Drugs 
(NSAIDs including COX-2-inhibitors) and statins. [16] As a proxy for health care 
consumption, we included from PHARMO the total number of unique medical 
diagnoses (International Classification of Disease 9th revision, clinical modification; 
ICD9-CM) in the 3 years before CM. As a second proxy we also considered the total 
number of unique prescriptions (the number of different drugs used expressed as ATC 
codes and excluding estrogens) in these 3 years. Age at CM diagnosis, calendar year 
of diagnosis, pathological subtype of CM, regression and body location of the primary 
tumor were also tested as potential confounders.
Statistical analysis
To test for statistical differences, χ2 and Student’s t-tests were used for categorical and 
continuous variables respectively. All statistical tests were performed two-sided with 
rejection of the null hypothesis at p <0.05. 
Multiple linear regression, using continuous log transformed Breslow thickness as 
dependent variable, was used to estimate the effect of estrogen use on local CM 
progression (adjusted coefficients and 95% confidence interval (CI)). Since differences 
on log scale correlate to proportions on normal scale (i.e., log A – log B = log A/B), the 
results will be presented as a percentage change. This estimated percentage change 
in Breslow Depth can be calculated with the following formula: 
(e coefficient – 1.00) x 100 %
Estrogen, OC and HRT variables were divided in categories of equal distances to ease 
the interpretation of the findings. Potential confounders were included in the 
multivariable model if they influenced the estimate by 10% or more. [17] Separate 
analyses will be performed for OC and HRT. To test for effect modification, interaction 
terms of different variables for estrogen use with age were tested in the multivariable 
linear model. As effect modification was present, separate analyses will be presented 
for different age groups (< 45 years, 45-55 years, ≥ 55 years; i.e., premenopausal, 
menopausal and postmenopausal age groups). 
All statistical analyses were performed using SPSS 16.0 (SPSS Inc. Chicago, IL). 
This publication is reported according to the STROBE guidelines. [18]




Study Population and Melanoma Characteristics
Of the 778 included female cases in the baseline study [15], 91 were excluded because 
of missing data on Breslow thickness or body location of the primary melanoma. The 
demographics are summarized in Table 1. Mean age of eligible women was 53.3 years 
[standard deviation (SD) 16.6]. 
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     mean ± standard deviation 53.3 ± 16.6 yr
     range 18 yr - 94 yr
Drug use (n, %)
     estrogen users a 178 (26 %)
     OC users a 151 (22 %)
     HRT users a   26 (3.8 %)
     statin users b   39 (5.7 %)
     NSAID users b 335 (49 %)
Melanomas 
    Breslow thickness
            median 0.90  mm
            interquartile range 0.5 mm  -  1.8 mm
    Body location (n, %)
            extremities 393 (57 %)
            trunk 220 (32 %)
            head & neck   74 (11 %)
    Pathological subtype c (n, %)
            superficial spreading 469 (68 %)
            nodular   91 (13 %)
            lentigo maligna   33 (4.8 %)
            other   94 (14 %)
    Regression d (n, %)   49 (7.1 %)
a At least 6 months of drug use.
b Ever drug use.
c Pathological CM subtype according to WHO classification.
d Regression mentioned in the pathologist report.
OC = oral contraceptive, HRT = hormonal replacement therapy, NSAID = non-steroidal anti-inflammatory agent,  
CM = cutaneous melanoma, WHO = world health organization.
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The melanoma characteristics are summarized in Table 1. Breslow thickness was 
non-normally distributed and therefore log-transformed. The distribution of Breslow 
thickness in AJCC categories was: 0-1 mm: 381 (56%), 1.01-2 mm: 161 (23%), 2.01-4 mm: 
103 (15%) and > 4 mm: 42 (6%). In Table 2, the Breslow thickness in AJCC categories 
and pathological subtype of melanoma are summarized for different women < 45 
years,  45-55 years and ≥ 55 years of age, separately.
Estrogen use
Estrogens (OC and/or HRT) were used by 178 women (26%) for more than half a year 
in the 3 years before diagnosis of CM. Of the estrogens used, 78% was ethinylestradiol. 
Cases using estrogens were prescribed an average estrogen day dose of 0.94 DDD per 
day [SD 0.21]. The results of univariable analysis are presented in Table 3.
estrogens and melanoma's breslow thickness
9
Table 2  Pathological subtype and Breslow depth in different age groups
Age group   (Total: n= 687)
< 45 yrs 45 – 55 yrs ≥ 55 yrs













< 1.01 mm 78 (66%) 75 (63%) 21 (64%) 63 (62%) 16 (84%) 123 (43%)
1.01 –  2.0 mm 22 (19%) 30 (25%) 9 (27%) 18 (18%) 0 (0%) 80 (28%)
2.01 –  4.0 mm 14 (12%) 12 (10%) 2 (6%) 16 (16%) 2 (11%) 56 (56%)
≥ 4.01 mm 4  (3%) 2  (2%) 1 (3%) 4 (4%) 1 (5%) 30 (10%)
Pathological subtype b
superficial spreading 100 (85%) 92 (77%) 25 (76%) 71 (70%) 13 (68%) 161 (56%)
nodular 7 (6%) 12 (10%) 4 (12%) 11 (11%) 1 (5%) 56 (19%)
lentigo maligna 0 (0%) 1 (0.8%) 0 (0%) 2 (2%) 2 (11%) 28 (10%)
other 11 (9%) 14 (12%) 4 (12%) 17 (17%) 3 (16%) 44 (15%)
a Breslow thickness in AJCC categories.
b Pathological CM subtype according to WHO classification. 






















































































































































































































































































   
   






























   
   




































   
   









































   
   

















































   
   





















   
   






























   
   



























































































































   
   

























































































































































































































































































































































































































Oral Contraceptives (OC) and Hormonal 
Replacement Therapy (HRT)
OC were used in the study period for more than 
half a year by 22% of the cases. Of the OC used, 99% 
was ethinylestradiol. During the study period, 3.8% 
of the cases used HRT (≥ 0.5 year). Of the HRT used, 
57% was estradiol and 33% were conjugated 
estrogens.
Multivariable analysis
We estimated the effect of estrogen use, OC or 
HRT on Breslow depth of CM with multiple linear 
regression, using continuous log transformed 
Breslow thickness as dependent variable. If an 
interaction term between age and estrogen use 
was added to the model, this resulted in a 
statistically significant term in the model suggesting 
effect modification by age (p<0.01). For this study, 
we therefore subsequently stratified all analyses 
for different age groups (< 45 years, 45-55 years, 
≥ 55 years; i.e., premenopausal, menopausal and 
postmenopausal age groups) (Table 4).
Women younger than 45 years
Among women aged younger than 45 years, use 
of OC (≥ 0.5 year) was not associated with a 
clinically relevant decrease in Breslow thickness 
after adjusting for age at diagnosis, pathological 
CM subtype and the total number of different 
diagnosis in the 3 years before CM (–1.4%; 95% 
CI= –18.5 to 19.5%). There was also no statistically 
significant effect of OC with increasing cumulative 
prescription duration or increasing cumulative dose 
(respectively 1.2%; 95% CI: –6.9 to 10.1% and 0.0%; 
95% CI: –7.9 to 8.5%). 
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Women aged 45 to 55 years
In multiple linear regression analysis adjusting for the confounders mentioned before, use 
of OC or HRT (≥ 0.5 year) among women aged 45 tot 55 years was associated with an 
average decrease in Breslow depth of 17.8 percent (95% CI= –38.6 to 10.1%). This association, 
however, did not reach statistical significance. In accordance, cumulative prescription 
duration and dose of OC or HRT did not statistical significantly affect melanoma thickness 
(respectively –8.3%; 95% CI: –18.9 to 3.7% and –7.1%; 95% CI: –17.9 to 4.9%).
Women 55 years and older
Among women aged 55 years and older, use of HRT (≥ 0.5 year) after adjusting for 
relevant confounders was associated with a statistically non-significant decrease in 
Breslow thickness of 15.2% (95% CI= –41.1 to 22.0%). The results for increasing 
cumulative prescription duration of HRT or increasing cumulative dose of HRT were 
similar (respectively –6.5%; 95% CI: –22.6 to 14.0% and –4.9%; 95% CI: –19.9 to 13.0%).
Discussion
The results of this study could not confirm that the use of OC or HRT (> 0.5 year in the 
3 years before CM) has a significant influence on Breslow thickness of CM. However, 
the association between estrogen use and Breslow thickness of CM seems to be 
modified by age (Table 2 and 4). Thus, also because of limited sample size, we cannot 
exclude decreased Breslow  depth of CM among patients aged 55 years and older and 
using HRT (i.e. possible type II error due to lack of power in the subgroup analyses). 
Moreover, because of collinearity, it is not possible to differentiate between effect 
modifying by age or different effects of ethinylestradiol (OC) and estrogens used in 
HRT (estradiol, conjugated estrogens). In explanation, synthetic estrogens may have 
no effect on Breslow depth whereas natural estrogens do or estrogens might only 
have effects on Breslow depth in postmenopausal women.
Nevertheless, the observed effects may be caused by an increased incidence of thin 
melanomas in this population instead of growth inhibition of CM. [5] Thus, the 
observed effects could also support a specific increase in the incidence of superficial 
spreading melanomas.
This nested case-control study is large and population-based. Pharmacy data are 
gathered prospectively, and therefore avoid recall bias. As we had detailed drug-dis-
pensing information, we were able to study dose-effect responses, differentiate 
between OC and HRT, and could also exclude low-dosed topically applied estrogens. 
estrogens and melanoma's breslow thickness
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Although we corrected for the pathological subtypes, we cannot exclude residual 
confounding. PHARMO and PALGA data, for instance, do not include data on most risk 
factors of (thick) melanomas such as family history of melanoma, skin type and other 
phenotypic characteristics, sun exposure history  or socioeconomic status. As these 
factors are unlikely to affect the likelihood of estrogen prescription, confounding by 
indication seems unlikely, except possibly socioeconomic status. In addition, there is 
no biologic basis to assume that menopausal complaints (e.g., flushing and vaginal 
atrophy) or possible causes of menopause (e.g., hysterectomy) are associated with the 
Breslow depth of melanomas of the skin. 
Conclusion
Our study does not show a statistically significant association between the use of oral 
contraceptives or hormonal replacement therapy and the Breslow thickness of 
cutaneous melanoma. However, we cannot exclude decreased Breslow thickness 




(1) Karagas MR, Stukel TA, Dykes J, Miglionico J, Greene 
MA, Carey M et al. A pooled analysis of 10 
case-control studies of melanoma and oral 
contraceptive use. Br J Cancer 2002, 86, 1085-1092.
(2) Schoenberg BS, Christine BW. Malignant 
melanoma associated with breast cancer. 
South Med J 1980, 73 (11), 1493-1497.
(3) Walker MJ, Beattie CW, Patel MK, Ronan SM, Das 
Gupta TK. Estrogen receptor in malignant 
melanoma. J Clin Oncol 1987, 5 (8), 1256-1261.
(4) Østerlind A, Tucker MA, Stone BJ, Jensen OM. 
The Danish case-control study of cutaneous 
malignant melanoma. III. Hormonal and 
reproductive factors in women. Int J Cancer 
1988, 42, 821-824. 
(5) Koomen ER, Joosse A, Herings RMC, Casparie 
MK, Bergman W, Guchelaar HJG et al. Estrogens, 
oral contraceptives and hormonal replacement 
therapy, increase the incidence of cutaneous 
melanoma: a population-based case control 
study. Ann Oncol 2009, 20, 358-63.
(6) Vries E de, Houterman S, Janssen-Heijnen MLG, 
Nijsten T, Schans SAM van de, Eggermont AMM 
et al. Up-to-date survival estimates and 
historical trends of cutaneous malignant 
melanoma in the south-east of The Netherlands. 
Ann Oncol 2007, 18, 1110-1116.
(7) Beattie CW, Ronan SG, Amoss MR jr. Estrogen 
influences the natural history of Sinclair Swine 
Cutaneous Melanoma. Cancer Research 1991, 
51, 2025-2028.
(8) Dobos J, Timar J, Bocsi J, Burian Z, Nagy K, Barna 
G et al. In vitro and in vivo antitumor effect of 
2-methoxyestradiol on human melanoma. Int J 
Cancer 2004, 112, 771-776.
(9) Feucht KA, Walker MJ, Das Gupta TK, Beattie 
CW. Effect of 17-beta-oestradiol on the growth 
of estrogen-receptor positive human 
melanoma in vitro and in athymic mice. Cancer 
Research 1988, 48, 7093-7101. 
(10) Lama G, Angelucci C, Bruzzese N, Iacopino F, 
Nori SL, D’Atri S et al. Sensitivity to human 
melanoma cells to oestrogens, tamoxifen en 
quercetin, is there any relationship with type I 
and II oestrogen binding site expression? 
Melanoma Research 1998, 8, 313-322.
(11) http://www.pharmo.nl/, PHARMO pharmacy 
database, visited June 3rd 2008.
(12) Lau HS, Boer A de, Beuning KS, Porsius A. 
Validation of pharmacy records in drug 
exposure assessment. J Clin Epidemiol 1997, 50, 
619-625.
(13) Herings R. Pharmo, a record linkage system for 
post marketing surveillance of prescription 
drugs in the Netherlands. In, thesis in pharma-
co-epidemiology and pharmacotherapy. The 
Netherlands, Utrecht University, 1993, 17-32.
(14) Casparie M, Tiebosch ATMG, Burger G, 
Blauwgeers H, van de Pol A, van Krieken JHJM 
et al. Pathology data banking and bio banking 
in The Netherlands, a central role for PALGA, 
the nationwide histopathology and 
cytopathology data network and archive. 
Cellular Oncology 2007, 29 (1), 19-24.
(15) Koomen ER, Joosse A, Herings RMC, Casparie 
MK, Bergman W, Nijsten T et al. Is statin use 
associated with a reduced incidence, reduced 
Breslow thickness or delayed metastasis of 
melanoma of the skin? Eur J Cancer 2007, 43, 
2580-2589.
(16) Freeman SR, Drake AL, Heilig LF, Graber M, 
McNealy K, Schilling LM et al. Statins, fibrates, 
and melanoma risk: a systematic review and 
meta-analysis. J Natl Cancer Inst 2006, 98 (21), 
1538-1546.
(17) Vandenbroucke JP, Von Elm E, Altman DG, 
Gøtzsche PC, Mulrow CD, Pocock SJ et al. 
Strengthening the reporting of observational 
studies in epidemiology (STROBE): explanation 
and elaboration. Ann Intern Med 2007, 147, 
163-194.









General discussion, future perspectives and conclusions
Epidemiology of melanoma
Cutaneous melanoma (CM) in general is a growing health problem in Caucasian 
populations. Fortunately, the majority of cases are usually diagnosed at an early stage 
of the disease, that is, while the disease is still confined to the local site. Prognosis in 
these melanoma patients is favorable with 5-year relative survival proportions 
reported to be as high as 90% for women and 81% for men in The Netherlands [1]. 
Nevertheless, CM incidence is among the top ten of leading cancer sites among both 
sexes in both the United States (US) [2] and in North-western European countries [3,4]. 
After surgical removal of the tumor, the majority of patients will survive CM, but will 
remain at risk of developing regional or distant metastases for many years. [5] This risk 
is low but extends over prolonged periods of time. In addition, these patients are at 
increased risk of new primary melanomas (~5% in 20 years). [6] As a consequence, 
melanoma can be considered a chronic, life-threatening disease which has a significant 
impact on the quality of life of these patients. [5] Moreover, the incidence of CM has 
increased rapidly over the last decades in these Caucasian populations. [2, 7] For 
example, in Sweden, over a 20-year period between 1987 and 2006, CM incidence has 
increased with an average annual increase of 2.3% among men and 2.1% among 
women. [3] For The Netherlands, de Vries and colleagues have reported an annual 
increase in CM incidence of 2.2% in women and 3.3% in men over a 10-year period 
between 1989 and 1998. [7] Although a 3% annual increase may not seem large, it 
increases exponentially to al ready 34% in just one decade (1.0310). In contrast with US 
data reported by the American Cancer Society indicating that CM incidence has been 
stable in the US since 2000 [2], we show in this thesis (chapter 2) that CM incidence is 
still significantly increasing among both sexes in The Netherlands (men: EAPC = 4.4%, 
95% CI = 3.9% to 4.9%; women: EAPC = 3.6%, 95% CI = 2.9% to 4.2%). Between 1989 
and 2006, the increase in CM incidence did not change (join point analysis) in 
The Netherlands. 
Risk factors for CM include a history of sunburns, especially in childhood, high chronic 
sun exposure, advanced age, prior melanoma, a family history of melanoma, presence 
of clinical atypical nevi, and phenotypic traits, such as fair skin type, freckles, light eye 
color and photosensitivity. Family history of melanoma and prior melanoma are likely 
to be surrogate markers for genetic risk factors. In the last two decades, melanoma 
research has focused on finding such genetic factors. Part of the familial clustering 
can be explained by rare mutations in CDKN2A (encoding p16INK4a and p14ARF) and 
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CDK4 which are high-penetrance genes. [8,9] In addition, some low-penetrance 
factors contributing to melanoma susceptibility, such as single-nucleotide 
polymorphisms in or near MC1R, ASIP, TYR and TYRP1, have been identified. These 
genes determine well-established melanoma risk factors as hair and skin pigmentation, 
but their exact role in melanoma development remains unclear. [10] As the majority 
of familial cases remain unaccounted for, one may expect future additional advances 
in revealing genetic susceptibility genes. An individual’s mutational status of such 
genes can in the future be used to develop personalized surveillance and prevention 
measures.
While the incidence of CM has increased over the last decades, mortality rates of CM 
seem to have stabilized or even slightly decreased. [11] In addition, CM patients are 
relatively young at diagnosis. [12-14] Consequently, the total burden of CM is expected 
to have increased in these populations. However, recent estimates of the burden of 
CM, other than just incidence and mortality rates, are sparse. Moreover, in most 
studies only a small number of the possible different measures1 of the burden of 
melanoma have been compared. [12,13,15,16] Estimates of the burden of melanoma 
within the Dutch population were not available. Data from the Belgium National 
Cancer Registry (1987-1992), however, have been published. These data showed that 
the years of life lost per death (average years of life lost, AYLL) was 8.1 years for men 
and 6.3 years for women prior to the age of 65 years. [13] Since then, the incidence of 
CM has increased and, moreover, life expectancy will also be affected beyond the age 
of 65 years. Therefore, these data are likely to underestimate the current burden of CM 
in the Dutch population. Indeed, in chapter 3, we demonstrated that the total burden 
of CM has accumulated in The Netherlands and that the AYLL in 2002-2206 was 17.7 
and 20.4 years for men and women, respectively. 
By estimating a series of different measures of burden, we determined the burden of 
CM to the Dutch population in 5-year periods between 1989 and 2006. These measures 
of burden were: cumulative incidence rates, cumulative mortality rates, number of 
years of life lost (YLL), average number of years of life lost (AYLL; the number of years 
of life lost per death;  YLL/deaths), number years of life lost to disability (YLD), the 
number of years of life lived with disease (YLWD),the average number of years lived 
with disability (AYLD), and the average number of years lived with disease (AYLWD) by 
Dutch CM patients.  
1  incidence & mortality rate, prevalence, number of years of life lost (YLL), average number of years of life lost (AYLL; 
the number of years of life lost per death;  YLL/deaths), number years of life lost to disability (YLD), the number of years 
of life lived with disease (YLWD),the average number of years lived with disability (AYLD), and the average number of 
years lived with disease (AYLWD).
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The incidence of melanoma almost doubled between 1989 and 2006 (cumulative 
incidence rate increased from 1.0-1.3% to 2.0-2.1%). Likewise, the cumulative mortality 
rates also doubled up to 0.61 for males and up to 0.40% for females. Suprinsingly, age 
at diagnosis of melanoma increased over time. 
On average, patients lived 21.5-28.4 years with a melanoma diagnosis and melanoma 
resulted in a loss of about 18-20 years before the age of 95 for those that died of their 
melanoma. Including all patients diagnosed with a melanoma, not only those that die 
from it, the average life loss is about 3 years.
Overall, the burden of melanoma to society increased rapidly between 1989 and 
2006.
As a consequence of the high burden of melanoma, some argue that melanoma is 
among the ‘Cinderella cancer types’. For example, Burnet and colleagues compared 
the average years of life lost due to 17 different cancer types with the research funds 
spent on these cancer types by the National Cancer Research Institute of the UK. This 
led to the conclusion that, based on this ratio, melanoma as well as tumors of the CNS, 
kidney and cervix would merit higher research funds. [16] Likewise, if one would 
define ranking not solely on the incident numbers or the estimated number of deaths 
due to a certain cancer type, but on a more detailed measure of the burden to the 
population, melanoma would most likely merit a higher ranking. [13] This disparity is, 
in part, due to the fact that relatively young people are affected by melanoma as 
compared to other malignancies, but, ironically, also due to the relatively favorable 
survival of most melanoma patients. Nevertheless, metastasis risk for CM patients is 
prolonged, effective treatment options are limited once (multiple) positive lymph 
nodes, skin metastasis or organ metastases have developed. In addition, CM incidence 
increases and patients with prior melanoma are at higher risk of a second primary 
melanoma. Therefore, in countries with high and increasing CM incidence, future 
health-care planning for melanoma care and surveillance is of great importance.
Although prognosis is favorable for the majority of CM patients, for some subgroups 
of melanoma patients, prognosis is poor. For example, patients with advanced stages 
of CM at diagnosis, such as regionally spread disease, have a dismal prognosis. In US 
data from 2008, CM patients with regional spread had a 5-year relative survival of 
65.2% (versus 98.5% for CM local disease). [2] With further spread of the disease, that 
is, if distant metastasis has occurred, no effective treatment options are available [17] 
and the 5-year survival proportion even drops to 15.3%. [2] 
Likewise, prognosis for patients with more rare subtypes of melanoma, such as acral 
lentiginous melanoma (ALM) or extracutaneous melanoma (ECM), is generally worse 
as compared to CM patients. [18,19] With data from the Surveillance Epidemiology 
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and End Results (SEER) dataset in the US, Bradford et al. recently estimated 5-year 
survival for ALM patients and CM patients to be 80.3% compared to 91.3% for CM 
patients. [18] However, for ECM subsites, reliable and recent incidence and survival 
estimates, for example, based on well-described national population-based databases 
or geographic regions, are largely lacking. Available European data are either outdated 
or concerned hospital-based series. [20,21] For the US, recent incidence data on ECM 
are available. Unfortunately, however, survival estimates and trends in the incidence 
of ECM were not reported. [22]
In chapter 2, we demonstrate that, in The Netherlands, 6.4% of all primary melanomas 
between 2003 and 2006 were ECM. In addition, we showed that, within the Dutch 
population between 1989 and 2006, five-year relative survival proportions of ECM 
patients were indeed worse in comparison with CM patients. Ocular melanoma was 
shown to be the most frequent subsite of ECM, and had the best survival. Five-year 
relative survival for ocular melanoma was 74% which was significantly less than the 
estimated 5-year relative survival for CM patients (86%; chapter 2). Mucosal melanomas 
were diagnosed less frequently, but survival of patients with this type of melanomas 
was dismal. Five-year relative survival for mucosal melanomas ranged from 15% for 
anorectal and esophageal melanomas combined to 40% for vulvar melanomas.
Incidence rates of ECM subsites with sufficient numbers, such as all mucosal 
melanomas, those of the ear-nose-throat region, and vulvar melanomas, did not show 
statistically significant trends in time (join point analyses and EAPC estimates). In 
contrast, CM incidence has significantly increased in the same time period among 
both sexes (men: EAPC = 4.4%, 95% CI = 3.9% to 4.9%; women: EAPC = 3.6%, 95% 
CI = 2.9% to 4.2%; chapter 2). 
The increase in CM incidence is often assumed to be related to increased sun exposure 
(during childhood) and increased awareness. As the majority of ECM are not exposed 
to direct ultraviolet light and often not visible for the patient, one may postulate a lack 
of similar time trends in ECM incidence. Indeed, we did not demonstrate such trends. 
However, due to low incident numbers, the confidence intervals of the EAPC were 
wide for some subsites. Therefore, we cannot prove that time trends in the incidence 
of ECM subsites were significantly different from the time trends in CM incidence. 
Moreover, it is statistically impossible to prove a lack of association or, as Carl Sagan 
formulated, ‘Absence of evidence is not evidence of absence’. 
Nevertheless, differences in the demographics of affected patients, and in clinico-
pathologic and molecular aspects, such as presence of c-KIT mutations, do suggest 
different pathways in the development of ECM as compared to CM. For example, a 
large proportion of CM lesions contain a BRAF- or NRAS-mutation [23], whereas 39% 
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of mucosal, 36% of acral, and 28% of melanomas on chronically sun-damaged skin 
harbor mutations and/or copy number variants of receptor tyrosine kinase KIT. [24] 
These differences, next to late diagnosis, may explain clinical heterogeneity, poor 
survival, diversity in melanoma biology, and response to therapy, and are likely to 
reflect differences in the causal pathways involved in the development of these 
melanoma subtypes.
Due to the rarity of ECM, incident numbers in some ECM subsites were low and, 
therefore, stratifying for the clinical stage of ECM at diagnosis in the survival analysis 
was impossible. Likewise, very refined clustering, such as separate clustering of 
anorectal and esophageal melanomas, was also impossible. Larger datasets, such as 
through Eurocare, could help in varying out such analyses and would, if present, 
improve chances of determining time trends in incidence and join points. However, 
data quality for these rare tumors may not be sufficient in some national cancer 
registries.
In conclusion, in this part of the thesis we have shown the incidence of CM has further 
increased in The Netherlands, and the total burden of CM has accumulated over the 
last decades. More than 5% of all invasive melanomas in The Netherlands have a 
extracutaneous origin, but survival of these patients is poor with 5-year relative 
survival proportions ranging from 74% to 15%, and the worst survival concerned 
mucosal melanomas. 
Prevention of melanoma
A number of observations suggest a high potential benefit for the prevention of 
melanoma. First, CM incidence is increasing and the total burden of CM is accumulating. 
Second, effective treatment options for stage IV melanoma are lacking. Third, 
metastasis risk is prolonged over long time periods. And, most importantly, prognosis 
strongly depends on the stage at diagnosis. 
Indeed, prevention has gained much interest in melanoma research. As mentioned 
before in this thesis, most of the established risk factors for melanoma are not 
amenable to intervention. Sun burns and sun exposure, as exceptions, are in theory 
amenable. Thus far, however, educational attempts and sun protection measures 
have not led to behavioral changes with regard to sun exposure and protection nor 
has the incidence of melanoma decreased or stabilized. [25-27] In a telephone survey 
among parents in the US, although the parents were aware of the need for sun 
protection for themselves and their children, many still considered a tanned skin to be 
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a healthy sign. Moreover, 13% of children sunburned during the past week or weekend, 
and 9% of their parents experienced a sunburn during the past weekend. [25] In 
addition, in a series of studies in the US, 87% of young adults going to the beach in 
2007 were aware of a link between skin cancer/melanoma and tanning. However, 
knowledge about limiting tanning was seemingly concurrent with an increase in the 
attitude that having a tan looks better. [26] Australia, where a predominantly 
susceptible fair-skinned population is combined with high ambient UV radiation 
levels, has one of the highest skin cancer incidence and mortality rates of the world. 
Since the 1980s, large sun protection and awareness campaigns have been 
implemented in this country. [28] In spite of these enormous efforts, incidence rates, 
especially among individuals aged 40 years and above, have not decreased. [27]
From these studies, one can conclude that although knowledge and awareness about 
melanoma can be improved, we do not seem to be able to sufficiently influence 
(long-term) UV risk behavior. This so-called ‘knowledge-behavior gap’ suggest that 
we need to explore alternative preventive measures that will either create opportunities 
to succeed in changing UV risk behaviors or will avoid the need for changing these 
behaviors in individuals at risk. Either way, such preventive measures will need to be 
more acceptable to the public it aims at, and should, obviously, be effective, safe, 
cost-efficient, and preferably easy to implement. As other known melanoma risk 
factors, such as prior melanoma, family history of melanoma, large numbers of nevi, 
clinical atypical nevi, skin phototype, freckles, light eye color, and advanced age, are 
not amenable, the number of alternative options is limited. 
Population-based skin cancer screening is one of the suggested possibilities. 
Prerequisites for screening to be appropriate have been defined by Wilson and 
Jungner in 1968. [29] Whether skin cancer screening meets these requirements, 
however, is uncertain. Arguments against screening in the general population could 
include that CM incidence may not be high enough, melanoma mortality is relatively 
low, any screening interval would probably be too long for the most aggressive 
melanomas, the fact that most melanomas already are diagnosed at an early stage, 
and diagnosis of suspected lesions may not be specific enough leading to a high 
number of false positives and unnecessary biopsies. Nevertheless, skin cancer 
screening remains much debated in literature [30], and a number of studies have 
focused on such an approach.
Free skin checks, often referred to as ‘melanoma Monday’, have been organized in 
both the USA [31] and countries in Europe [32]. These skin checks are successful in 
creating good publicity, an opportunity for education on melanoma, and sometimes 
a large number of the public attending. The number needed to prevent (NNP) one 
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melanoma, in explanation, the number of pathologically proven melanomas 
calculated per participant, varied from one melanoma per 110 (Belgium) [32], 277 (UK) 
[33] or 667 (Australia) [31] attendees. The lower NNPs resulted from studies in which 
high risk subpopulations were selectively invited to attend the free skin checks. In a 
US study that was neither randomized nor controlled, a reduced melanoma mortality 
was reported. [34] However, these study designs are insufficient to assess the merits 
of (skin) cancer screening for which a RCT design is indispensable. 
In Australia, such a RCT was planned. Population screening was carried out in small 
Queensland towns, where some residents were selected for the screening, and 
compared with control towns, where mass screening was not offered. [35] This trial 
showed that such a population skin cancer screening program was feasible, increased 
melanoma awareness, and resulted in a higher number of CM diagnosed among men 
older than 50 years. [36] Specificity of screening for melanoma was 86%, and the 
positive predictive value was 2.5%. Follow-up of participants with a negative screening 
examination was, however, not conducted. Therefore, the number of true negative 
results and the true specificity is unknown. [37] Lack of true RCTs precludes true 
assessment of cancer screening programs as only these study designs can exclude 
lead time, length time and volunteer bias. Unfortunately, lack of funding, even in 
Australia with the highest world-wide incidence of CM, hampered the original plan to 
extend the work to a larger national trial which is needed to establish the overall 
merits of skin cancer screening. 
Overall, these data suggest that skin cancer screening may not be efficient enough 
for a screening program aimed at the general public, but could be beneficial for 
selected high risk populations, such as men aged 50 years and older.
Another preventive measure, as an alternative or additional to classic sun prevention 
measures, would be the use of motivational interviewing by dermatologists to enhance 
patient motivation to reduce UV risk behaviors. Such motivational interviewing has 
been successfully implemented in health care settings by physicians to modify a variety 
of behaviors such as smoking. [38] In addition, cancer chemoprevention, more 
specifically melanoma chemoprevention, is another alternative option with potential to 
be an effective preventive measure among individuals at high risk of CM (Table 1). 
Chemoprevention of melanoma
The concept of cancer chemoprevention was first described and defined by Sporn et 
al. in 1976. They defined ‘cancer chemoprevention’ as ‘the use of natural or synthetic 
drugs to reverse, suppress, or prevent premalignant molecular or histological lesions 
from progressing to invasive cancer’. [39]
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Agents proposed in literature for cancer chemoprevention differ both in origin and 
type of application. For example, macronutrients, micronutrients, such as vitamins & 
antioxidants, non-nutritive phytochemicals and several drugs have been suggested. 
In addition, for some agents, such as retinoids, both oral and topical application has 
been suggested. Some authors suggest that ‘diet modification should be considered 
as a preferred preventive intervention given the low toxicity, low cost, and relative 
ease of implementation’. [40] However, any a priori statement on an agent’s safety 
based on its origin is premature. For any agent, irrespective of their origin, the first 
requirement should be efficacy. In addition, the safety of a substance as a cancer 
chemopreventive agent can only be assessed after the target population and effective 
dosages have been established. History has taught us that even agents that were 
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Table 1  Potential target populations for melanoma chemoprevention in  
a high risk strategy
Risk factor Risk estimate Reference
Previous invasive CM SIR = ~ 4 - 25 [42,43]
Atypical mole syndrome SMR = ~ 18 [44]
Invasive CM in first-degree relatives1 RR = ~ 2 - 10 [45,46]
Clinical atypical (dysplastic) nevi RR (single) =
RR (2-4 nevi) =
RR (5-9 nevi) =






Several large nevi (3-5 moles ≥ 3 mm in
diameter on arms or lower legs)
RR = ~ 2.1 - 3.4 [46]
MC1R variants RR = ~ 1.5 - 2.5 [48]
Red hair color RR = ~ 2 [46]
High solar exposure in early childhood (<10 yrs) RR / OR = ~ 2 - 4 [49]
History of severe sunburn RR / OR = ~ 1.5 - 2.5 [46,49]
Past sunbed use at ages <35 yrs RR = ~ 1.2 [50]
Occupation (airline crew) SIR = ~ 2.5 [51]
Occupational chemical / toxic exposure2 Risk estimate = ~ 1.5 - 3.0 [52]
1   One or more first-degree relatives (parent, sibling or child) with invasive cutaneous melanoma.
2   These include: pesticides, polycyclic aromatic hydrocarbon (PAHs), benzene, and polychlorinated  
biphenyls (PCBs), trichloroethylene solvents, dioxin, and polyvinyl chloride (PVC), ionizing and  
non-ionizing radiation.
SIR = Standardized Incidence Ratio, SMR = Standard Morbidity Ratio, RR = Relative Risk, OR = Odds Ratio.
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considered to be safe can, in fact, have serious safety issues. For example, beta 
carotene in a (long-term) chemoprevention trial of lung cancer has been associated 
with an increase rather than a reduction of the incidence of lung cancers. 
This unexpected toxicity, that had not been observed previously, most likely was 
explained by differences in drug dosing scheme, more specifically the cumulative 
dose, and the target population. [41] 
For melanoma chemoprevention, several potential high risk populations can be 
considered. These are presented in Table 1. The level of CM risk in a target population 
should be high enough in order to lead to a sufficiently high NNP and to outweigh 
the disadvantages of long-term chemopreventive therapy. Nevertheless, simply 
selecting the subpopulations with the highest risk estimates may not always lead to 
the best results from a public health perspective.
Several strategies are available for cancer prevention. First, one can aim primary 
prevention of the initial cancer in individuals at risk, secondary prevention of invasive 
cancer in patients with premalignant conditions, or one can aim at tertiary prevention 
among cancer patients in order to prevent second primary cancers. [53] Because the 
absolute risk of getting a melanoma is small, tertiary cancer chemoprevention, at least 
as a first goal, would seem to be the most realistic as these patients would be at 
sufficiently high risk of developing a second invasive melanoma. Moreover, in tertiary 
prevention, one could select a chemopreventive agent for its (additional) potential to 
prevent metastasis and, thus, combine adjuvant and chemopreventive effects 
increasing the potential overall benefit.
Second, cancer prevention can be performed according to a high risk strategy or the 
population strategy. In the high risk strategy, one detects certain individuals in the 
population that are most susceptible to the disease, and aims preventive interventions 
at these high risk individuals. In contrast with the population strategy, where one 
attempts to control the determinants of incidence in order to lower the overall risk of 
the total population. [54] In explanation, sun protection campaigns to change 
awareness and UV risk behavior of the general public are examples of the population 
strategy and examples of primary cancer prevention.
Advantages of population strategies include that the preventive intervention usually 
is radical (one attempts to eliminate the ‘true cause’), all individuals at risks are aimed 
at and, thus, there is a large potential benefit for the population, and the intervention 
often is behaviorally appropriate. Disadvantages, however, include that the benefit on 
an individual level can be small (the so-called prevention paradox, a small risk for a 
large number of individuals at risk may give rise to more cases than a small number of 
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subjects at high risk of disease) which may lead to poor motivation of physicians and 
subjects. Moreover, as the potential benefit at an individual level can be small, the 
risk-benefit ratio, for a number of the subjects aimed at, can be worrisome. The high 
risk strategy, on the other hand, has the advantage that the intervention is appropriate 
to the individual which supports both the motivation of the physician as well as the 
patient, it leads to a cost-effective use of resources (intervention on a subset of the 
population), and the benefit-risk ratio is more favorable. [54] Nevertheless, the 
advantages of the population strategy, obviously, also reveal the disadvantages of the 
high risk strategy.
As mentioned, the limited effects of sun protection programs have stressed the 
importance of enhancing patient motivation in melanoma prevention which seems 
to be one of the key issues. Therefore, the high risk strategy (see Table 1) which 
supports the patient’s and physician’s motivation may be of interest. As most chemo-
preventive agents have demonstrated toxicity at some level (chapter 4), the high risk 
strategy certainly would be the choice of interest for melanoma chemoprevention.
For melanoma chemoprevention, several candidate drugs have been suggested. 
However, it is unclear which of these have the potential to be useful and safe. 
Therefore, in chapter 4, we carried out a systematic literature search in Medline, 
Embase, Web of Science and The Cochrane Library. We selected scientific papers on 
drug chemoprevention of cutaneous melanoma, restricted our review to drugs for 
which human data were available from clinical trials or observational research, and 
also included papers identified through cross referencing if they met these definitions. 
The efficiency of our literature search was relatively low (~75% of the finally included 
references did not emerge from the systematic literature search, and ~95% of the 
output of the literature search was excluded). This was probably caused by the fact 
that no MESH term is defined for ‘chemoprevention’. Research would certainly benefit 
from such a MESH term.
Our systematic literature search identified 13 potential chemopreventive drug classes 
for CM. For 7 of these, human efficacy data were available. Consequently, we focused 
our review on the drug classes of NSAIDs, statins, fibrates, retinoids, imiquimod, dehy-
droepiandrosterone, and acetaminophen. On this subset from literature, we 
subsequently conducted a qualitative review. 
In summary, the general conclusions from this review are that considerable preclinical 
evidence of efficacy as a melanoma chemopreventive drug exists for aspirin, NSAIDs, 
and statins, but clinical efficacy and long-term safety data with doses required for 
melanoma chemoprevention are still sparse. Moreover, validated preclinical models 
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are urgently needed to move melanoma chemoprevention forward. In future research, 
special attention should be paid to explore possible differential effects within a drug 
class, temporal dose-response relationships, and to possible synergistic or antagonistic 
effects. In addition, research should also focus on how to define the target populations 
and large randomized trials in high risk populations are required. Thus far, lack of 
definite data on efficacy in humans and profound long-term safety data in the 
required doses, preclude the use of chemopreventive drugs for melanoma in current 
practice. However, the use of relatively safe drugs indicated for other health effects 
but with additional chemoprophylactic properties in cancer development, such as 
low-dosed aspirin and statins, may be encouraged in people at increased risk of 
cancer. 
Success factors for melanoma chemoprevention to be useful in patient practice will 
likely be: 1) little-or-no toxicity, to ensure safety, tolerability, and adherence (note: 
even mild but inconvenient side effects may have significant influence on adherence), 
2) a sufficiently motivated target population, 3) a clear-cut definition of the high risk 
subpopulations at whom chemoprevention should target based upon validated 
prediction models, mutational status and, if possible, validated early biomarkers of 
invasive melanoma risk, and 4) a clear-cut definition of contraindications and 
predictors for individuals prone for the adverse events the chemopreventive drug 
may cause in order to withhold the drug from these individuals or to present additional 
preventive measure to them.
In chapter 5, we investigated the association between use of statins and the incidence 
of CM. In addition, the potential effects of prior statins use on Breslow’s thickness at 
diagnosis of CM as well as effects on time to metastasis were studied. 
None of the statin-related independent variables in our study consistently supports a 
risk reduction of statin use on the incidence of CM. Possibly, the average daily doses 
in our population (median: 1.3 to 2.0 DDD) are not high enough to show a chemopre-
ventive effect. Follow-up may have been too short and adherence may have been too 
poor. However, in spite of several studies and (systematic) reviews published on the 
subject, evidence for a reduced melanoma incidence with statin use is lacking so far. 
[55,56]
Interestingly, our data did suggest that statin use is associated with a significantly 
reduced Breslow’s thickness at diagnosis (–19.2%, 95% CI = –33.2, –2.3, p = 0.03). As 
non statin-users in our database had a mean Breslow’s thickness of 1.8 mm, this would 
indicate an average reduction in the depth of the lesion of 0.35 mm with statin use. 
Among men this effect was even more pronounced with a reduction in Breslow’s 
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thickness of –27.8% (95% CI = –43.7%, –7.4%, p = 0.01). Male non-statin users had a 
mean Breslow’s thickness of 2.1 mm. Therefore, statin use for 0.5 year or more would 
result in a mean reduction of 0.58 mm. One could also argue that statin use among 
men is simply associated with earlier diagnosis of a CM lesion and not with slower 
progression of the CM lesion as especially male cases had a significant higher number 
of unique ICD diagnoses compared to male controls (0.84 versus 0.66, p = 0.02). 
However, if it is causal, this is an important finding since Breslow’s thickness at 
diagnosis is one of the strongest prognostic determinants. [57, 58]
In chapter 6 we studied potential effects on melanoma incidence associated with 
the exposure to non-steroidal anti-inflammatory drugs (NSAIDs), both acetylsalicylic 
acid (aspirin) and non-acetylsalicylic acid-NSAIDs. CM incidence was not significantly 
associated with ever non-ASA NSAID use (OR = 1.10, 95% CI = 0.97–1.24) or ever ASA 
use (OR = 0.92, 95% CI = 0.76–1.12) during the 3 years before index date. The use of 
larger quantities of non-ASA NSAIDs (>600 pills in 3 years) seemed to be protective for 
CM but did not reach significance (OR = 0.67, 95% CI = 0.36–1.23). The explanation, in 
part, could be the relatively short time of observation (3 years), limited sample size in 
this subgroup (<225 patients), and/or that non-ASA NSAIDs were administered as 
analgetics (‘on demand’ use). However, continuous low-dose use of ASAs was 
associated with a reduced likelihood of developing CM in women (OR = 0.54, 95% CI 
= 0.30–0.99) but not in men (OR = 1.01, 95% CI = 0.69–1.47). A significant trend (p=0.04) 
from no use, non-continuous use to continuous use of ASAs was observed in 
women. 
In conclusion, in accordance with three large observational studies [59-61], we did not 
find a reduced CM incidence among overall non-ASA NSAID or ASA users. However, 
our results do suggest that, among women, continuous low-dosed ASA may be 
associated with a reduced incidence of CM in women. Gender-related differences in 
the pharmacokinetics and -dynamics of ASA [62,63] as well as gender-related 
differences in the biology of melanoma could be involved [64,65].
ACE inhibitors and angiotensin II antagonists have also been suggested as chemopre-
ventive agents. In chapter 7 we described an exploratory study investigating a 
possible etiological association between use of these agents on melanoma incidence 
and progression.
The use of ACEi or ARb did not seem to protect against the development of cutaneous 
melanoma nor was it associated with decreased Breslow’s depth. However, the limited 
numbers of ACEi and ARb users, especially for the stratified analyses, has led to limited 
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statistical precision. Thus, these study results cannot exclude an association between 
ACEi and ARb exposure and either a (moderately) increased or decreased incidence of 
cutaneous melanoma. Moreover, residual confounding cannot be excluded. For 
example, sun exposure may be indirectly related to ACEi and ARb exposure because 
it may be associated with increased physical activity and a reduced chance of 
hypertension. Likewise, high social economic status is associated with increased sun 
exposure and may also be associated with a reduced chance of hypertension. Both 
these potential biases would in an underestimation of any effect of ACEi and ARb and 
would thus produce bias toward the null. 
The design of the studies described in chapters 5, 6, and 7 may have several limitations 
because, at the time of designing these studies and often still, effective chemopre-
ventive dosages, latency times, possible differential effects within subclasses, possible 
synergistic and antagonistic effects, and required temporal relationships were 
unknown. In retrospect, the duration of follow up prior to developing a melanoma 
should have been longer. In explanation, the latency time between exposure and 
effects on CM incidence could be substantially longer than three years. To compare, 
melanoma carcinogenesis may involve over 10 years. [66] Such latency times after 
exposure are, however, unknown, and will depend on the precise chemopreventive 
mechanism of action which determines the stage of development from benign nevus, 
dysplastic nevus, in situ melanoma until invasive cutaneous melanoma in which the 
agent is effective. In research practice, available data will limit study design 
possibilities.
Our relatively short follow-up (3 years) resulted from the decision to use only cases 
and controls with complete follow-up to guarantee that cases and controls were 
active members of the PHARMO network and, thus, all prescription drugs dispensed 
would be registered in PHARMO. Due to sample size limitations, we did not study the 
effects of drug use longer than 3 years before cutaneous melanoma. In retrospect, 
one may prefer to select cohorts of drug users (in explanation, statin-users, NSAID 
users, ASA-users, ACE and ARB users) and compare the melanoma incidence among 
these cohorts with a cohort of non-drug-users. Alternatively, one could compare with 
a cohort of users of a drug unlikely to have any chemopreventive or causative effect 
on melanoma. In such a design, one could perform Cox regression in order to 
efficiently use all available follow-up and, in addition, one could compare with 
melanoma incidence among both non-drug-users as well as drug users. 
Currently, we cannot point out which agents are likely to be the most efficacious. 
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However, agents with additional major health benefits and few (long-term) adverse 
events, such as low-dosed aspirin, would in theory, have the best chance to result in 
a positive risk-benefit ratio. Nevertheless, efficacy essentially is the first important 
feature in this decision making process.
Ideally, effectiveness at the individual level would dictate the drug of choice in order 
to reach the best prediction of the benefit for the patient and, additionally, to create 
the best motivation among patients and physicians. As any chemopreventive effect 
would always demand long-term drug treatment in the order of at least 5-10 years, 
patient motivation is required for compliance to be achieved.
Important in this respect to point out is the fact that molecular diagnostics and new 
melanoma biomarkers have generated great interest in research. For example, some 
initiatives focus on such melanoma markers to predict prognosis or even therapeutic 
efficacy. Goal is to develop a more accurate, therapeutically predictive classification of 
human melanomas, and, in addition to select patient populations that would profit 
from specific therapeutic interventions. [67] Useful markers may include both classic 
prognostic factors such as Breslow’s thickness and ulceration, as well as molecular 
markers indicating (new) pathophysiological melanoma subtypes. Hopefully, in a few 
years, we will have melanoma marker tests comparable with the tests available in 
some adjuvant or therapeutic settings, such as for estrogen and progesterone 
receptors in breast and prostate cancer or with the FDA approved assays for HER2, 
epidermal growth factor receptor and KIT [68]. For example, many targeted agents 
such as imatinib and cetuximab are effective only if their respective molecular markers 
are available for pharmaceutical intervention. Candidate markers for melanoma would 
include both validated susceptibility genes, such as mutational status of the high-
penetrance genes CDKN2A, CDK4, and possibly of low-penetrance genes MC1R, ASIP, 
TYR and TYRP1, as they may prove to be markers for distinct melanoma subtypes, as 
well as molecular markers related to the mechanism of action of the (targeted) drug 
or chemopreventive agent to be used.
For cancer chemoprevention such biomarker strategies could be of great interest. For 
example, for chemoprevention among patients with a previous tumor, so-called 
tertiary cancer prevention, it may be interesting to be able to select the type of 
chemopreventive agent based on both molecular and histopathological aspects of 
the previous tumor, and the patient’s risk factors.
If chemopreventive drug candidates could be tested for efficacy in validated 
melanoma models predictive for certain tumor types, for example, in a validated KIT 
mutated melanoma model, a BRAF melanoma model or a RAS mutated model, 
information would become available as to which agent is likely to be most efficacious 
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for which tumor type (targeted therapy). New and promising drugs in melanoma 
treatment, such as the BRAF inhibitor PLX4032 and the anti-CTLA4 antibody 
ipilimumab, as well as potential synergistic combinations (PLX 4032 combined with 
statins) should be tested in such models. Final goal would then be to test all melanoma 
patients for several biomarkers and use these biomarker results to classify their tumor 
(in combination with classical prognostic factors), predict prognosis, select which 
therapeutic interventions are indicated (excision range, sentinel node procedure, 
additional therapies, such as interferon, chemotherapy et cetera), to decide whether 
the patient would likely benefit from chemoprevention in order to prevent second 
primaries or to delay melanoma progression and, if so, to select the chemopreventive 
agent of choice. Ideally, one would select both the therapeutic interventions, adjuvant 
therapies as well as possible (chemo)preventive options on an individual level in such 
a strategy.
Before such a strategy could be developed, however, research progress is needed to 
(better) define available and new predictive biomarkers, to validate experimental 
melanoma models predicting the behavior of certain melanoma tumor types, such as 
a BRAF, N-RAS or c-KIT mutated melanomas, to test potential candidate chemopre-
ventive drugs in these experimental models, to create melanoma risk prediction 
models, and to create prediction rules to select the chemopreventive drug which is 
most likely to be efficacious. 
The chemopreventive drugs tested in validated experimental models should focus on 
those agents of a drug class that are pharmacologically and chemically most distinct 
and keeping in mind which agents of the drug class are most likely to result in an 
acceptable risk-benefit ratio. For example, as representatives of NSAIDs one should 
consider the distinct properties of several NSAIDs taking into account which NSAIDs 
score best with respect to cardiovascular risks, bleeding risks, which NSAIDs have 
differential pharmacologic effects, such as low-dosed aspirin, and which agents 
represent distinct chemical subclasses. Present experimental research has often 
focused on a very limited subset of NSAIDs and has included NSAIDs which have been 
established to have a more worrisome safety profile.
In addition, validated experimental melanoma models could be helpful in defining 
dose-effect relationships and temporal cause-effect relationships in melanoma 
chemoprevention, and in possible heterogeneity of effects between different 
melanoma cancer subtypes and different agents of a drug class.
Predictive models should include prognostic information that can be available at 
diagnosis (or shortly after) and should consider both risk factors predictive for a 
second melanoma, factors prognostic for metastasis risk (such as Breslow’s thickness 
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and ulceration), molecular markers (S100, MC1R, c-KIT, BRAF, N-RAS), as well as 
mutational status (such as CDKN2A/p16INK4A mutations, CDK4 mutations, MC1R 
variants). Prediction rules to select the chemopreventive drug of choice, however, 
may additionally include information on available patient risk factors that predict 
potential adverse effects of potential chemopreventive drugs (for example, risk factors 
for or evidence of previous ulcers or bleeding with respect to NSAID therapy).
Hormonal and gender differences in melanoma
In many of the studies presented in this thesis we were confronted with numerous 
gender differences in (the chemoprevention of) melanoma. For example, in chapter 
2 and 3, gender differences in epidemiological measures of CM and ECM, such as the 
incidence, mortality, age at diagnosis, and several measures of the burden of 
melanoma were present. In chapter 5, statin use was associated with a reduced 
Breslow’s depth only among men. In addition, in chapter 6, we demonstrated that 
continuous low-dosed aspirin use may be associated with a reduced incidence of CM 
in women, but not in men. Moreover, in the PHARMO-PALGA dataset we studied, 
estrogen use, both oral contraceptives (OC) and hormonal replacement therapy (HRT), 
was associated with an increased incidence of CM (chapter 8). Based upon these 
observational studies we can only speculate about the causality. However, the 
significant dose-effect relationships between estrogen use and CM incidence we 
detected did support our hypothesis. Nevertheless, most previous studies on estrogen 
use and melanoma are not in agreement with our findings. [69-71] In chapter 9 we 
could not confirm an association between either OC use or HRT and Breslow’s 
thickness.
Several issues related to the studies presented in chapters 8 and 9 should be 
mentioned here. First, we studied estrogen use, either OC or HRT, regardless of 
whether they were used as unopposed estrogens or as combined estrogen-proges-
tin. In breast cancer, combined preparations have demonstrated a clear risk increase, 
whereas only a slight increase was observed for unopposed estrogens. [72,73] Future 
studies of hormonal influences on CM, should therefore also study progestagenic 
effects, both progestin single therapy as well as in combined preparations. Second, 
we need to learn from the debate on the effects of HRT on coronary heart disease and 
breast cancer. [74] In this debate, conflicting results from observational research and 
randomized controlled trials were finally brought together by analyzing the data 
according to time since start of HRT. Similar data analysis seems indicated to study 
estrogen use and melanoma incidence. Such analysis methods, however, would 
require very large datasets with long follow up periods. 
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Third, procarcinogenic effects of estrogens through the ER-β receptor, the 
hypothesized mechanism for a potential increase in CM incidence, do seem to be 
realistic, at least for lung cancer, as was demonstrated in a post-hoc analysis of the 
Women’s Health Initiative Trial. [75]
Gender differences in melanoma have also been described in other countries and 
datasets. For example, female gender has been demonstrated to be an independent 
predictor of survival in several populations of different geographical origin, such as in 
a German dataset [65], in The Netherlands Cancer Registry [76], in both the UK and 
Australia [77], and in the Sunbelt Melanoma Trial (North America) [78]. A female 
survival benefit was maintained after adjusting for well-established prognostic factors 
and, thus, is independent of Breslow’s thickness, histological subtype, and tumor site. 
[76] Even more striking, this female survival benefit seems to disappear on ageing and 
is no longer present for women aged 65 years and older. [65] 
Although chemopreventive studies in melanoma usually do not stratify across gender 
or predefine a statistical method to check for effect modification by gender, our 
results at least indicate that such gender differences should not be excluded in 
advance.
In conclusion, several findings all indicate that there must be some complex 
relationship between gender, possibly through hormones, and melanoma 
development and progression. These relationships have been studied over a long 
time, but these gender differences in melanoma are still not well understood. 
Influence of hormonal factors playing a role in these gender differences can still not 
be excluded. Nevertheless, the modest level of association between CM incidence 
and OC use that resulted from our studies is not in agreement with previous studies 
[69-71], and as CM risk is generally low, we can conclude there is no need to change 
OC prescription. Abandoning regular prescribing of HRT for uncomplicated 
menopausal complaints should be advocated, but for more urgent reasons than 
increased melanoma risk.
The power of a pharmaco-epidemiologic approach to the investigation 
of drug effects on a malignancy 
We showed that it is feasible to study etiological research questions on unintended 
drug effects on a rare malignancy, such as cutaneous melanoma, with a pharmacoep-
idemiological approach through the linking of large national pathology and pharmacy 
databases. As such drugs, such as statins, are used by a relatively small proportion of 
the general population, gathering the required sample sizes would otherwise not 
have been feasible. This approach, therefore, creates research oppourtunities for many 
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other research questions on drugs and malignancies. For nearly all malignancies, data 
are well registered in The Netherlands and drug dispensing records are available for 
about 25% of the country within PHARMO. However, we should focuss only on 
research topics in which it is realistic to assume that exposure allocation is unrelated 
to the outcome of interest. Within this type of study, one may use proxy’s of 
health care consumption, such as the number of different drugs an individuals uses or 
the number of different diagnoses registered in the LMR, to gain information on 
possible ascertainment bias. More importantly, the type of probabilistic linkage we 
used between the PHARMO database and other registries has meanwhile been 
validated. [79] 
Although, a pharmacoepidemiological approach creates many opportunities in 
studying (unintended) drug effects on a malignancy, the design, collection and 
analysis of such studies coincides with many hurdles and pitfalls. For instance, defining 
the indexdates, required follow up (‘follow back’) periods in PHARMO in the right time 
relation with this indexdate, defining the exposure time window, and a minimal 
exposure threshold (either in minimal exposure time, minimal daydose or a minimal 
cumulative dose) is a complex issue. Assumptions with regard to temporal relationships 
between exposure and occuring events including latency times, effective chemopre-
ventive dosages, and possible differential effects within subclasses need to be made 
and restrictions, sensitivity analyses or adjustments during analysis should be 
implemented to prevent biases. This type of research may be subject to some specific 
biases, such as guarantee-time bias or immortal time bias (as a consequence of 
exposure definition, exposed versus non-exposed seem to have a survival benefit), 
protopathic bias (exposure results from symptoms of the subclinical malignancy), and 
ascertainment bias (sampling chances differ between subgroupes; for instance 
individuals may not always be unsubscribed form the parmacy database if they 
moved out of the area).
Some of the difficulties we encountered were the lack of some therapeutic / 
prognostic information (metastases that were not pathologically confirmed), 
information available in plain text field only requiring reading and scoring of all 
pathological records manually (e.g., pathological details of the melanoma, such as 
Breslow’s thickness, subtype, and anatomical location), and some technical difficulties 
such as the fact that PALGA is not a patient centric database necessitating linkage of 
each pathological record to the PHARMO records.
In conclusion, linking large national databases such as PHARMO and PALGA creates 
many research opportunities and may enable researches to study rare (adverse) events 
caused by drugs used in the (general) population. Improvements to large national 
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databases (in-hospital drug use, standardization of diagnostic information in electronic 
records) such as PHARMO and PALGA will further expand such research possibilities.  
Conclusions
CM is a growing health problem in Caucasian populations. We showed that CM 
incidence is still significantly increasing among both sexes in The Netherlands. 
Fortunately, prognosis is often favorable. Nevertheless, for ECM cases and advanced 
stages of CM, prognosis is less favorable. ECM compromised 6.4% of all primary 
melanomas. Five-year relative survival proportions for patients with ECM ranged from 
74% for ocular melanomas until 15-40% for mucosal melanomas. Although, CM 
incidence continued to accumulate, we did not demonstrate such time trends for 
ECM incidence. Overall, the total burden of melanoma is increasing in The 
Netherlands. 
Melanoma prevention has focused on education and sun protection measures. 
Thusfar, this has not led to behavioral changes or to a decreased or stabilized 
melanoma incidence. Cancer chemoprevention could be an alternative approach in 
which an agent is used to reverse, suppress, or prevent premalignant molecular or 
histological lesions from progressing to invasive cancer. Considerable preclinical 
evidence of efficacy is available in literature for aspirin, NSAIDs, and statins as 
melanoma chemopreventive drugs. However, lack of definite data on efficacy in 
humans and profound long-term safety data in the required doses, preclude the use 
of chemopreventive drugs for melanoma in current practice. 
Investigating unintended drug effects in a (rare)malignancy by a pharmacoepidemio-
logical approach is feasible, can be validated, and may enable studies that would 
otherwise not have been feasible. 
None of the statin-related independent variables in our study consistently supports a 
risk reduction of statin use on the incidence of CM. However, our data did suggest 
that statin use is associated with a significantly reduced Breslow’s thickness at 
diagnosis. This effect was even more pronounced among men and, if causally related, 
is an important finding as Breslow’s thickness at diagnosis is one of the strongest 
prognostic determinants.
Among users of non-steroidal anti-inflammatory drugs (NSAIDs), both acetylsalicylic 
acid (aspirin, ASA) and non-acetylsalicylic acid-NSAIDs, we did not find a reduced CM 
incidence. However, our results do suggest that, among women, continuous 
low-dosed ASA may be associated with a reduced incidence of CM in women. 
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The use of ACE inhibitors (ACEi) or angiotensin II antagonists (ARb) did not seem to 
protect against the development of cutaneous melanoma nor was it associated with 
decreased Breslow’s depth. Due to limited statistical precision, however, we cannot 
exclude an association between ACEi and ARb exposure and either a (moderately) 
increased or decreased incidence of cutaneous melanoma. 
Gender may have a complex relationship with melanoma development and 
progression as indicated by several findings. Hormonal factors playing a role in these 
gender differences can still not be excluded. Although not in agreement with previous 
studies, we showed a modest level of association between (higher) exposure to 
estrogens, both oral contraceptives (OC) and hormonal replacement therapy (HRT), 
and increased CM incidence. As CM risk is generally low, we can conclude there is no 
need to change OC prescription. Abandoning regular prescribing of HRT for 
uncomplicated menopausal complaints should be advocated, but for more urgent 
reasons than increased melanoma risk. 
Overall, based on the current evidence, one cannot point out which agents are likely 
to be the most efficacious, but (tertiary) cancer chemoprevention, especially with 
agents that exhibit additional major health benefits and few (long-term) adverse 
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Melanoma is an accumulating health problem in Caucasian populations. Cutaneous 
melanoma is responsible for the majority of skin cancer deaths and is, therefore, 
considered the most aggressive form of skin cancer. Moreover, its incidence among 
Caucasian populations has increased over the past decades whereas mortality rates 
are stabilizing or in some areas even decreasing. Overall, the total burden of cutaneous 
melanoma is expected to be increasing in The Netherlands. In rare cases, melanomas 
arise on noncutaneous sites, so-called extracutaneous melanoma. Due to its rareness, 
the epidemiology of extracutaneous melanoma is poorly described in literature.
As the burden of cutaneous melanoma is expected to increase, effective treatment 
options for advanced melanoma are lacking, and beneficial prognosis of melanoma 
patients strongly depends on early diagnosis, melanoma prevention is likely to be a 
key issue in melanoma disease control. Although sun protection programs and 
educational attempts have led to increased awareness, they have not resulted in 
behavioral changes to sun exposure and protection nor to a decrease in cutaneous 
melanoma incidence. In addition, most melanoma risk factors are not amenable. 
Alternative approaches to melanoma prevention, such as cancer chemoprevention 
are, therefore, important research topics. Several agents, such as statins, non-steroidal 
anti-inflammatory drugs including aspirin, and angiotensin-converting enzyme 
inhibitors, have been claimed to have chemopreventive properties. However, it is 
unknown which of these potential chemopreventive agents have the best potential 
to be useful and safe. 
This thesis presents:
- cancer registry-based studies from The Netherlands on the epidemiology of 
extracutaneous melanoma and on the burden of disease due to cutaneous 
melanoma (epidemiology of melanoma)
- a qualitative review, based on a systematically literature search, discussing candidate 
drugs for melanoma chemoprevention, their possible mechanisms of action and 
summarizing the existing evidence for their chemopreventive efficacy, safety and 
tolerability (chemoprevention of melanoma)
- pharmacoepidemiological studies testing hypotheses on chemopreventive activity 
on melanoma of statins, non-steroidal anti-inflammatory drugs, angiotensin-con-
verting enzyme inhibitors, and angiotensin II receptor blockers (chemoprevention 
of melanoma)
- pharmacoepidemiological studies on the hypothesized association between 





In chapter 2 we explored the (long-term trends in the) incidence and survival of 
extracutaneous melanoma in The Netherlands. Based on data from the Netherlands 
Cancer Registry combined with vital status, we determined the incidence and relative 
survival of extracutaneous melanoma between 1989 and 2006. We estimated 
extracutaneous melanoma incidence rates, long-term trends in extracutaneous 
melanoma incidence, and 5-year relative survival proportions and compared them 
with those of cutaneous melanoma. 
Between 2003 and 2006, extracutaneous melanoma compromised 6.4% of all primary 
melanomas in The Netherlands. Of all extracutaneous melanoma subsites, ocular 
melanomas were the most common extracutaneous melanoma subsite with European 
Standardized incidence Rates of 10.7 and 8.2 per million person-years for males and 
females, respectively. In addition, ocular melanomas had the best survival. Five-year 
relative survival for extracutaneous melanoma was worse if compared to cutaneous 
melanoma for all subsites, but differed largely between anatomical subtypes ranging 
from 74% for ocular melanomas to 15% for certain subsites of mucosal melanomas. In 
contrast with cutaneous melanoma for which an annual increase in incidence of 4.4 
percent for men and 3.6 percent for women was detected, no statistically significant 
trends in the incidence of (subsites of) extracutaneous melanoma were observed. 
Chapter 3 describes the total burden of cutaneous melanoma within The Netherlands. 
As we hypothesized, the total burden of cutaneous melanoma increased between 
1989 and 2006. The cumulative incidence of cutaneous melanoma almost doubled 
between 1989 and 2006. In addition, the number of melanoma deaths, the number of 
years of life lost (YLL), the number of years lost due to disability (YLD), and the number 
of years of life lived with disease (YLWD) all accumulated in time. On average, patients 
lived 21.5-28.4 years with a melanoma diagnosis and melanoma resulted in a loss of 
about 18-20 years per before the age of 95 for those that died of their melanoma. 
Including all patients diagnosed with an melanoma, not only those that die from it, 
the average life loss is about 3 years.
Overall, the burden of melanoma to society increased rapidly between 1989 and 
2006. 
Chemoprevention of melanoma
In chapter 4 we discuss the available evidence for candidate drugs that have potential 
to be used in melanoma chemoprevention. Cancer chemoprevention, as defined by 
Sporn et al., is the use of an agent to reverse, suppress, or prevent premalignant 
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molecular or histological lesions from progressing to invasive cancer. A systematic 
literature search was performed and a qualitative review of the selected scientific 
papers on drug chemoprevention of cutaneous melanoma is presented. This review 
show that considerable preclinical evidence of efficacy as a melanoma chemopreven-
tive drug exists for aspirin, non-steroidal anti-inflammatory drugs, and statins. 
However, definite data on efficacy in humans and profound long-term safety data in 
the required doses are lacking. Therefore, only relatively safe drugs indicated for other 
health effects but with additional chemopreventive properties in cancer development, 
such as low-dosed aspirin and statins, can currently be encouraged in people at 
increased risk of cancer. Less evidence is available for other potential chemopreven-
tive drugs, such as fibrates, retinoids, imiquimod, dehydroepiandrosterone, and 
acetaminophen. 
In the next part of the thesis, we report on a number of pharmacoepidemiological 
studies using a general population-based dataset (PHARMO) with drug-dispensing 
data from the pharmaco-morbidity linkage network linked with the national 
pathological database (PALGA). 
Chapter 5 presents a case-control study into the hypothesized association between 
the incidence and progression of CM and exposure to statins (3-hydroxy-3-methylgl-
utaryl-coenzyme A reductase inhibitors). We study both the association between use 
of statins and the incidence of cutaneous melanoma as well as the potential effects of 
prior statins use on Breslow’s thickness at diagnosis of cutaneous melanoma. 
Cutaneous melanoma risk was not associated with statin use for at least 0.5 year in the 
3 years before diagnosis. Although none of the statin-related independent variables 
consistently supported a risk reduction of statin use on the incidence of cutaneous 
melanoma, statin use was associated with a reduced Breslow’s thickness at diagnosis 
(–19%, 95% CI = –33, –2.3). This apparent disparity suggests that statins slow melanoma 
progression but do not protect against cutaneous melanoma development. However, 
the disparity could also result from the relatively short follow-up.
Surprisingly, after stratification for gender, the finding of a reduced Breslow’s thickness 
among statin users was confirmed for men (–27.8%, 95% CI =–43.7, –7.4) but not for 
women (–4.8%, 95% CI=–29.6, 28.8). This suggest a clinically relevant reduction of 0.58 
mm on average in Breslow’s thickness among men. As Breslow’s thickness at diagnosis 
is one of the strongest determinants for prognosis, this should be considered an 
important finding. However, (residual) bias cannot be excluded and our study is the 
first study to investigate statin use as a determinant of Breslow’s depth. Therefore, 




In chapter 6 we study the association between use of non-steroidal  anti-inflammatory 
drugs (NSAIDs) on melanoma development. We included both acetylsaliylic acid 
(aspirin, ASA) as well as non-ASA NSAIDs.
Cutaneous melanoma incidence was not significantly associated with ever ASA use 
(adjusted OR = 0.92, 95% CI = 0.76-1.12) or ever non-ASA NSAID use (adjusted 
OR = 1.10, 95% CI = 0.97-1.24). However, continuous use of low-dose ASAs was 
associated with a significant reduction of CM risk in women (adjusted OR = 0.54, 95% 
CI = 0.30-0.99) but not in men (adjusted OR = 1.01, 95% CI = 0.69-1.47). A significant 
trend (p = 0.04) between categories of ASA use from no use, non-continuous use to 
continuous use was observed in women. 
Continuous use of low-dose ASAs may be associated with a reduced incidence of 
cutaneous melanoma in women, but not in men.
Angiotensin-converting enzyme inhibitors (ACEi ) and possibly angiotensin II receptor 
blockers (ARb) have also been claimed to have chemopreventive properties. In 
chapter 7 we explored the possibility of an association between exposure to ACEi 
and ARb and the development of cutaneous melanoma. 
This study showed no statistically significant associations between the incidence of 
melanoma and the use of ACEi (adjusted OR= 1.0, 95% CI = 0.8-1.3) or ARb (adjusted 
OR = 1.0, 95% CI = 0.7-1.5). In addition, the use of ACEi or ARb was not associated with 
decreased Breslow’s thickness. Thus, the use of ACEi or ARb does not seem to protect 
against the development of cutaneous melanoma. However, due to limited numbers 
of ACEi and ARb users, we cannot exclude an association between ACEi and ARb 
exposure and either a (moderately) increased or decreased incidence of cutaneous 
melanoma. Moreover, residual confounding cannot be excluded. For example, sun 
exposure may be indirectly related to ACEi and ARb exposure because it may be 
associated with increased physical activity and a reduced chance of hypertension. 
Likewise, high social economic status is associated with increased sun exposure and 
may also be associated with a reduced chance of hypertension. Both these potential 
biases would in an underestimation of any effect of ACEi and ARb and would thus 
produce bias toward the null. 
Hormonal and gender differences in melanoma
To our surprise, female melanoma cases in the previous studies (chapter 5, 6 and 7) 
were more likely to be estrogen users than controls. After reviewing literature, we 
were confronted with several clues indicating possible hormonal influences in 
melanoma. First, hyperpigmentation is a side-effect of oral contraceptive (OC) use 
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and may also occur during pregnancy (chloasma) or with the use of hormonal 
replacement therapy (HRT) both indicating an effect of estrogens on melanocyte 
proliferation. Second, the pattern of cutaneous melanoma incidence rates with 
advancing age in women mimic those of breast cancer and differs from the pattern of 
cutaneous melanoma rates among men. In addition, improved survival among female 
melanoma patients as compared to males has been demonstrated to remain after 
adjusting for demographic and tumor characteristics. 
As female sex steroids could be involved, we decided to study exposure to estrogens, 
both oral contraceptives (OC) and hormonal replacement therapy (HRT), and a 
possible association with the incidence of CM in more detail. In chapter 8 an 
association between estrogen use, both OC and HRT, was confirmed for exposure 
expressed as use for at least half a year, and for the highest categories of cumulative 
dose and prescription duration. The results suggest a cumulative dose-dependent 
increased risk of cutaneous melanoma with the use of estrogens, both OC and HRT. 
However, most previous studies on estrogen use and melanoma are not in agreement 
with our findings. 
As some in vitro studies have suggested a direct inhibitory effect on melanoma tumor 
growth, the use of OC and HRT may be associated with a decreased Breslow’s 
thickness. If so, the clinical impact of an increased cutaneous melanoma incidence 
with OC and HRT use would be limited. In chapter 9 we investigated if estrogen use 
is associated with a decreased Breslow’s thickness. However, we could not confirm an 
association between either OC use or HRT and Breslow’s thickness.
In conclusion, the modest level of association between cutaneous melanoma 
incidence and OC use that resulted from our studies is not in agreement with previous 
studies, and as cutaneous melanoma risk is generally low, we can conclude there is no 
need to change OC prescription. Abandoning regular prescribing of HRT for 
uncomplicated menopausal complaints should be advocated, but for more urgent 
reasons than increased melanoma risk.
In chapter 10 the results of this thesis are discussed, possible future directions are 
outlined and final conclusions are drawn. Since 1989-1998, cutaneous melanoma 
incidence has further increased between 1998 and 2006 in The Netherlands. Likewise, 
the total burden of cutaneous melanoma has accumulated over the last decades. 
These new estimates of the incidence and burden of cutaneous melanoma should be 
used in health-care planning for melanoma care and surveillance.
Although prognosis is favorable for the majority of melanoma patients, prognosis is 




subsites was poor compared to cutaneous melanoma patients but differed 
substantially for extracutaneous melanoma subsites being most favorable for ocular 
melanomas. 
Several strategies for cancer chemoprevention exist, such as primary, secondary or 
tertiary cancer prevention and the population or the high risk strategy. As most 
chemopreventive agents have demonstrated toxicity at some level and long-term 
compliance is required, the high risk strategy would be the choice of interest for 
melanoma chemoprevention. Because the absolute risk of getting a melanoma is 
small, tertiary cancer chemoprevention, at least as a first goal, would seem to be the 
most realistic as these patients would be at sufficiently high risk of developing a 
second invasive melanoma. As an additional advantage, in tertiary prevention, one 
could select a chemopreventive agent for its (additional) potential to prevent 
metastasis. 
Based on current evidence, it is not yet possible to determine which candidate chemo-
preventive drug(s) is likely to be the most efficacious in medical practice. However, 
considerable preclinical evidence of chemopreventive efficacy exists for aspirin, 
NSAIDs, and statins. Lack of definite data on efficacy in humans and profound 
long-term safety data in the required doses, however, preclude the use of chemo-
preventive drugs for melanoma in current practice. Future research should explore 
possible differential effects within a drug class, temporal dose-response relationships, 
and possible synergistic or antagonistic effects. 
In addition, focus should be on how to define high risk subpopulations at whom 
chemoprevention to target on. Such strategies should be based upon validated 
prediction models. Candidate items to select for such prediction models could include 
individual melanoma risk factors including an individual’s mutational status of genetic 
susceptibility genes, validated early biomarkers of invasive melanoma risk, validated 
molecular and histopathological aspects of any prior tumor, and individual risk factors 
predicting adverse events of the chemopreventive drug.
In addition, we conclude that gender may have a complex relationship with melanoma 
development and progression as indicated by several findings. Although these 
relationships have been studied over a long time, gender differences and possible 
hormonal influences in melanoma remain are still poorly understood.
To understand these gender differences in melanoma, future studies are warranted. 
However, as cutaneous melanoma risk is generally low, we can conclude there is no 
need to change OC prescription. In contrast, abandoning regular prescribing of HRT 
for uncomplicated menopausal complaints should be advocated, but for more urgent 








Melanomen vormen een groeiend gezondheidsprobleem in Caucasische populaties. 
Huidmelanomen zijn verantwoordelijk voor bijna 90% van de huidkankersterfte en 
zijn daarmee de meest agressieve vorm van huidkanker. Bovendien is de incidentie 
van huidmelanomen in de laatste decennia sterk toegenomen in Caucasische 
populaties, terwijl de melanoomgerelateerde mortaliteit stabiliseerde of in sommige 
gebieden zelfs een geringe afname liet zien. In het algemeen wordt aangenomen dat 
de totale ziektelast ten gevolge van huidmelanomen in Nederland toeneemt.
In zeldzame gevallen kunnen melanomen op andere lokalisaties dan de huid ontstaan, 
de zogenaamde extracutane melanomen. Vanwege hun zeldzaamheid is de 
epidemiologie van dit type melanomen slechts summier beschreven in de medische 
literatuur.
Aangezien de verwachting is dat de ziektelast ten gevolge van huidmelanomen 
toeneemt, effectieve behandelopties voor gevorderde stadia van melanomen 
ontbreken en een goede prognose sterk afhankelijk is van vroege diagnose, wordt 
preventie van melanomen beschouwd als de sleutel om de ziektelast als gevolg van 
huidmelanomen in de populatie te beperken.
Hoewel preventieprogramma’s gericht op voorlichting en het beperken van 
(excessieve) blootstelling aan ultraviolette straling hebben geleid tot een toegenomen 
risicobesef, heeft dit nog niet geleid tot een verandering in zonblootstelling en be-
schermingsgedrag of tot een afname in de incidentie van huidmelanomen. Bovendien 
zijn de meeste risicofactoren voor huidmelanomen niet toegankelijk voor preventie. 
Alternatieve vormen van preventie zoals kanker chemopreventie zijn daarom 
belangrijke onderzoeksthema’s.
Van verschillende geneesmiddelen zoals statines, prostaglandinesynthetaseremmers 
(NSAIDs) inclusief aspirine en ACE (angiotensin-converting enzyme) remmers worden 
chemopreventieve eigenschappen verondersteld. Het is echter onbekend welke van 
deze potentiële chemopreventieve middelen de beste kans maakt om bruikbaar en 
veilig te zijn. 
Dit proefschrift beschrijft:
- Nederlandse kankerregistratie studies naar de epidemiologie van extracutane 
melanomen en de ziektelast als gevolg van huidmelanomen in de populatie 
(epidemiologie van melanomen) 
- een kwalitatief overzicht, gebaseerd op systematisch literatuuronderzoek, waarin 
de mogelijke werkingsmechanismen van kandidaat geneesmiddelen voor de 




tieve effectiviteit, veiligheid en tolerabiliteit wordt bediscussieerd (chemopreventie 
van melanomen)
- farmacoepidemiologische studies waarin hypotheses over de chemopreventieve 
activiteit van statines, NSAIDs, ACE remmers en angiotensine II antagonisten op 
huidmelanomen worden getest (chemopreventiie van melanomen)
- farmacoepidemiologische studies waarin de veronderstelde associatie tussen 
gebruik van oestrogenen en melanomen wordt bestudeerd (hormonale en 
 geslachtsverschillen bij melanomen)
Epidemiologie van melanomen
In hoofdstuk 2 bestudeerden we de (lange termijn trends in de) incidentie van 
extracutane melanomen en de relatieve overleving na vaststellen van de diagnose 
extracutaan melanoom in Nederland. De incidentie en relatieve overlevingsproportie 
werd bepaald met behulp van gegevens over de periode 1989-2006 uit de Nederlandse 
kankerregistratie gecombineerd met informatie over de vitale status. Incidentiecijfers, 
lange termijn trends in incidentie en 5-jaars overlevingsproporties van extracutane 
melanomen werden geschat en vergeleken met die van huidmelanomen. Tussen 
2003 en 2006 vertegenwoordigden extracutane melanomen 6,4% van alle primaire 
melanomen in Nederland. Van alle sublokalisaties kwamen oogmelanomen het 
meeste voor met Europese gestandaardiseerde incidentiecijfers (rates) van 10,7 en 8,2 
per miljoen persoonsjaren voor respectievelijk mannen en vrouwen. Bovendien 
hadden patiënten met oogmelanomen de beste overleving. Vijf-jaars relatieve over-
levingsproporties voor extracutane melanomen van alle sublokaties waren slecht 
vergeleken met huidmelanomen, maar varieerden aanzienlijk tussen de anatomische 
subtypes van 74% voor oogmelanomen tot 15% voor bepaalde sublokaties van 
mucosale melanomen. In tegenstelling tot huidmelanomen die een jaarlijkse toename 
in incidentie van 4,4 procent voor mannen en 3,6 procent voor vrouwen lieten zien, 
werd geen statistisch significante trend geobserveerd in de incidentie van (subtypen 
van) extracutane melanomen. 
Hoofdstuk 3 beschrijft de totale ziektelast van huidmelanomen in Nederland. Zoals 
we verwachtten, nam de totale ziekte last als gevolg van huidmelanomen in Nederland 
toe tussen 1989 en 2006. De cumulatieve incidentie van huidmelanomen verdubbelde 
bijna tussen 1989 en 2006. Bovendien namen het aantal melanoomgerelateerde 
sterftegevallen, het aantal verloren levensjaren, het aantal verloren levensjaren als 
gevolg van invaliditeit en het aantal jaren geleefd met melanoom allemaal toe in de 
tijd.  Gemiddeld genomen, alle melanoompatiënten in acht genomen, blijkt dat een 
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patiënt met een melanoom ongeveer drie jaar korter leeft dan een vergelijkbaar 
persoon zonder melanoom. Echter, als alleen patiënten die sterven met als 
doodsoorzaak een melanoom in ogenschouw worden genomen, dan sterven zij 
gemiddeld ongeveer 20 jaar eerder in vergelijking met de algemene populatie. 
Dat betekent daarmee ook dat veel patiënten leven met de diagnose melanoom en 
met een zekere angst voor progressie van de ziekte en/of het opnieuw ontstaan van 
huidkanker.
Chemopreventie van melanomen
In hoofdstuk 4 wordt het beschikbare bewijs voor de verschillende kandidaat 
geneesmiddelen voor chemopreventie van melanomen bediscussieerd. Kanker 
chemopreventie, zoals gedefinieerd door Sporn et al., is het gebruik van een middel 
om te voorkomen dat premaligne laesies progressie vertonen tot een invasieve kanker 
danwel om deze progressie te onderdrukken of om te keren.
Een systematisch literatuuronderzoek werd uitgevoerd en een kwalitatieve 
samenvatting van de geselecteerde wetenschappelijke artikelen naar chemopreventie 
met geneesmiddelen van huidmelanomen wordt gepresenteerd. Dit overzichtsartikel 
laat zien dat substantieel preklinisch bewijs bestaat voor de effectiviteit van aspirine, 
NSAIDs en statines als chemopreventief geneesmiddel tegen huidmelanomen. 
Definitieve gegevens met betrekking tot de effectiviteit in mensen en degelijke 
gegevens over de lange termijn veiligheid in de benodigde doseringen ontbreken 
echter. Daarom kunnen momenteel alleen relatief veilige geneesmiddelen die reeds 
geïndiceerd zijn voor andere indicaties maar tevens aangetoonde chemopreventieve 
eigenschappen hebben met betrekking tot kankerontwikkeling, zoals laaggedoseerde 
aspirine en statines, worden geadviseerd voor mensen met een verhoogd risico op 
kanker. Van andere mogelijke chemopreventieve geneesmiddelen, zoals fibraten, 
retinoïden, imiquimod, dehydroepiandrosteron en paracetamol, is het bewijs minder 
overtuigend.
In het volgende deel van dit proefschrift rapporteren we een aantal farmaco-
epidemiologische onderzoeken uitgevoerd met behulp van een dataset van het 
PHARMO instituut voor farmacoepidemiologisch onderzoek met gegevens van 
afleveringen van geneesmiddelen die gebaseerd is op de algemene populatie en die 
is gekoppeld aan de nationale pathologie database (PALGA). 
Hoofdstuk 5 presenteert een patiënt-controle onderzoek naar de associatie tussen 
de incidentie en progressie van huidmelanomen en de blootstelling aan statines 




zowel de associatie tussen statinegebruik en de incidentie aan huidmelanomen als 
het mogelijke effect van statinegebruik in het verleden op de Breslow dikte bij 
diagnose van een huidmelanoom. Het risico op een huidmelanoom was niet 
geassocieerd met statinegebruik gedurende minimaal een half jaar in de 3 jaar voor 
diagnose. Hoewel geen van de statinegerelateerde variabelen consequent een 
verlaagd risico op het onstaan van een melanoom onderschreef, was statinegebruik 
wel geassocieerd met een verminderde Breslow dikte bij diagnose (–19%, 95% BI = 
–33, –2.3). Deze ogenschijnlijke tegenstelling suggereert dat statines de progressie 
van melanomen vertraagt, maar geen effect hebben op het onstaan van een 
huidmelanoom. Echter, deze discrepantie kan ook het gevolg zijn van de relatief korte 
follow-up.
Tot onze verrassing, werd onze bevinding van een verminderde Breslow dikte na 
stratificatie voor geslacht bevestigd voor mannen (–27.8%, 95% BI =–43.7, –7.4), maar 
niet voor vrouwen (–4.8%, 95% BI=–29.6, 28.8).  Dit suggereert een klinisch relevante 
reductie van gemiddeld 0,58 mm in de Breslow diepte bij mannen. Aangezien Breslow 
diepte bij diagnose één van de belangrijkste voorspellers voor de prognose is, moet 
dit als een belangrijke bevinding worden beschouwd. Echter, residuele confounding 
kan niet worden uitgesloten en ons onderzoek is het eerste waarin statinegebruik als 
een determinant voor Breslow dikte wordt onderzocht. Daarom is validatie van onze 
resultaten noodzakelijk.
In hoofdstuk 6 bestuderen we de associatie tussen het gebruik van prostaglandine-
synthetaseremmers (NSAIDs) en het ontstaan van melanomen. We onderzochten 
zowel acetylsalicylzuur (aspirine, ASA) als de overige NSAIDs. De incidentie van 
huidmelanomen was niet significant geassocieerd met het ooit gebruiken van aspirine 
(gecorrigeerde OR = 0.92, 95% BI = 0.76-1.12) of met het ooit gebruiken van één van de 
overige NSAIDs (gecorrigeerde OR = 1.10, 95% BI = 0.97-1.24). Continu gebruik van een 
lage dosis aspirine, echter, was bij vrouwen geassocieerd met een significante reductie 
van het risico op een huidmelanoom (gecorrigeerde OR = 0.54, 95% BI = 0.30-0.99) 
maar niet bij mannen (gecorrigeerde OR = 1.01, 95% BI = 0.69-1.47). Een significante 
trend (p = 0.04) tussen de categorieën van aspirine gebruik van geen, niet-continu 
naar continu gebruik aan aspirine werd gezien bij vrouwen. 
Continu laaggedoseerde aspirine kan bij vrouwen, maar niet bij mannen, is 
geassocieerd met een afgenomen incidentie aan huidmelanomen.
Van angiotensine-converterende enzym inhibitoren (ACE remmers, ACEi ) en mogelijk 
ook angiotensine II receptor blokkers (ARb) is beweerd dat ze chemopreventieve 
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eigenschappen hebben. In hoofdstuk 7 exploreren we de mogelijkheid van een 
associatie tussen blootstelling aan ACEi en ARb en de ontwikkeling van huidmelanomen.
Dit onderzoek liet geen statistisch significante associatie zien tussen de incidentie van 
huidmelanomen en het gebruik van ACEi (gecorrigeerde OR= 1.0, 95% BI = 0.8-1.3) of 
ARb (gecorrigeerde OR = 1.0, 95% BI = 0.7-1.5). Bovendien was het gebruik van ACEi of 
ARb niet geassocieerd met een verlaagde Breslow dikte. Het gebruik van ACEi en ARb 
lijkt dus geen beschermend effect te hebben op de ontwikkeling van huidmelanomen. 
Als gevolg van de lage aantallen ACEi en ARb gebruikers kunnen we echter een 
associatie tussen blootstelling aan ACEi en ARb met een (matig) verhoogd of verlaagde 
incidentie aan huidmelanomen niet geheel uitsluiten. Bovendien kan residuele 
confounding niet uitgesloten worden. Verhoogde blootstelling aan zonlicht 
bijvoorbeeld, kan indirect gerelateerd zijn blootstelling aan ACEi of ARb, omdat 
toegenomen fysieke activiteit geassocieerd is met een lagere kans op hypertensie 
(een indicatie voor het voorschrijven van ACEi of ARb). Op vergelijkbare wijze kan een 
hogere sociaal economische status geassocieerd zijn met zowel een verhoogde zon-
blootstelling als een verminderde kans op hypertensie. Allebei deze mogelijke 
bronnen van vertekening zouden leiden tot een onderschatting van een effect van 
ACEi en ARb op de incidentie van huidmelanomen en zouden dus een bias geven 
richting nul(hypothese).
Hormonale en geslachtsverschillen bij melanomen 
Tot onze verrassing waren vrouwelijke melanoompatiënten in de voornoemde studies 
(hoofdstukken 5, 6 en 7) vaker gebruikers van oestrogenen dan hun controles. Nader 
literatuuronderzoek toonde verschillende aanwijzingen die hormonale invloeden op 
melanomen suggereren. Allereerst, is hyperpigmentatie een bijwerking van orale 
anticonceptiva (OAC) en treedt ook wel op tijdens de zwangerschap (chloasma) of 
met het gebruik van hormonale suppletie therapie (HST) wat een effect van 
oestrogenen op de melanocyten proliferatie suggereert. Ten tweede is het patroon 
van de incidentie van huidmelanomen bij vrouwen van toenemende leeftijd 
vergelijkbaar met dat van borstkanker en verschilt dit incidentiepatroon met dat van 
mannen. Bovendien hebben vrouwelijke melanoompatiënten een betere overleving 
vergeleken met mannen die ook na correctie voor verschillen in demografische en 
tumor karakteristieken blijft bestaan.
Aangezien vrouwelijke hormonen een rol zouden kunnen spelen, besloten we een 
meer gedetailleerde analyse uit te voeren naar een mogelijke associatie tussen 
gebruik van oestrogenen, zowel orale anticonceptiva (OAC) als hormonale suppletie-




In hoofdstuk 8 werd een associatie tussen oestrogeengebruik en de incidentie van 
huidmelanomen bevestigd voor zowel OAC als HST en voor het totaal aan oestro-
geengebruik uitgedrukt als minstens een half jaar gebruik, de hoogste categorie van 
de cumulatieve dosering en de prescriptieduur. De resultaten suggereren een 
cumulatief dosisafhankelijk verhoogd risico op huidmelanomen bij oestrogeenge-
bruik (zowel OAC als HST). De meeste voorgaande onderzoeken naar oestrogeenge-
bruik en melanomen komen echter niet overeen met onze resultaten.
Aangezien sommige in vitro studies een direct inhiberend effect van oestrogenen op 
de celgroei van melanomen suggereren, kan gebruik van OAC en HST gerelateerd zijn 
aan een verlaagde Breslow dikte.  Als dat zo is, dan beperkt dat de eventuele klinische 
impact van een toegenomen incidentie aan huidmelanomen bij OAC en HST gebruik. 
In hoofdstuk 9 onderzochten we of oestrogeengebruik geassocieerd is met een 
afgenomen Breslow dikte. Een associatie tussen ofwel OAC gebruik ofwel HST gebruik 
en Breslow dikte bij diagnose konden we echter niet bevestigen.
Kortom, de matige associatie tussen de incidentie van huidmelanomen en OAC 
gebruik die wij in onze onderzoeken aantoonden komt niet overeen met eerdere 
studies en aangezien het risico op een huidmelanoom gering is kunnen we 
concluderen dat dit geen aanleiding vormt om het voorschrijfgedrag voor OAC te 
wijzigen. Zeer terughoudend zijn met het voorschrijven van HST voor ongecompli-
ceerde menopauzale klachten is te adviseren, maar vanwege andere redenen dan 
een verhoogd risico op huidmelanomen.
In hoofdstuk 10 worden naast de resultaten uit dit proefschrift, mogelijke toekomstige 
richtingen voor onderzoek en de uiteindelijke conclusies besproken. Sinds 1989-1998 
is de incidentie van huidmelanomen verder toegenomen in Nederland. Evenzo is de 
totale ziektelast van huidmelanomen toegenomen in de laatste decennia. Deze 
nieuwe schattingen van de incidentie en ziektelast van huidmelanomen zou moeten 
worden gebruikt bij de (capaciteits)planning van de behandeling en het vervolgen 
van patiënten met een melanoom voor de toekomst.
Hoewel de prognose voor de meerderheid van melanoompatiënten gunstig is, is die 
voor sommige subgroepen van patiënten slecht. De overlevingsproportie voor alle 
sublokaties van extracutane melanomen was slecht vergeleken met die van 
huidmelanomen en varieerde aanzienlijk voor de verschillende sublokaties met de 
meest gunstige overleving voor oogmelanomen. 
Er bestaan verschillende strategieën voor kanker chemopreventie, zoals primaire, 
secundaire of tertiaire kanker preventie en de populatie of hoogrisico strategie. 
Aangezien de meeste chemopreventieve middelen (enige vorm van) toxiciteit hebben 
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getoond en lange termijn therapietrouw is vereist, lijkt de hoogrisico strategie 
aangewezen voor de chemopreventie van melanomen. Omdat het absolute risico 
voor het krijgen van een melanoom klein is, lijkt tertiaire chemopreventie, in eerder 
geval als eerste doel, het meest realistisch aangezien voor deze patiënten een 
voldoende hoog risico geldt op een tweede melanoom. Bijkomend voordeel bij 
tertiaire preventie is dat een chemopreventief middel gekozen kan worden dat 
potentie heeft om metastasering te voorkomen.
Op basis van het huidige bewijs in de wetenschappelijke literatuur is het nog niet 
mogelijk om aan te geven welk chemopreventief geneesmiddel hoogst waarschijnlijk 
het meest effectief zal zijn.  Voor aspirine, NSAIDs en statines bestaat echter 
substantieel preklinisch bewijs. Gebrek aan gegevens met betrekking tot effectiviteit 
in mensen en lange termijn veiligheid in de benodigde doseringen sluiten het gebruik 
van chemopreventieve geneesmiddelen in de melanomen patiëntenzorg op dit 
moment uit. Toekomstig onderzoek zou zich kunnen richten op mogelijke differentiële 
effecten binnen een geneesmiddelklasse, dosisrespons relaties in de tijd en mogelijke 
synergistische of antagonistische effecten.
Daarnaast zou de aandacht in nieuw onderzoek moeten uitgaan naar hoe hoogrisico 
subpopulaties waarop chemopreventie zich zou moeten richten het beste gedefinieerd 
kunnen worden. Dergelijke strategieën zouden gebaseerd moeten zijn op gevalideerde 
predictiemodellen. Kanididaat variabelen om te selecteren voor deze predictie-
modellen zouden individuele risicofactoren voor melanomen kunnen zijn, zoals de 
mutatiestatus van ziektegerelateerde genen, gevalideerde vroege biomarkers van 
invasieve melanomen, gevalideerde moleculaire en histopathologische aspecten van 
eerdere tumoren en individuele risicofactoren die bijwerkingen en complicaties als 
gevolg van het chemopreventieve geneesmiddel voorspellen.
We concluderen bovendien dat geslacht een complexe relatie met het ontstaan en 
de progressie van melanomen heeft. Hoewel deze relaties al over een lange periode 
worden bestudeerd, zijn geslachtsverschillen en mogelijke hormonale invloeden nog 
steeds slecht begrepen fenomenen.
Om deze geslachtsverschillen bij melanomen beter te begrijpen is toekomstig 
onderzoek vereist. Aangezien het risico op een melanoom klein is, kunnen we echter 
concluderen dat er geen reden is het voorschrijfgedrag voor OAC te veranderen. Het 
voorschrijven van HST voor ongecompliceerde menopauzale klachten, echter, moet 
wel afgeraden worden, maar vanwege meer dringende redenen dan een verhoogd 
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